montrÉal (canada) - ccac · montrÉal (canada) august 21-25, 2011 2011 ... program overview.....20...

Eighth World Congress on Alternatives and Animal Use in the Life Sciences

Hosted by the Canadian Council on Animal Care

MONTRÉAL (CANADA)August 21-25, 2011

2011

The Three Rs Together It’s PossibleReplacement • Reduction • RefinementFinal Program

3

TABLE OF CONTENTS

TAB

LE O

F CO

NTE

NTS

Welcome ........................................................................................................................4

Congress Committees .................................................................................................5

Acknowledgements .......................................................................................................6

Awards and Grants ........................................................................................................8

Practical Information ...................................................................................................11About Montréal ....................................................................................................11General Information..............................................................................................13Registration .........................................................................................................15Information for Chairs, Presenters and Exhibitors .................................................16Convention Floor Plan ..........................................................................................17

Social Program .............................................................................................................19

Scientific Program .......................................................................................................20Program Overview ................................................................................................20

Sunday, August 21 (Pre-Congress Satellite Meetings) .....................................21Monday, August 22 .........................................................................................22Tuesday, August 23 ........................................................................................24Wednesday, August 24 ...................................................................................26Thursday, August 25 .......................................................................................28

Scientific Sessions ...............................................................................................29Monday, August 22 .........................................................................................29Tuesday, August 23 ........................................................................................39Wednesday, August 24 ...................................................................................50

Poster Sessions ...................................................................................................62Monday, August 22 .........................................................................................62Tuesday, August 23 .........................................................................................70Wednesday, August 24 ...................................................................................90

Exhibitions ..................................................................................................................104Multimedia Exhibition of Alternatives in Education and Training ...........................104Exhibiting Companies and Associations ..............................................................105

Indexes ........................................................................................................................107Index of Chairs and Presenters ...........................................................................107

Index of Sessions ...............................................................................................110

2011

4

Dear WC8 participants,

The Canadian Council on Animal Care (CCAC) is proud to be the first national authority overseeing animal use in science to be given the opportunity to host a World Congress on Alternatives and Animal Use in the Life Sciences (WC). This honour recognizes Canada’s, and more especially the CCAC’s, contributions to the area of refinement of animal use in science. Since its establishment in 1968, the CCAC has continuously encouraged the development and adoption of best practices in animal care and use in science, a central theme at the WC3 in 1999 when the Three Rs Declaration of Bologna was adopted. So, while advances in vitro methods, particularly for regulatory testing, remain a main focus of the WCs, in keeping with the spirit of Bologna, the 8th World Congress on Alternatives and Animal Use in the Life Sciences (WC8) will also have an emphasis on refinement of laboratory animal use. In addition, through greater involvement of scientists from both the biomedical and biological sciences, the WC8 will chart new territory in examining the Three Rs as applied to basic research. Following on from the 7th World Congress Calling on Science, the WC8 will provide a forum that supports quality science and recognizes the increasing need for an integrated approach to human, animal and environmental health. In Canada, policy on the use of animals in science is developed with input from scientific researchers and teachers, veterinarians, animal care staff, regulators and the public. This tradition of consensus-building inspired the WC8 motto “The Three Rs – Together it’s Possible”. The goal of the WC8 is to bridge the distance between science, policy and education by identifying mechanisms to enable effective knowledge transfer and the translation of science-based evidence into good animal practices and non-animal alternatives that will result in higher quality science.

The WC8 brings together close to 900 professionals, including researchers, veterinarians, animal welfare organizations, public representatives, members of institutional animal care and use/ethics committees, and regulatory experts. These participants will join us from more than 50 countries for the unique opportunity to exchange scientific, ethical, and animal welfare knowledge, further progressing the ethical principles of the Three Rs (Refinement, Replacement and Reduction) enunciated by Russell and Burch in 1959.

We are pleased to host the WC8 in Montréal’s most hospitable and gracious hotel — Fairmont The Queen Elizabeth — located at the center of Montréal’s vibrant cultural and commercial district. The hotel reflects Montréal’s elegance and charm. It is connected to the extensive underground city of boutiques, restaurants and cafés and is within walking distance of sports and cultural attractions.

As Co-Chairs of the WC8, we extend a warm welcome to all the participants and accompanying persons. We look forward to an opportunity to reconnect with old acquaintances and to make new friends with a view to working together to advancing Three Rs in science and education.

Sincerely,

Clément Gauthier Executive Director, CCAC

Herman Koëter Managing Director, Orange

House Partnership

WELCOME

WE

LCO

ME

Co-Chairs, Eighth World Congress on Alternatives and Animal Use in the Life Sciences

5

CONGRESS CO-CHAIRS STEERING COMMITTEE ALTERNATIVE CONGRESS TRUST

Clément Gauthier, CanadaHerman Koëter, Belgium

Gilly Griffin, CanadaCoenraad Hendriksen, NetherlandsRobert Kavlock, USAYasuo Ohno, JapanAndrew Rowan, USAAdrian Smith, NorwayMichel Tremblay, Canada

Michael Balls, UKThomas Hartung, USACoenraad Hendriksen, NetherlandsHerman Koëter, BelgiumAndrew Rowan, USAHorst Spielmann, Germany

Emeritus TrusteesAlan Goldberg, USABert van Zutphen, Netherlands

François Auger, CanadaFernando Benavides, USAAndrew Bennett, UKBas Blaauboer, NetherlandsDavid Blakey, CanadaGeoff Dandie, AustraliaFraser Darling, UKDavid Dewhurst, UKSuzanne Fitzpatrick, USAGilly Griffin, Canada (Chair)Carol Howard, USARichard Isbrucker, CanadaMaggy Jennings, UKNick Jukes, UKHajime Kojima, JapanMarcel Leist, GermanyLyne Létourneau, CanadaPaul Locke, USASusanna Louhimies, BelgiumRichard McFarland, USA

David Mellor, New ZealandTsutomu Miki Kurosawa, JapanFrauke Ohl, NetherlandsJon Richmond, UKMerel Ritskes-Hoitinga, NetherlandsVera Rogiers, BelgiumMargaret Rose, AustraliaAdrian Smith, NorwayMartin Stephens, USAWilliam Stokes, USAMark Torchia, CanadaMichel Tremblay, CanadaPatricia Turner, CanadaJan van der Valk, NetherlandsTamara Vanhaecke, BelgiumDan Weary, CanadaCarl Westmoreland, UKHanno Würbel, GermanyJoanne Zurlo, USA

ORGANIZING SECRETARIAT

Eighth World Congress Secretariat1510-130 Albert St.

Ottawa ON CANADAK1P 5G4

email: [email protected]

SCIENTIFIC PROGRAM COMMITTEE

CONGRESS COMMITTEES

CO

NG

RE

SS

CO

MM

ITTEE

S

2011

6

The World Congress Co-Chairs and the Alternatives Congress Trust would like to express their gratitude to all those who are generously supporting the Eighth World Congress on Alternatives and Animal Use in the Life Sciences (WC8).

ACKNOWLEDGEMENTS

AC

KN

OW

LED

GE

ME

NTS

Canadian Association for Laboratory Animal MedicineCanadian Association for Laboratory Animal Science

Canadian Federation of Humane Societies Canadian Veterinary Medical Association

Charles RiverColgate Palmolive

Laboratory Animals LimitedMerck Animal Health

NovozymesSociety of Toxicology

The American Society for the Prevention of Cruelty to AnimalsThe Association of Primate Veterinarians

The European Partnership for Alternative Approaches to Animal Testing The International Council for Laboratory Animal Science

The International Foundation for Ethical Research3R Research Centre, Radboud University Nijmegen Medical Centre

Logos and names of sponsors are reproduced with their permission

GOLD SPONSORS AND BENEFACTORS

SILVER SPONSORS

BRONZE SPONSORS

SUPPORTERS

PLATINUM SPONSORS AND PATRONS OF THE WC8

Our Miss iOn To offer women and men the world over the best quality, most effective, safest cosmetics and thereby satisfy all their beauty needs and desires in all their infinite diversity

Our AMbiTiOn To innovate without recourse to animal testing

Our COnviCTiOnTo invest continuously in science and technology

Our TrusT PACTTo b u i l d t r u s t w i t h s t a k e h o l d e r s

Alternative Strategies forSafety Assessment

2011

8

The Awards Ceremony will take place in Le Grand Salon and Marquette Ballroom on Thursday August 25 from 9:45 to 10:30.

The Humane Society of the United States’ Russell and Burch Award

The Humane Society of the United States (HSUS) presents the Russell and Burch Award in honour of William Russell and Rex Burch who formulated the Three Rs approach. It is awarded to scientists who have made outstanding contributions to the advancement of alternative methods in the areas of biomedical research, testing, or higher education. Recognizing the important role that scientists play in limiting the use and suffering of animals in laboratories, the Award carries a $5,000 prize. Candidates are judged on the scientific merit and impact of their contribution, and their professional commitment to the alternatives field.

Charles River Laboratories’ Excellence in Refinement Award

The Charles River Laboratories’ Excellence in Refinement Award, sponsored by Charles River’s Commitment to Humane Animal Research Through Excellence and Responsibility (CHARTER) Program in cooperation with the John’s Hopkins Center for Alternatives to Animal Testing (CAAT), honours an individual who has made an outstanding contribution to the development, promotion and/or implementation of refinement alternatives. This award is based on the conviction that the humane care of laboratory animals is both a moral imperative and a scientific necessity. The Award includes $5,000 to further the recipient’s scientific endeavours.

Johns Hopkins Center for Alternatives to Animal Testing Recognition Award

The Johns Hopkins Center for Alternatives to Animal Testing (CAAT) Award, presented at every World Congress on Alternatives and Animal Use in the Life Sciences, honours an organization or individual who has made an outstanding contribution to the field of the Three Rs, the development of alternative methods, or the field of in vitro science.

Henry Spira Award

The Henry Spira Award was established in 1999 to honour the memory of Henry Spira, a pioneer in the animal rights movement whose campaign for the use of alternative methods led to the founding of CAAT. The Award was created to honour animal activists in the animal welfare, protection, or rights movements who work to achieve progress through dialogue and collaboration.

Doerenkamp-Zbinden Foundation Awards

The origins of the Doerenkamp-Zbinden Foundation (DZF) lie in the award of a yearly prize for distinguished services to animal protection in science. Next to scientists, persons in the fields of animal protection or philosophy and public persons may be awarded the DZ Prize in so far as they have distinguished themselves in the sense of replacement and reduction of animal experiments. The 2011 prize is bestowed with CHF 25,000.

Dieter Lütticken Award

Merck Animal Health, a leading animal health company, offers the Dieter Lütticken Award to promote scientists or life science research institutions working in research areas that serve the Three Rs concept i.e. reducing, refining or replacing the use of animals in testing for development and production of veterinary medicines. The total funding for the award is €20,000 and will be presented during the Award Ceremony.

Dr. Ethel Thurston Scholarships

The American Fund for Alternatives to Animal Research (AFAAR) (alternativestoanimalresearch.org) has awarded two scholarships of $2,100 each to doctoral students of merit who demonstrate a commitment to A

WA

RD

S A

ND

GR

AN

TS

AWARDS AND GRANTS

9

and priority interest in replacing the use of animals in research and teaching. The Awards are in support of their participation in the WC8 and are made under the direction of the New England Anti-Vivisection Society to honour AFAAR’s founder, the late Dr. Ethel Thurston.

Willy van Heumen Award on Alternatives

The Willy van Heumen Award is a €25,000 prize offered every two years by the Foundation for the Advancement of Animal Alternatives. This Foundation is based in the Netherlands. The name of the prize refers to the Foundation’s founder. Candidates for the Award are selected in close cooperation with ZonMw, the major grant-giving organization in the field of medical research in the Netherlands.

The Eighth World Congress on Alternatives and Animal Use in the Life Sciences Travel Grants

The WC8 has provided 24 Travel Grants to students and young scientists whose abstracts have been selected for either oral or poster presentation. These WC8 Travel Grants (covering registration fee, hotel accommodation and travel expenses) were awarded based on (i) the quality of the work proposed for the oral or poster presentation; and (ii) the particular needs expressed by the applicant.

The Eighth World Congress on Alternatives and Animal Use in the Life Sciences Poster Awards

Six poster awards will be presented during the plenary session on Thursday August 25, 2011. Recipients of the $1,000 CAD awards will be selected during the WC8 by members of the Alternatives Congress Trust. An award will be given to one poster in each of the WC8 Themes (except for Theme I where two awards will be given because of the large number of posters to be presented). The selection committee will select the awardees based on the quality of the presentation, the scientific merit of the work on which the poster is based, and the contribution of the work to further the implementation of Replacement, Reduction or Refinement of animal use. These Awards have been made possible through the generous support of the Doerenkamp-Zbinden Foundation.

AW

AR

DS

AN

D G

RA

NTS

a formula for progress

Chimpanzees are complex, long-lived creatures who share 96 percent

of our DNA. Yet while their emotional needs and capacity for suffering

are much like our own, the immunological and physiological differences

between us make them poor models for human disease research.

There are better alternatives. That’s why more than 700 researchers,

scientists and health professionals have signed in support of efforts to end

the use of chimps in harmful research and testing in the United States, and

to provide permanent sanctuary to chimpanzees currently in laboratories.

Join them. Sign on at humanesociety.org/supportchimps. PRACTICAL INFORMATION

11

Montréal is often described as a Parisian New York but it is a spirited, bold and complex mix of contrasts that completely defies comparison. Montréal’s renowned duality of Old World charm infused with North American energy lies at its very heart; however, it is the plurality of cultures that really makes this metropolis tick.

A shutterbug’s dream, you could snap away at warp speed and capture a new story with every click. It doesn’t matter where you go on the island; every neighborhood is different. Montréal is as romantically traditional as it is cutting-edge innovative, as cosmopolitan dynamic as it is small-town friendly. Yet despite this diversity, an underlying homogeneity exists in this vibrant population who collectively and confidently “live and let live”.

Official Languages

French and English. The majority of people in Montréal are bilingual.

Currency

Financial institutions will provide a rate of exchange when switching your currency for Canadian dollars.

Credit Cards

All major credit cards are widely accepted throughout Montréal and Canada. Bank machines can be found everywhere and debit cards are widely used. If using a foreign debit card at a bank machine, your money will be disbursed in Canadian funds.

Electrical Current

110-120 Volts, 60 cycles AC

Water

Canadian tap water is among the cleanest in the world and is very safe to drink.

Climate

In August, the climate is very pleasant in Montréal, with a mean temperature of 26.3 °C (max. 34.2 °C and min. 18.3 °C) and a mean relative humidity of 58%.

Clothing

Casual wear is acceptable most of the time. Some Montréal establishments (nightclubs and bars) have a ‘no jeans, no running shoes policy,’ and certain dining rooms require men to wear jackets to dinner.

Tipping

Tips, gratuities or service charges are not usually automatically added to a bill in Canada. In general, a tip of up to 15% of the sub-total (before taxes) is given. This applies to waiters, waitresses, barbers, hairdressers, taxi drivers, etc. At hotels, airports and railway stations, bellhops, doormen, redcaps (porters), etc. are generally paid $1-$2 per item of luggage.

Shopping - Rue Ste-Catherine

Rue Ste-Catherine is located two blocks north of the hotel and is one of the best-known streets in Montréal. Situated in the hub of the city, it is accessible from the hotel by the underground passage. The following shopping outlets and services are all within walking distance from the Fairmont The Queen Elizabeth: Place Ville Marie, Eaton Centre, Montréal Trust Shopping Centre, Promenades de la Cathédrale Shopping Centre, Complexe Les Ailes, La Baie Department Store, Birks Jewelers, Les Cours Mont-Royal, Ogilvy and Holt Renfrew.

PRACTICAL INFORMATION

ABOUT MONTRÉAL

AB

OU

T MO

NTR

ÉA

L

2011

12

Botanical Garden and Insectarium

Montréal’s Botanical Garden is the second largest botanical garden in the world. It features plant and animal species from all over the planet. The Insectarium is a section of the Botanical Gardens with a butterfly pavilion, and a collection of 25,000 insects on display. The Botanical Garden is located a 10 minute walk from the Fairmont the Queen Elizabeth. For more information, call 514-868-3000.

Bell Centre (Le Centre Bell)

The Bell Centre is home to the National Hockey League’s Montréal Canadiens. It is a five minute walk from the hotel. Le Centre Bell offers guided tours in French and English.

Six Flags La Ronde Amusement Park

This amusement park features 35 different rides, with something for every member of the family. It is located on Ile Ste-Hélène, about a 15 minute drive from the Fairmont Queen Elizabeth. It is also accessible via subway. It is open from mid-May to September. For more information, call: 1-800-797-4537 or 514-872-4537.

Montréal Casino

The Montréal Casino is one of the largest casinos in the world. It captures all the excitement, drama, and international allure of the world class city that is its home: Montréal. Likewise, the casino spares no effort to ensure you the thrill of a lifetime and unforgettable memories.

Mount Royal

Mount Royal is a small mountain and park overlooking the city, which offers great views from several scenic points. Those who enjoy strolling in nature will appreciate Mount Royal’s many paths. Bird watching is possible at the bird sanctuary. It is also the home of the Université de Montréal, the second largest French-language university in the world. On top of the mountain, St. Joseph’s Oratory of Mount Royal is worth visiting.

Old Montréal

Discover the city’s oldest district with its wealth of history and architecture that is unique in North America and features a variety of museums, boutiques, art galleries and restaurants. Other sightseeing opportunities and attractions in the old port include IMAX (3-D movies on a giant screen), bateau mouche cruises, and the site of several summer and winter festivals. There is also the SOS Labyrinth (Mayaventura) which is great for kids, cycling, rollerblading and the Lachine Canal with its 8.7 miles (14 km) of recreational paths. Old Montréal is located about a five minute walk from the Fairmont The Queen Elizabeth.

Olympic Stadium

Across the street from the Botanical Garden, the Olympic Stadium is located about 15 minutes away from Fairmont The Queen Elizabeth and is easily accessible by subway. Visit the Montréal Tower Observatory, located in the highest inclined tower in the world, with its 175 metre elevation and 45-degree angle. Also on-site is the Biodôme, an oasis in the heart of the city. The Montréal Biodôme recreates some of the most beautiful ecosystems of the Americas. For more information on these attractions, call: 514-252-4141.

AB

OU

T M

ON

TRÉ

AL


13

Fairmont The Queen Elizabeth

Fairmont The Queen Elizabeth is at the center of Montréal’s vibrant cultural and commercial district. It is located above the train station and connected to the extensive underground city of boutiques, restaurants and cafés, and is within walking distance of sports and cultural attractions.

900 René Lévesque Blvd. W, Montréal, Quebec, Canada, H3B 4A5 Tel: 1-866-540-4483 (toll free) or 514-861-3511(local number)

Breakfasts

Continental breakfast will be provided free of charge to all registered WC8 participants on Monday August 22, Tuesday August 23, Wednesday August 24 in the Congress hallway. On Thursday August 25, it will be served in Hochelaga 1-6.

Lunches

Box lunches will be distributed free of charge in Le Grand Salon to all registered WC8 participants on Monday August 22, Tuesday August 23 and Wednesday August 24. Relevant coupons will be inserted in name badge holders.

Refreshment Breaks

Light refreshments will be available free of charge to all registered WC8 participants on Monday August 22, Tuesday August 23, Wednesday August 24 and Thursday August 25.

Attendance Certificates

Certificates of attendance will be distributed along with name badge holders at the registration desk on the Mezzanine level upon arrival.

Internet Access

An internet kiosk will be available in the Congress hallway throughout the WC8 Internet access is also available in all guest rooms at a cost of $16.00 a day. Internet access is free of charge to all Fairmont President Club Members.

Language

The official language of the WC8 is English. Simultaneous translation will not be provided.

No-smoking

Smoking in the WC8 area is not allowed.

GENERAL INFORMATION

GE

NE

RA

L INFO

RM

ATION


2011

14

GE

NE

RA

L IN

FOR

MAT

ION

Cell Phones

Participants are kindly requested to turn off or switch their cell phones to silent mode in the rooms where scientific sessions are held.

Montréal Tourist Kiosk

The tourist kiosk is located on the Mezzanine level and is open at the following times: Sunday, August 21 14:00 – 21:00 Monday, August 22 7:30 – 10:30 Tuesday, August 23 13:00 – 19:00

Insurance

The Organizing Secretariat cannot accept liability for personal injuries sustained or for the loss of, and/or damage to, property belonging to WC8 participants, either during or as a result of the WC8.


15

Registration Desk

Location: Mezzanine level

The on-site registration desk is open during the following times:

Sunday, August 21 15:00 – 19:00 Monday, August 22 7:00 – 18:00 Tuesday, August 23 7:00 – 18:00 Wednesday, August 24 7:00 – 18:00

Registration Fees (Excluding Applicable Taxes)

Please note all fees are in Canadian dollars.

Full Participation $950.00 Full Participation - Students/Young Scientists $700.00 Accompanying Person $475.00 Accompanying Person + Gala Dinner $625.00 1 Day Registration $350.00 1 Day Registration + Gala Dinner $500.00

What is Covered by the Registration Fees?

Full Participation includes access or admission to:• opening and closing ceremonies• satellite meetings, Sunday, August 21 (pre-registration required)• all scientific events• exhibition• Welcome Cocktail, Sunday, August 21• breakfasts and light lunches on Monday, Tuesday and Wednesday, August 22 – 24

• Get-Together Party, Monday, August 22

• Gala Dinner, Wednesday, August 24Registration for Accompanying Persons includes access or admission to:• opening and closing ceremonies• breakfasts and light lunches on Monday, Tuesday and Wednesday, August 22 – 24 • exhibition • Get-Together Party, Monday, August 221 Day Registration includes access or admission to: • scientific events on that day• breakfast and lunch for that day• relevant social activities (excluding the Gala Dinner).The registration fee does not include accommodation and travel costs.

Payment

On-site payment for registration should be made at the Registration Desk, located on the Mezzanine level, by credit card (American Express, Visa, MasterCard and Diners Club are accepted).


RE

GIS

TRATIO

N

REGISTRATION

2011

16

Information for Chairs

Please refer to the Index of Chairs and Presenters and the Scientific Sessions to confirm the date, location and time of your session. Session rooms should be located in advance and Chairs should arrive at least fifteen minutes before the session starts. Please respect the time allotted to each presentation to ensure the sessions flow smoothly. An information session for Chairs will be held in the Mackenzie room on Sunday, August 21 at 17:30 to 18:30.

Information for Oral Presenters

Please refer to the Index of Chairs and Presenters and the Scientific Sessions to confirm the date, location and time of your session. Please arrive at least fifteen minutes before your session starts.

Each session room will be provided with a laptop. The use of personal laptops should be avoided since it may cause delays and technical problems.

Presenters will have access to computers in the Yamaska room to work on their PowerPoint presentation prior to their session. Please verify that your presentation is uploaded no less than 3 hours before the session in which you are speaking.

Information Regarding Poster Display

Posters will be presented according to theme in Hochelaga 4-5-6 on Monday, Tuesday and Wednesday. Please refer to the chart below for set up, display and dismantling times for each theme.

Each poster was assigned a number upon submission of the abstract and should be mounted on the board marked with the same number. It is the responsibility of the individual to set up and dismantle their poster at specified times, as indicated below. Push-pins and Velcro can be used to attach posters to the soft surface provided.

Information for Exhibitors

Exhibitor booths will be located in Hochelaga 1-2-3 on Monday, Tuesday and Wednesday. Please refer to the chart below for set up, display and dismantling times.

Each exhibitor was assigned a specific booth number. Please refer to the Exhibiting Companies and Associations page to confirm the specific location of your booth(s). It is the responsibility of the individual(s) to set up and dismantle their booth(s) on specified times, as indicated below.

Refreshments will be served in the exhibition area on Monday, Tuesday and Wednesday, to encourage visibility.

INFORMATION FOR CHAIRS, PRESENTERS AND EXHIBITORS

THEME SET UP TIME DISPLAY TIME DISMANTLING TIMEI Monday, August 22, 17:30-19:30 Tuesday, August 23, 7:30-15:15 Tuesday, August 23, 15:15-17:15

II Sunday, August 21 15:00-20:00 Monday, August 22, 7:30-15:45 Monday, August 22, 15:45-17:30

III Sunday, August 21, 15:00-20:00 Monday, August 22, 7:30-15:45 Monday, August 22, 15:45-17:30

IV Tuesday, August 23, 17:15-19:15 Wednesday, August 24, 7:30-15:15 Wednesday, August 24, 15:15-19:15

V Tuesday, August 23, 17:15-19:15 Wednesday, August 24, 7:30-15:15 Wednesday, August 24, 15:15-19:15

SET UP TIME DISPLAY TIME DISMANTLING TIMESunday, August 218:00 – 14:00

Monday, August 22Tuesday, August 23Wednesday, August 247:30 – 18:00

Wednesday, August 2418:00 – 21:00

GES Canada/Clarkson-Conway is the official service contractor for exhibitor booths. Their service center staff will be available in the exhibition area throughout the WC8 to assist exhibitors.

INFO

RM

ATIO

N F

OR

CH

AIR

S, P

RE

SE

NTE

RS

AN

D E

XHIB

ITO

RS


17

CONVENTION FLOOR PLAN


CO

NV

EN

TION

FLOO

R P

LAN

“Eliminating animal testing is an ambitious goal, but working together...can make this goal a reality.”

19

“Eliminating animal testing is an ambitious goal, but working together...can make this goal a reality.”

Welcome Cocktail

Sunday, August 21, 19:00 to 20:00Location: Congress hallway

All WC8 participants and attendees are invited.

Get-Together Party – Celebration of CAAT’s 30th Anniversary

Monday, August 22, 19:00 to 22:00 Location: Bonsecours Market, Old Montréal Main sponsor: The Johns Hopkins Center for Alternatives to Animal Testing (CAAT)

Please join us for a celebration of CAAT’s 30th birthday!

This event will be held at De La Commune Hall, located in the magnificent Bonsecours Market, overlooking the majestic St. Lawrence River. Inaugurated in 1847, Bonsecours Market is widely recognized as one of Canada’s ten finest heritage buildings and is a celebrated landmark.

Buffet tables will feature products from the Province of Québec and entertainers will be engaging with the participants to make this evening a memorable one!

Buses will depart at the corner of Mansfield and René-Lévesque and will transport participants to and from the celebration site. Buses will continuously pick up participants at the hotel and bring them to the Bonsecours Market from 18:30 until 19:30. Buses will take participants back to the hotel from 21:15 to 22:15.

This event is included in all registration fees.

Gala Dinner

Wednesday, August 24, 19:30 to 23:00 Location: Windsor Station, 1100 Avenue des Canadiens-de-MontréalWindsor Station, built between 1887 and 1889, is now a designated national historic site. It is within walking distance (5 minutes) of Fairmont The Queen Elizabeth.

Extra tickets for the Gala dinner can be purchased for accompanying persons and one-day registrants at the on-site registration desk.

SOCIAL PROGRAM

SO

CIA

L PR

OG

RA

M

SOCIAL PROGRAM

2011

20

PROGRAM OVERVIEW

The WC8 ims to bridge the distance between science and policy and to identify opportunities for collaborations through a dynamic program.

The program includes:

Theme I - Safety and Efficacy Testing of Chemicals, Pharmaceuticals and Biologicals • International developments in the Three Rs and regulatory testing• Alternative method development, including pharmaceuticals and biologics• Translation of data from high throughput tests to risk assessment

Theme II - Policy/Law on Animal Use, Public Engagement and Ethics Review • Public participation in animal policy decision making • Use of policy and regulations to implement the Three Rs• Setting limits and resolving conflicts between the Three Rs

Theme III - Incorporation of the Three Rs in Education and Training • Alternatives to using animals in teaching and training• Evaluating the pedagogical merit of using animals

Theme IV - Animal Welfare for Refinement and High Quality Science • Linking the Three Rs to animal welfare• Farm animal welfare and the Three Rs• Wildlife welfare and the Three Rs

Theme V - Replacement and Reduction in Basic Research • Emerging science and the potential for replacement in biomedical research• Systems biology as the future approach to understanding human (and animal) diseases• Systematic review of animal experiments

Throughout this program, scientific and poster sessions are color-coded based on their placement within these five themes.

PR

OG

RA

M O

VE

RV

IEW

SCIENTIFIC PROGRAM

21

SUNDAY, AUGUST 21, 2011 (PRE-CONGRESS SATELLITE MEETINGS)

Reduction and Refinement Through Good Design and Monitoring

Location: DuluthTime: 9:00 – 17:00Organizer: Canadian Council on Animal Care

Alternatives to the Pertussis Test

Location: MackenzieTime: 12:30 – 17:00Organizer: Health Canada

21st Century Toxicology: Updates on Current Efforts

Location: Harricana Time: 9:00 – 12:00Organizer: The Humane Society of the United States

Animal Protection Satellite Meeting

Location: Harricana Time: 13:00 – 17:00 Organizers: The Center for Alternatives to Animal Testing (CAAT) and the Human Toxicology Project

Consortium

Meeting of Three Rs Organizations (closed meeting)

Location: BersimisTime: 13:00 – 15:00 Organizer: The Center for Alternatives to Animal Testing (CAAT)

The CeeTox Repeat Dose Systemic Toxicity Panel

Location: Bersimis Time: 17:00 – 18:00, followed by a receptionOrganizer: CeeTox, Inc.

Other events taking place on Sunday, August 21

• Welcome Cocktail: Refer to the Social Program, page 19 • Exhibitor booths set up: Refer to the Information for Chairs, Presenters and Exhibitors, page 16 and the

Exhibiting Companies and Associations, page 105• Poster presentations set up: Refer to the Information for Chairs, Presenters and Exhibitors, page 16• Information session for Chairs: Refer to the Information for Chairs, Presenters and Exhibitors, page 16

PR

OG

RA

M O

VE

RV

IEW

SU

ND

AY, AU

GU

ST 21, 2011

SCIENTIFIC PROGRAM

2011P

RO

GR

AM

OV

ER

VIE

W

SCIENTIFIC PROGRAM22

TIME LE GRAND SALON MARQUETTE

JOLLIET DULUTH MACKENZIE

7:30 - 9:00

9:00 - 9:15 Opening Ceremonies

9:15 - 10:00 Plenary 1Living the good life – how far can Refinement go?

10:00 - 10:15 BREAK

10:15 - 12:15 Scientific Session I-1Potency and safety testing of human vaccines

Scientific Session I-2Addressing systems toxicology

Scientific Session II-2Ethics review

12:15 - 12:45 LUNCH

12:45 - 14:00 Additional Session I-18Report on the ICCVAM International workshop on vaccines

Additional Session I-14 Comparing the challenges of implementing new non-animal methods in the US and Europe

14:00 - 15:30 Scientific Session I-7Potency and safety testing of veterinary vaccines

Scientific Session I-8Safety testing for chemically-induced eye injuries: Recent Three Rs advances

Scientific Session II-1Public accountability

15:30 - 15:45 BREAK

15:45 - 16:45 Additional Session I-16Alternatives for potency testing for rabies

II-1 continued

16:45 - 17:30 Plenary 2Engineering performance or performing engineering standards? Globalization and the application of the Three Rs

19:00 - 22:00 GET-TOGETHER PARTY - Bonsecours Market, Old Montréal

MO

ND

AY, A

UG

US

T 22

, 201

1

MONDAY, AUGUST 22, 2011PROGRAM OVERVIEW

PR

OG

RA

M O

VE

RV

IEW


HARRICANA CHAUDIÈRE MATAPÉDIA

BERSIMIS PÉRIBONKA RICHELIEU

SAINT-LAURENT GATINEAU

SAINT- FRANÇOIS

(LOBBY)

HOCHELAGA SAINT-MAURICE

1-3 4-6

Altweb Project Team Meeting (closed)

Exhibition

Theme II poster session

Theme III poster session

BREAK

Multim

edia exhibition

Scientific Session III-1Innovative teaching in the life sciences

Scientific Session IV-1Indicators of animal welfare to implement refinement

Scientific Session V-1Novel methodologies and their potential in vitro application for drug development and safety assessment

Additional Session II-9The EPAA, a model for private-public partnerships supporting the advancement of Three R approaches

Additional Session IV-9National cancer institute guidelines – a tool for implementing more humane endpoints?

Scientific Session III-6Training animal-based scientists

Scientific Session IV-2Farm animal research and the Three Rs

Scientific Session V-2Systematic reviews of animal experiments

Additional Session II-7The role of partnerships in advancing the Three Rs - Together it’s possible!

BREAK

III-6 continued (panel discussion)

IV-2 continued V-2 continued II-7 continued

GET-TOGETHER PARTY - Bonsecours Market, Old Montréal

MO

ND

AY, AU

GU

ST 22, 2011

2011P

RO

GR

AM

OV

ER

VIE

W


TIME LE GRAND SALON MARQUETTE

JOLLIET DULUTH MACKENZIE

7:30 - 8:30

8:30 - 9:30 Plenary 3Implementing the Three Rs through policy – The EU Directive

9:30 - 9:45 BREAK

9:45 - 12:00 Scientific Session I-3 Biological and biotechnology-based therapeutics

Scientific Session I-4Validation and Three Rs strategies for assessment of endocrine-active substances

Scientific Session II-3Public law – the Three Rs in regulation addressing animal use

12:00 - 12:30 LUNCH

12:30 - 13:45 Additional Session II-8 Science and politics in food safety assessment and their impact on experimental animal use

13:45 - 15:00 Scientific Session I-9Advances in Three Rs alternatives for reproductive and developmental toxicity

Scientific Session I-11Three Rs approaches to skin sensitization

Scientific Session II-4 Implementing the Three Rs – alternatives to legislation

15:00 - 15:15 BREAK

15:15 - 16:15 Additional Session I-15Shellfish toxin testing: how are the Three Rs being progressed in this field?

16:15 - 17:15 Plenary 4A challenge to the ultimate Three Rs – in silico approach to evaluate chemical safety for humans

TUE

SD

AY, A

UG

US

T 23

, 201

1

TUESDAY, AUGUST 23, 2011PROGRAM OVERVIEW

PR

OG

RA

M O

VE

RV

IEW


HARRICANA CHAUDIÈRE MATAPÉDIA



SAINT- FRANÇOIS

(LOBBY)


1-3 4-6

Exhibition

Theme I poster session

BREAK

Multim

edia exhibition

Scientific Session III-3 Development of non-animal teaching/training models

Scientific Session IV-3 Wildlife science and the Three Rs

Scientific Session V-3 Cell culture and tissue engineering

Additional Session I-13 Toxicity testing in the 21st century (Tox21)

Additional Session II-10 Role of international bodies in spreading Three Rs efforts globally

Additonal Session V-9 Improving reporting of animal-based research

Scientific Session III-4 Replacement alternatives and teaching objectives – determining if and when student learning objectives require the use of an animal

Scientific Session IV-4 Multi-imaging modalities, telemetry and the Three Rs

Scientific Session V-4 Refinement and Reduction in the use of genetically-engineered animals

I-13 continued

BREAK

Additional Session IV-7 VET2011: Advancing animal welfare training for veterinarians

V-4 continued I-13 continued

TUE

SD

AY, AU

GU

ST 23, 2011

2011P

RO

GR

AM

OV

ER

VIE

W


TIME LE GRAND SALON

MARQUETTE

JOLLIET DULUTH MACKENZIE HARRICANA CHAUDIÈRE MATAPÉDIA

7:30 - 8:30

8:30 - 9:30 Plenary 5Alternative training methods for clinical education – considerations

9:30 - 9:45 BREAK

9:45 - 12:00 Scientific Session I-5 Nanotoxicology and the Three Rs

Scientific Session I-6Advances in alternative methods for ecotoxicology

Scientific Session II-5Validation of Three Rs alternative methods

Scientific Session III-5 Introducing multi-media to the curriculum

12:00 - 12:30 LUNCH

12:30 - 13:45 Additional Session 1-17Update on new in vitro models for detection and potency assessment of botulinum neurotoxin

13:45 - 15:00 Scientific Session I-10Safety testing for carcinogenicity and genetic toxicity: recent Three Rs advances

Scientific Session I-12Epigenetics and its increasing relevance in toxicology and risk assessment

Scientific Session II-6Setting limits and resolving conflicts between the Rs

Scientific Session III-2 Innovative training in human and veterinary medicine

15:00 - 15:15 BREAK

15:15 - 16:15 Additional Session II-11 The International Cooperation on Alternatives Test Method

II-6 continued

16:15 - 17:15 Plenary 6Pursuing Medawar’s challenge for full Replacement

19:30 - 23:00 Gala Dinner - Windsor Station

WE

DN

ES

DAY

, AU

GU

ST

24, 2

011

WEDNESDAY, AUGUST 24, 2011PROGRAM OVERVIEW

PR

OG

RA

M O

VE

RV

IEW




SAINT- FRANÇOIS

(LOBBY)


KAMOURASKA 1-2 (3RD FLOOR)

1-3 4-6

Exhibition

Theme IV poster session

Theme V poster session

BREAK

Multim

edia exhibition

BREAK

Scientific Session IV-5Can pain research benefit research animals?

Scientific Session V-5 Developments in stem cell research as the basis for sustainable availability of differentiated human cells and tissues

Additional Session V-7Relevance, reproducibility and robustness – the other Three Rs important to science and animal welfare (SCAW)

Additional Session IV-8 Ending severe pain and distress in animal experiments by 2025?

Additional Session V-8(a)Tutorial for Go3Rs search engine

Scientific Session IV-6 Broadening the application of Refinement

Scientific Session V-6 Animal reduction through the better use of mechanistically-

Additional Session I-19 Toxicity testing strategies – progress in skin sensitization testing (COLIPA)

BREAK BREAK

based translational animal disease models

Additional Session V-8(b)Tutorial for Go3Rs search engine

Gala Dinner - Windsor Station

WE

DN

ES

DAY, A

UG

US

T 24, 2011

2011

28

Breakfast will be available in Hochelaga 1-6 from 7:30 to 8:30

Plenary Session 7 – Concluding Messages

Time: 9:00 – 9:45Location: Le Grand SalonChair: Gilly GriffinTheme I — Safety and Efficacy Testing of Chemicals, Pharmaceuticals and BiologicalsTheme II — Policy/Law on Animal Use, Public Engagement and Ethics ReviewTheme III — Incorporation of the Three Rs in Education and TrainingTheme IV — Animal Welfare for Refinement and High Quality Science Theme V — Replacement and Reduction in Basic Research

Award Ceremony

Time: 9:45 – 10:30Location: Le Grand Salon Refer to the Awards and Grants page.

Coffee Break

Time: 10:30-10:45Location: Congress hallway

Plenary Session 8 – Presentation of the Montréal Declaration

Time: 10:45 – 11:15Location: Le Grand SalonCo-Chairs: Herman Koëter, Brussels, Belgium Clément Gauthier, Ottawa, Canada

WC9 Presentation

Time: 11:15 – 11:30Location: Le Grand SalonWC9 Co-Chairs: Dagmar Jírová, Šrobárova, Czech Republic Horst Spielmann, Berlin, Germany

Closing Ceremonies

Time: 11:30 – 11:45Location: Le Grand SalonWC8 Co-Chairs: Herman Koëter, Brussels, Belgium Clément Gauthier, Ottawa, Canada

THU

RS

DAY

, AU

GU

ST

25, 2

011

THURSDAY, AUGUST 25, 2011PROGRAM OVERVIEW

PR

OG

RA

M O

VE

RV

IEW

SCIENTIFIC PROGRAM

SC

IEN

TIFIC S

ES

SIO

NS


MO

ND

AY, AU

GU

ST 22, 2011

MONDAY, AUGUST 22, 2011SCIENTIFIC SESSIONS

Altweb Project Team Meeting

Location: Saint-LaurentBy invitation

Opening Ceremonies

Location: Le Grand Salon

9:15 – 10:00

Plenary Session 1 Living the good life – how far can Refinement go?

Location: Le Grand Salon Chair: Andrew Rowan, Washington DC, USA

• Plenary Speaker: Dan Weary Vancouver, Canada

10:15 – 12:15

Session I-1 Potency and safety testing of human vaccines

Location: Jolliet Co-Chairs: Coenraad Hendriksen, Bilthoven, Netherlands Maria Baca-Estrada, Ottawa, Canada

• I-1-107: EDQM’s Three Rs activities in the field of quality control of vaccinesC. MilneStrasbourg, France

• I-1-048: Development of 3Rs alternatives for determining potency and toxicity of vaccines in Cuba: current challenges and research projects in progressM.L.C. CuervoHavana, Cuba

• I-1-167: Three Rs acceptance and implementation: obstacles and opportunities for new technologyM. Long1, M.-J. Schiffelers2

1Ottawa, Canada; 2Utrecht, Netherlands

• I-1-672: The consistency approach in lot release testing of vaccinesC. HendriksenBilthoven, Netherlands

• I-1-148: Alternative safety testing strategy for acellular pertussis vaccines R. IsbruckerOttawa, Canada

7:30 – 9:00

9:00 – 9:15

9:15 – 10:00

10:15 – 12:15

2011S

CIE

NTI

FIC

SE

SS

ION

S


MO

ND

AY, A

UG

US

T 22

, 201

1

10:15 – 12:15

• I-1-326: Alternatives to animal use for the LAL-assayI. SpreitzerLangen, Germany

Session I-2 Addressing systems toxicology

Location: Duluth Chair: Paul Jennings, Innsbruck, Austria Hans Raabe, Gaithersburg, USA

• I-2-460: Integrated testing strategies and in vitro-in vivo extrapolations: their role in chemical risk assessments B.J. BlaauboerUtrecht, Netherlands

• QSAR Application Toolbox: practical application for predicting skin sensitization and repeated dose toxicityO. MekenyanBourgas, Bulgaria

• I-2-218: Human multi-organ chips — a possible solution for animal free systemic ADMET testingG. LindnerBerlin, Germany

• I-2-231: Long term Cyclosporin A increases transepithelial electrical resistance in renal proximal tubule monolayers: a possible role of claudin rearrangementP. JenningsInnsbruck, Austria

• I-2-237: Cardiac safety testing of human pharmaceuticals using fresh human tissueS. LynaghGlasgow, UK

• I-2-110: Challenges and solutions associated with transfer of in vitro cellular monolayer techniques to 3-D tissue modelsR. CurrenGaithersburg, USA

Session II-2 Ethics review

Location: Mackenzie Co-Chairs: Gilles Demers, Ottawa, Canada Virginia Williams, Wellington, New Zealand

• II-2-649: Ethical review of animal experiments: current practice and future challengesM. JenningsHorsham, UK

10:15 – 12:15

SC

IEN

TIFIC S

ES

SIO

NS


MO

ND

AY, AU

GU

ST 22, 2011

• II-2-553: Ethical review of the use of animals in science — a reflection on the journey and future directions M. RoseSydney, Australia

• II-2-555: The costs and benefits of animal experimentsA. KnightLondon, UK

• II-2-084: A New Zealand commitment to continuous improvement in AEC decision-making: giving operational effect to key principlesV. WilliamsWellington, New Zealand

Session III-1 Innovative teaching in the life sciences

Location: Harricana Co-Chairs: David Dewhurst, Edinburgh, UK Pilar Vinardell, Barcelona, Spain

• III-1-101: Is animal-free teaching in the life sciences better teaching? D. DewhurstEdinburgh, UK

• III-1-062: Challenges of using alternatives to animals in laboratory classes in physiology: the Spanish experienceM.P. VinardellBarcelona, Spain

• III-1-205: Alternatives to animals in teaching: experience in an Indian medical schoolR. RaveendranPondicherry, India

• III-1-413: Animal use in pharmaceutical drug discovery and development – current status and future directionsE. ChenKing of Prussia, USA

• III-1-448: Educating the next generation of in-vivo scientists: meeting the needs of industry & academiaD.I. LewisLeeds, UK

10:15 – 12:15

2011S

CIE

NTI

FIC

SE

SS

ION

S


10:15 – 12:15

MO

ND

AY, A

UG

US

T 22

, 201

1

10:15 – 12:15

Session IV-1 Indicators of animal welfare to implement refinement

Location: Bersimis Co-Chairs: David Mellor, Palmerston North, New Zealand Marilyn Brown, Wilmington, USA

• IV-1-072: Affective states and the assessment of laboratory-induced animal welfare impacts D. MellorPalmerston North, New Zealand

• IV-1-610: The sensitivity of animals and application of the Three RsM. BrownWilmington, USA

• IV-1-609: Reliance on behaviour as a metric of animal welfareK. BayneFrederick, USA

• IV-1-069: Complementary roles for systematic analytical evaluation and qualitative whole animal profiling in welfare assessment for Three Rs applicationsN. BeausoleilPalmerston North, New Zealand

• IV-1-520: Behaviour changes during rat euthanasia may be a poor indicator of aversionI.J. MakowskaVancouver, Canada

• IV-1-490: Impact of simple environmental improvements on affective behavior, physiology and immune system reactivity of C57BL/6 and BALB/c miceP.V. TurnerGuelph, Canada

Session V-1 Novel methodologies and their potential in vitro application for drug development and safety assessment

Location: Saint-Laurent Co-Chairs: Yasuo Ohno, Tokyo, Japan Marcel Leist, Konstanz, Germany

• V-1-353: A novel platform for automated production and screening of scaffold-free organotypic microtissuesM. DrewitzHannover, Germany

• V-1-400: The application of pattern recognition data mining and knowledge discovery for systems to replace rodent models in fundamental researchB.A. LidburyCanberra, Australia

SC

IEN

TIFIC S

ES

SIO

NS


MO

ND

AY, AU

GU

ST 22, 2011

10:15 – 12:15

• V-1-430: Plants as animals’ alternatives in the production of antibodies and other therapeutic agentsA.S. AfolabiAbuja, Nigeria

• V-1-584 Organotypic in vitro human epithelial models (EpiAirway, EpiDerm-FT) with engineered toxicologic reporter functionsP.J. HaydenAshland, USA

• V-1-617 Optimized 1- and 3-diminesional isolation and expansion of multipotent human adipose tissue-derived stem cells: evaluation of their multipotencyE. RamboerBrussels, Belgium

• V-1-372 A mechanistic rationale for the prediction of skin irritancy effects implemented in a workflow processC. YangColumbus, USA

Additional Session II-9 The EPAA, a model for private-public partnerships supporting the advancement of Three R approaches – an EPAA supported session

Location: Saint-François Chair: Cornelis Brekelmans, Brussels, Belgium

• II-9-692: EPAA, a public-private partnership and its role within the EU policy on alternative approachesC. BrekelmansBrussels, Belgium

• II-9-693: EPAA’s role in promoting alternatives for meeting regulatory requirements for safety and potency assessment of vaccinesJ. DescampsBrussels, Belgium

• II-9-694: EPAA communication policy and its virtual «market place» J. KreysaIspra, Italy

• II-9-695: 2010 EPAA Science Award: proofing the relevance of the Ex Vivo Eye Irritation Test (EVEIT) as a self-contained in vitro substitute for the Draize Eye Irritation Test F. SpölerAachen, Germany

• II-9-696: Round table on public-private initiatives in other regions; potential for cooperationO. de SilvaAulnay-sous-Bois, France

2011S

CIE

NTI

FIC

SE

SS

ION

S


MO

ND

AY, A

UG

US

T 22

, 201

1

12:45 – 14:00

12:45 – 14:00

12:45 – 14:00

Additional Session I-14 Comparing the challenges of implementing new non-animal methods in the US and Europe: supported jointly by ESTIV and ASCCT

Location: Mackenzie Chair: Bas Blaauboer, Utrecht, Netherlands

• Challenges in development and implementation of the Three Rs in industry: a European perspectiveC. EskesTicino, Switzerland

• Challenges in development and implementation of the Three Rs in academia: a European perspectiveH. SpielmannBerlin, Germany

• Challenges in development and implementation of the Three Rs in industry: a North American perspectiveM. AardemaCincinnati, USA

• Challenges in development and implementation of the Three Rs in academia: a North American perspectiveK. SullivanWashington DC, USA

Additional Session I-18 Report on the ICCVAM international workshop on vaccines

Location: Jolliet Chair: William Stokes, Research Triangle Park, USA

• Alternative methods to Reduce, Refine, and Replace the use of animals in human vaccine potency and safety testing: recommendations from the 2010 NICEATM-ICCVAM international workshopR. McFarlandRockville, USA

• Alternative methods to Reduce, Refine, and Replace the use of animals in veterinary vaccine potency and safety testing: recommendations from the 2010 NICEATM-ICCVAM international workshopJ. Kulpa-EddyRiverdale, USA

SC

IEN

TIFIC S

ES

SIO

NS


MO

ND

AY, AU

GU

ST 22, 2011

12:45 – 14:00

14:00 – 15:30

14:00 – 15:30

Additional Session IV-9 National cancer institute guidelines – a tool for implementing more humane endpoints?

Location: Bersimis Discussion moderated by Fraser Darling, London, UK

14:00 – 15:30

Session I-7 Potency and safety testing of veterinary vaccines

Location: Jolliet Co-Chairs: Marlies Halder, Ispra, Italy Oksana Yarosh, Ottawa, Canada

• I-7-257: The reduction of animal-based safety testing of veterinary vaccines H. DraayerKalamazoo, USA

• I-7-677: Successful development and validation of an in vitro replacement assay for Leptospira Vaccine Potency TestsJ. Kulpa-EddyRiverdale, USA

• I-7-472: Major challenges in the development of potency tests for fish vaccinesJ.F. RodriguezVictoria, Canada

• I-7-449: In vitro detection of tetanus toxicity by a combined assay taking into account binding and enzymatic activityH. Behrensdorf-NicolLangen, Germany

Session I-8 Safety testing for chemically-induced eye injuries: recent Three Rs advances

Location: Duluth Co-Chairs: Rodger Curren, Gaithersburg, USA Nathalie Alépée, Aulnay-sous-Bois, France

• I-8-673: Chemical Injuries and the corneal responseR. BeuermanSingapore

• I-8-444: Human eye exposure to surfactant solutions; in silico determination R.M. WaltersSkillman, USA

2011S

CIE

NTI

FIC

SE

SS

ION

S


MO

ND

AY, A

UG

US

T 22

, 201

1

14:00 – 16:45

• I-8-363: Measuring depth of injury (DoI) in the Bovine Corneal Opacity and Permeability (BCOP) assayJ.V. JesterIrvine, USA

• I-8-055: A procedure for application of eye irritation alternative methods on cosmetic ingredientsY. YingGuangzhou, China

• I-8-503: Development of a non-animal testing strategy for ocular hazard labeling of some specific EPA-regulated productsJ.R. FowleWashington DC, USA

14:00 – 16:45

Session II-1 Public accountability

Location: Mackenzie Co-Chairs: Maggy Jennings, Horsham, UK Suzanne Fitzpatrick, Silver Spring, USA

• II-1-674: Strategies and tools for effective public participation A. KrishnaswamyKamloops, Canada

• II-1-196: Openness and public accountability — the why, who, what and how of itB.T. ReedHorsham, UK

• II-1-087: The use of genetically-engineered animals in research: an exploration of stakeholder opinionsE.H. OrmandyOttawa, Canada

• II-1-168: Freedom of information and animal experimentsA. CurrieLondon, UK

• II-1-405: Who is concerned about animal care and use in developing countries?F.A. FakoyaSt. George’s, Grenada

• II-1-573: Young people’s perceptions of the use of animals in scientific and medical research in the United KingdomD.I. LewisLeeds, UK

SC

IEN

TIFIC S

ES

SIO

NS


MO

ND

AY, AU

GU

ST 22, 2011

14:00 – 16:45

14:00 – 16:45

14:00 – 16:45

Session III-6 Training animal-based scientists

Location: Harricana Chair: Jan van der Valk, Utrecht, Netherlands

Discussants:S. Louhimies M. Rose M. BrownBrussels, Belgium Sydney, Australia, Wilmington, USAT. Kurosawa G. Demers C. Gauthier Osaka Japan Ottawa, Canada Ottawa, Canada

Session IV-2 Farm animal research and the Three Rs

Location: Bersimis Co-Chairs: Marina von Keyserlingk, Vancouver, Canada Dorte Bratbo Sørensen, Copenhagen, Denmark

• IV-2-652: Beyond harm reduction: good lives for farm animals D. Fraser Vancouver, Canada

• IV-2-611: Species-specific approaches are needed for effective implementation of the Three Rs in farm animal researchD.J. MellorPalmerston North, New Zealand

• IV-2-075: Positive reinforcement training in large experimental animalsD.B. SørensenFrederiksberg, Denmark

• Recent progress in farm animal welfare assessments: a report from the 2011 International WAFL ConferenceP.V. TurnerGuelph, Canada

Session V-2 Systematic reviews of animal experiments

Location: Saint-Laurent Co-Chairs: Marlies Leenaars, Nijmegen, Netherlands Michelle Hudson, Nottingham, UK

• V-2-543: Systematic reviews of animal studies: a necessary step to take M. Ritskes-HoitingaNijmegen, Netherlands

• V-2-355: Study quality and publication bias in experimental studies of neurological diseasesE.S. SenaEdinburgh, UK

2011S

CIE

NTI

FIC

SE

SS

ION

S


MO

ND

AY, A

UG

US

T 22

, 201

1

14:00 – 16:45

15:45 – 16:45

16:45 – 17:30

• V-2-163: The ARRIVE guidelines to improve the retrospective analysis of animal studiesN. Percie du SertLondon, UK

• Discussion of the Montréal declarationModerators: M. Leenars and M. Ritskes-Hoitinga

Additional Session II-7 The role of partnerships in advancing the Three Rs: together it’s possible! – an ILAR-supported Session

Location: Saint-François Chair: Lida Anestidou, Washington DC, USA

Panelists: Kathryn Chapman, London, UK Marcelle Holloway, Brussels, Belgium Joanna Edwards, Leeds, UK Ngaire Dennison, Dundee, UK

Discussants: Richard McFarland, Rockville, USA Judy MacArthur Clark, London, UK

15:45 – 16:45

Session I-16 Alternatives for potency testing for rabies

Location: Jolliet Co-Chairs: Marlies Halder, Ispra, Italy Oksana Yarosh, Ottawa, Canada

• I-16-381: Drivers and barriers to acceptance and use of 3R models for the quality control of veterinary rabies vaccines M.-J. SchiffelersUtrecht, Netherlands

• I-16-073: Potency testing of rabies vaccine: on the way to a new era L. BrucknerMittelhaeusern, Switzerland

• I-16-255: Rabies vaccines for human use: potency testing without mouse challenge?E. KamphuisLangen, Germany

16:45 – 17:30

Plenary Session 2 Engineering performance or performing engineering standards? Globalization and the application of the Three Rs

Location: Le Grand Salon Chair: Michel Tremblay, Montréal, Canada

• Plenary Speaker: Gail Davies London, UK

SC

IEN

TIFIC S

ES

SIO

NS


TUE

SD

AY, AU

GU

ST 23, 2011

TUESDAY, AUGUST 23, 2011SCIENTIFIC SESSIONS

8:30 – 9:30

9:45 – 12:00

8:30 – 9:30

Plenary Session 3 Implementing the Three Rs through policy – The EU Directive

Location: Le Grand Salon Chair: Coenraad Hendriksen, Bilthoven, Netherlands

• Plenary Speaker: Susanna Louhimies Brussels, Belgium

9:45 – 12:00

Session I-3 Biological and biotechnology-based therapeutics

Location: Jolliet Co-Chairs: Laura Andrews, Boston, USA John Devine, Evansville, USA

• I-3-066: Consideration of alternative approaches for the purpose of reducing animal numbers in the preclinical development of biotherapeutic productsL. AndrewsBoston, USA

• I-3-656: Minimising non-human primate use in monoclonal antibody (mAb) development K. ChapmanLondon, UK

• I-3-480: Informal communication with US FDA: pre-preIND approach to reduction of animal use in translational research and product developmentR. McFarlandRockville, USA

• I-3-356: Better prediction of immunogenicity of biopharmaceuticals in humans, is it possible?C. KrulZeist, Netherlands

• I-3-380: In vitro MABEL approach for nonclinical safety assessment of MEDI-565 (MT111), a novel CEA/CD3-bispecific single-chain BiTE antibodyP.C. RyanGaithersburg, USA

• I-3-620: Pharmaceutical testing of follicle stimulation hormone (FSH): a new cell-based assay for the replacement of the Steelman-Pohley in vivo assayC. GieseBerlin, Germany

2011S

CIE

NTI

FIC

SE

SS

ION

S


TUE

SD

AY, A

UG

US

T 23

, 201

1

9:45 – 12:00

9:45 – 12:00

Session I-4 Validation and Three Rs strategies for assessment of endocrine-active substances

Location: Duluth Co-Chairs: Warren Casey, Raleigh-Durham, USA Susanne Bremer, Ispra, Italy

• I-4-530: Use of Tox 21 tools from screening and prioritization to risk assessment: when, how and what?J.R. FowleWashington DC, USA

• I-4-130: BG1Luc ER TA test method: results of an international validation study and proposed performance standardsW. CaseyRaleigh-Durham, USA

• I-4-054: H295R cells: an in vitro model for the risk assessment of single fungicides and mixtures of them modulating estrone biosynthesisP. SteinbergHannover, Germany

• I-4-155: 3Rs alternatives for detection of endocrine disruptors: broadening our possibilitiesT. RamirezLudwigshafen am Rhein, Germany

• I-4-272: Supporting the implementation of the EU Community Strategy on endocrine disruptersS. BremerIspra, Italy

• I-4-287: A strategy for reducing animal use in the U.S. EPA’s endocrine disruption screening programC. WillettNorfolk, USA

• I-4-308: Detection of endocrine activity in vitro – current status of tests developed in the framework of the EU project “ReProtect”M. SchwartzWuppertal, Germany

Session II-3 Public law - the Three Rs in regulation addressing animal use

Location: Mackenzie Co-Chairs: Lyne Létourneau, Québec City, Canada Paul Locke, Baltimore, USA

• II-3-104: Good regulatory practice: Directive 2010/63/EEC, a missed opportunity?J. RichmondFife, UK

SC

IEN

TIFIC S

ES

SIO

NS


TUE

SD

AY, AU

GU

ST 23, 2011

9:45 – 12:00

• II-3-475: The Animal Welfare Act: a regulatory roadblockK. HesslerPortland, USA

• II-3-522: How different countries control animal experiments outside recognised establishmentsD.J. FryManchester, UK

• II-3-210: From mouse to machine: how have attitudes and individuals affected the progress of the Three Rs in shellfish toxin testing?N. DennisonDundee, UK

Session III-3 Development of non-animal teaching/training models

Location: Harricana Co-Chairs: Nick Jukes, Leicester, UK Ramasay Raveendran, Pondicherry, India

• III-3-712: An ethical scoring system for the production and assessment of alternatives in education and trainingS. MartinsenOslo, Norway

• III-3-115: Ex vivo pulsed heart model for cardiac surgical and interventional product development and trainingJ.P. MatonickSomerville, USA

• III-3-146: Transparent laproscopic simulator with adjustable physiological conditions for product development and surgical trainingE. VailheSomerville, USA

• III-3-291: STARR trainer, an alternative to live animal usage, for product development and surgeon trainingJ. GastrichCincinnati, USA

• III-3-442: The use of rat skull model for teaching learning methods for bleedingM.L. StreberMexico City, Mexico

• III-3-459: Simulation of animal experiments using mannequins, chemical sensors and computer softwareC.R. PatilShirpur, India

2011S

CIE

NTI

FIC

SE

SS

ION

S


TUE

SD

AY, A

UG

US

T 23

, 201

1

9:45 – 12:00

9:45 – 12:00

Session IV-3 Wildlife science and the Three Rs

Location: Bersimis Co-Chairs: Marc Cattet, Saskatoon, Canada Chris Darimont, Santa Cruz, USA

• IV-3-529: A mouse in the cage is not the same as the two in the bush! M.C. WallaceLubbock, USA

• IV-3-253: Molecular tools can obviate animal killing in biosystematics studies of anuransV. SharmaAjmer, India

• IV-3-343: Computer simulation models as an alternative to animal-based trap testingM. HiltzVegreville, Canada

• IV-3-481: Biases in bear studies: a consideration of capture effects on research resultsM. CattetSaskatoon, Canada

• IV-3-501: Ranking the negative impacts of wildlife control methods may help to advance the Three RsN.J. BeausoleilPalmerston North, New Zealand

Session V-3 Cell culture and tissue engineering

Location: Saint-Laurent Co-Chairs: François A. Auger, Québec City, Canada Gladys Ouédraogo, Aulnay-sous-Bois, France

• V-3-121: Human organs-on-chip: 3D human tissue engineering as a technological innovation, an intelligent replacement alternative to animal testing H. HosseinkhaniTaipei, Taiwan

• V-3-269: Temporal transcriptomic alterations during renal epithelial monolayer formationL. AschauerInnsbruck, Austria

• V-3-419: Direct oxygen supply to liver-derived cells using oxygen permeable membranesY. SakaiTokyo, Japan

• V-3-424: Assessment of acute, long-term and chronic respiratory toxicity using a long shelf-life 3D model of the human airway epithelium (MucilAir™)S. ConstantPlan-les-Ouates, Switzerland

SC

IEN

TIFIC S

ES

SIO

NS


TUE

SD

AY, AU

GU

ST 23, 2011

9:45 – 16:15

• V-3-417: A human tissue-engineered vascular substitute with a functional vasa vasorumM. TondreauQuébec City, Canada 9:45 – 16:15

Additional Session I-13 Toxicity Testing in the 21st Century

Location: Saint-François Chair: Robert Kavlock, Research Triangle Park, USA

• I-13-679: Tox21: overview and progress in screening the 10,000 chemical libraryC. AustinRockville, USA

• I-13-680: Tox21: Activities of the National Toxicology Program/NIEHS R. TiceResearch Triangle Park, USA

• I-13-681: Predictive models of systemic toxicity R. NoteAulnay-sous-Bois, France

• I-13-682 : AXLR8 strategic directions for development of alternatives in the EU H. SpielmannBerlin, Germany

• I-13-683: The OCED QSAR Toolbox O. MekenyanBourgas, Bulgaria

• I-13-684: ToxCast update — predictive signatures and Phase II D. DixResearch Triangle Park, USA

• I-13-685: High throughput screening using HepaRG M. MennecozziIspra, Italy

• I-13-686: v-Embryo — Developing virtual models of embryonic development based on HTS detected toxicity pathways T. KnudsenResearch Triangle Park, USA

• I-13-687: Readiness for application L. RitterGuelph, Canada

2011S

CIE

NTI

FIC

SE

SS

ION

S


TUE

SD

AY, A

UG

US

T 23

, 201

1

12:30 – 13:45

12:30 – 13:45

12:30 – 13:45

12:30 – 13:45

Additional Session II-8 Science and politics in food safety assessment and their impact on experimental animal use

Location: Mackenzie Chair: Herman Koëter Brussels, Belgium

Additional Session II-10 Role of international bodies in spreading Three Rs efforts globally

Location: Harricana Co-Chairs: Gilles Demers, Ottawa, Canada Tsutomu Miki Kurosawa, Osaka, Japan

• The role of ICLAS in the application of the Three RsG. DemersOttawa, Canada

• The role of CIOMS in the application of the Three RsK. BayneFrederick, USA

• Three Rs in the OIE Laboratory Animal Welfare Working GroupT. KurosawaOsaka, Japan

Additional Session V-9 Improving reporting of animal-based research

Location: Saint-Laurent Co-Chairs: Nathalie Percie du Sert, UK Jeffrey Everitt, Research Triangle Park, USA

• Recent efforts to improve the reporting of animal research – ILARJ. EverittResearch Triangle Park, USA

• Recent efforts to improve the reporting of animal research – NC3RsN. Percie du SertLondon, UK

• Discussion on the pros and cons of reporting guidelinesModerators: N. Percie du Sert and J. Everitt

SC

IEN

TIFIC S

ES

SIO

NS


TUE

SD

AY, AU

GU

ST 23, 2011

13:45 – 15:00

13:45 – 15:00

13:45 – 15:00

Session I-9 Advances in Three Rs alternatives for reproductive and developmental Toxicity

Location: Jolliet Co-Chairs: Barbara Hales, Montréal, Canada Robert Chapin, Groton, USA

• I-9-657: Predicting reproductive and developmental toxicity: A tiered strategyG. DastonCincinnati, USA

• I-9-258: The embryonic stem cell test as tool to assess structure-dependent teratogenicity: the case of valproic acidA. SeilerBerlin, Germany

• I-9-300: BLTK1 murine Leydig tumor cells: a novel model for evaluating the steroidogenic effects of reproductive and developmental toxicantsA.L. ForgacsEast Lansing, USA

• I-9-647: hESC-based in vitro toxicity testing — a test strategy for assessing prenatal toxicityJ. HeschelerCologne, Germany

Session I-11 Three Rs approaches to skin sensitization

Location: Duluth Co-Chairs: Carl Westmoreland, Sharnbrook, UK Anthony Gaspari, Maryland, USA

• I-11-626: Alternative approaches for the evaluation of skin sensitisation and their use for quantitative risk assessment of cosmetic ingredients J. KreysaIspra, Italy

• I-11-051: The COLIPA research and method development program for identifying and characterizing skin sensitizers without animal testingP. AebyMarly, Switzerland

• I-11-651: Modeling for the molecular mechanisms of allergens on the innate immune synapseA. GaspariBaltimore, USA

• I-11-125: Assessing the sensitization potential of compounds without animal testingE.L. RoggenBagsvaerd, Denmark

2011S

CIE

NTI

FIC

SE

SS

ION

S


TUE

SD

AY, A

UG

US

T 23

, 201

1

13:45 – 15:00

13:45 – 15:00

• I-11-323: Towards the development of a BioMEMS-based microsystem to assess chemical sensitization: Allergy-on-a-ChipM. YarmushPiscataway, USA

Session II-4 Implementing the Three Rs – alternatives to legislation

Location: Mackenzie Co-Chairs: Jon Richmond, Fife, UK Joanne Zurlo, Baltimore, USA

• II-4-582: Information retrieval on alternative methods to animal experiments — one of the factors that affect implementation of the Three Rs in research and testing B. GrüneBerlin, Germany

• II-4-064: Shaping Three Rs behavior through an accreditation programK. BayneFrederick, USA

• II-4-436: Scientist’s views on Three Rs: comparison of Canadian and UK scientistsN. FenwickOttawa, Canada

Session III-4 Replacement alternatives and teaching objectives – determining if and when student learning objectives require the use of an animal

Location: Harricana Co-Chairs: Merel Ritskes-Hoitinga, Nijmegen, Netherlands David Dewhurst, Edinburgh, UK

• III-4-158: New innovative elements in the FELASA Category C course for researchers: towards a more effective literature search and systematic reviews of animal studiesM. LeenaarsNijmegen, Netherlands

• III-4-479: Replacement and in vivo learning objectives in European competence trainingT. NevalainenKuopio, Finland

• III-4-209: Reducing the number of animals used in teaching and training of graduate students and scientists — possibilities and limitationsK. AbelsonCopenhagen, Denmark

• III-4-583: A survey of animal use and alternatives in higher education in EuropeD. DewhurstEdinburgh, UK

SC

IEN

TIFIC S

ES

SIO

NS


TUE

SD

AY, AU

GU

ST 23, 2011

13:45 – 15:00

13:45 – 16:15

• III-4-409: Alternatives to animal testing in the faculty of veterinary medicine of the National Autonomous University of MexicoL.R. TorresMexico City, Mexico

Session IV-4 Multi-imaging modalities, telemetry and the Three Rs

Location: Bersimis Co-Chairs: Patricia Turner, Guelph, Canada Fraser Darling, London, UK

• IV-4-699: Application of radiotelemetric recording to study mouse models of gestational pathologyA. CroyKingston, Canada

• IV-4-097: A novel in vivo approach to measure multiple organ system functions simultaneously: combining automated sampling/delivery systems with radio telemetry (ABST)R. BialeckiWilmington, USA

• IV-4-375: PET and MRI improve safety testing with far less animals (<50%)D. De GrootZeist, Netherlands

Session V-4 Refinement and Reduction in the use of genetically-engineered animals

Location: Saint-Laurent Co-Chairs: Fernando Benavides, Smithville, USA Frederik Dagnaes-Hansen, Aarhus, Denmark

• V-4-671: Gene supplementation and editing in livestock for biomedical & agricultural applications S.C. FahrenkrugMinnesota, USA

• V-4-109: Optimizing fluorescent protein choice for transgenic embryonic medaka modelsG. LemkineEvry, France

• V-4-067: The Importance of genetic background in mouse and rat modelsF. BenavidesSmithville, USA

• Breeding: a tool to improve genetically engineered mice welfareH. HéonMontréal, Canada

2011S

CIE

NTI

FIC

SE

SS

ION

S


TUE

SD

AY, A

UG

US

T 23

, 201

1

15:15 – 16:15

15:15 – 16:15

• New technologies and developments in the production of genetically modified rodents to implement and promote the Three Rs M. CowanMontréal, Canada

15:15 – 16:15

Additional Session I-15 Shellfish toxin testing: how are the Three Rs being progressed in this field?

Location: Mackenzie Chair: Ngaire Dennison, Dundee, UK

• I-15-240: Evolving from the mouse to the optoelectronic mouse for phycotoxin analysis in shellfishK. CampbellBelfast, UK

• I-15-431: Regulatory and methodical shortcomings in assessment of marine biotoxins in fish and shellfishM. DaneshianKonstanz, Germany

• I-15-559: Removing the mouse from shellfish toxin testing – fifteen years of the Three RsN. DennisonDundee, UK

Additional Session IV-7 VET2011: Advancing Animal Welfare Training for Veterinarians

Location: Harricana Chair: Bonnie Beaver, College Station, USA

• Animal welfare training in the North American veterinary curriculum: the AVMA Welfare Curriculum Project P.V. TurnerGuelph, Canada

• Board certification in animal welfare in North America B. BeaverCollege Station, USA

• Setting international standards for training of laboratory animal veterinarians (OIE/IACLAM/ILAR)K. BayneRockville, USA

• Welfare training for veterinary studentsT. KurosawaOsaka, Japan

• Discussion on animal welfare training in the veterinary curriculum

Moderators: P.V. Turner and B. Beaver

SC

IEN

TIFIC S

ES

SIO

NS


TUE

SD

AY, AU

GU

ST 23, 2011

16:15 – 17:00

16:15 – 17:00

Plenary Session 4 A challenge to the ultimate Three Rs — in silico approach to evaluate chemical safety for humans

Location: Le Grand Salon Chair: Herman Koëter, Brussels, Belgium

• Plenary Speaker: M. Hayashi Iwata, Japan

2011S

CIE

NTI

FIC

SE

SS

ION

S


WE

DN

ES

DAY

, AU

GU

ST

24, 2

011

WEDNESDAY, AUGUST 24, 2011SCIENTIFIC SESSIONS

8:45 – 9:30

9:45 – 12:00

8:45 – 9:30

Plenary Session 5 Alternative training methods for clinical education – considerations

Location: Le Grand Salon Chair: Gilly Griffin, Ottawa, Canada

• Plenary Speaker: Mark Storch Cincinnati, USA

9:45 – 12:00

Session I-5 Nanotoxicology and the Three Rs

Location: Jolliet Co-Chairs: Alison Elder, Rochester, USA Mark Lafranconi, Cincinnati, USA

• I-5-648: Alternative in vitro assays in nanomaterial toxicologyT. HartungBaltimore, USA

• I-5-053: Three Rs and the safety assessment of nanotech drugsA. JacobsSilver Spring, USA

• I-5-351: Development of an integrated aerosol measurement system in the i-LungM. ForjanVienna, Austria

• I-5-425: A simple method for testing the toxicity of nanomaterials on 3D air-liquid interface human airway epithelia (MucilAir™)S. HuangPlan-les-Ouates, Switzerland

• I-5-432: Use of normal human 3-dimensional (NHu-3D) tissue models (EpiDerm, EpiAirway) for nanotoxicology applicationsP. HaydenAshland, USA

SC

IEN

TIFIC S

ES

SIO

NS


WE

DN

ES

DAY, A

UG

US

T 24, 2011

9:45 – 12:00

9:45 – 12:00

Session I-6 Advances in alternative methods for ecotoxicology

Location: Duluth Co-Chairs: Michelle Embry, Washington DC, USA Scott Belanger, Cincinnati, USA

• 1-6-172: Fish cell lines as alternatives to fish toxicity testsK. SchirmerDübendorf, Switzerland

• 1-6-340: Quantitative and comparative analysis of alternatives to in vivo tests for endocrine disrupting chemicals (EDCs) in fish and amphibiansS. ScholzLeipzig, Germany

• 1-6-423: Adverse outcome pathways and extrapolation tools to advance the Three Rs in ecotoxicology D.L. VilleneuveDuluth, USA

• 1-6-536: What reductions in fish use can be made employing alternatives for wastewater effluent assessment?P.B. DornHouston, USA

• 1-6-447: Product stewardship “incorporating the 3Rs while improving bioaccumulation assessments”B. HokeNewark, USA

• 1-6-114: Harmonizing and optimizing fish testing methods: the OECD framework projectG. AnkleyDuluth, USA

Session II-5 Validation of Three Rs alternative methods

Location: Mackenzie Co-Chairs: William S. Stokes, Research Triangle Park, USA Joachim Kreysa, Ispra, Italy

• II-5-561: Validation of the 21st Century Toxicology Toolbox: challenges, opportunities, and the way forward W.S. StokesResearch Triangle Park, USA

• II-5-688: Post-approval validation issues: the example of the 3T3 NRU in vitro phototoxicity assayJ. KreysaIspra, Italy

2011S

CIE

NTI

FIC

SE

SS

ION

S


WE

DN

ES

DAY

, AU

GU

ST

24, 2

011

9:45 – 12:00

• II-5-289: Reduction of animal use through validation of a chemical method of detection for paralytic shellfish toxins W. RourkeDartmouth, Canada

• II-5-203: The limited value of acute toxicity tests in safety assessment S. RobinsonCheshire, UK

Session III-5 Introducing multi-media to the curriculum

Location: Harricana Co-Chairs: Laura Ducceschi, Jenkintown, USA René Remie, Almere, Netherlands

• III-5-320: The usage of alternatives at the Norwegian School of Veterinary ScienceK.A. HansenOslo, Norway

• III-5-659: Teaching surgical techniques in the twenty first century R. RemieAlmere, Netherlands

• III-5-440: Personalized resources on human and animal biology: lessons from U.S. Veterinary Medical Education L.A. HartDavis, USA

• III-2-500: Modular delivery of core surgical skills instruction in veterinary medicineD.D. SmeakColumbus, USA

• III-5-402: Development of the 3Rs platform website in Korea for exchanging knowledge and sharing examples of best practice to replace laboratory animal use in education G.H. LeeSeoul, Republic of Korea

• III-5-511: A collaborative multi-language website and database for alternatives in education and training N. JukesLeicester, UK

SC

IEN

TIFIC S

ES

SIO

NS


WE

DN

ES

DAY, A

UG

US

T 24, 2011

9:45 – 12:00

9:45 – 12:00

Session IV-5 Can pain research benefit research animals?

Location: Bersimis Co-Chairs: Alicia Karas, North Grafton, USA Miki Kurosawa, Osaka, Japan

• IV-5-526: Assessment of pain in small laboratory animals using behaviour & facial expressions M. LeachNewcastle, UK

• IV-5-658: Studying pain in rodents using facial expressionJ. S. MogilMontréal, Canada

• IV-5-157: Non-invasive pain assessment in mice subjected to vasectomyK.R. JaobsenCopenhagen, Denmark

• IV-5-453: Can a focus on the translatability of preclinical pain research benefit research animals?S.E.G. DuffusOttawa, Canada

• IV-5-556: ATLAS: an evidence-based web resource for pain control in laboratory animalsA.Z. KarasNorth Grafton, USA

Session V-5 Developments in stem cell research as the basis for sustainable availability of differentiated human cells and tissues

Location: Saint-Laurent Co-Chairs: Vera Rogiers, Brussels, Belgium Jeffrey Biernaskie, Calgary, Canada

• V-5-422: Focus on stem cells as sources of human target cells for in vitro research and testingV. RogiersBrussels, Belgium

• V-5-702: Dermal stem cells: an accessible multipotent precursor with potential application for drug screening and therapeuticsJ. BiernaskieCalgary, Canada

• V-5-429: A stem cell based test battery to detect developmental neurotoxicantsM. LeistKonstanz, Germany

2011S

CIE

NTI

FIC

SE

SS

ION

S


WE

DN

ES

DAY

, AU

GU

ST

24, 2

011

9:45 – 12:00

• V-5-410: Reconsidering pluripotency tests: do we still need teratomas?J. HeschelerCologne, Germany

• V-5-184: Characterization of developmental changes and electrophysiological functions in contracting cardiomyocytes derived from human iPS cellsJ. KiyokawaGotemba, Japan

• V-5-703: Skin-derived precursor cells, a promising source for hepatic progenyV. RogiersBrussels, Belgium

Additional Session V-7 Relevance, reproducibility and robustness – the other Three Rs important to science and animal welfare: a SCAW — supported session

Location: Saint-François Co-Chairs: Jeffrey Everitt, Raleigh-Durham, USA Joanne Zurlo, Baltimore, USA

• Introduction – Relevance, reproducibility and robustnessJ. EverittRaleigh-Durham, USA

• V-7-689: Picking the right species J. Huxley-JonesStevenage, UK

• V-7-690: Emerging sciences for earlier prediction of safer new chemical entitiesW. PennieGroton, USA

• V-7-691: The NCI experimental therapeutics program: opportunities for the 3Rs in drug discovery and developmentM. DavisRockville, USA

• Panel DiscussionModerators: J. Everitt and J. Zurlo

SC

IEN

TIFIC S

ES

SIO

NS


WE

DN

ES

DAY, A

UG

US

T 24, 2011

12:30 – 13:45

12:30 – 13:45

12:30 – 13:45

12:30 – 13:45

Additional Session I-17 Update on new in vitro models for detection and potency assessment of botulinum neurotoxin

Location : Duluth Co-chairs: Warren Casey, Research Triangle Park, USA Martin Stephens, Washington DC, USA

• Methods for the detection of botulinum neurotoxin activity: BoTest(tm), BoTest(tm) Matrix, and BoCell(tm) AssayW. TuckerMadison, USA

• Three R alternatives to botulinum neurotoxin testing: Status report of the International Expert Working Group (BoNT-EWG) initiated by the German Federal Institute for Risk Assessment (BfR) and and co-chaired by the German Federal Institute for Drugs and Medical Devices (BfArM)M. LiebschBerlin, Germany

• Replacing mouse LD50 for botulinum toxin potency testing: review of approaches taken by NIBSCD. SesardicPotters Bar, UK

Additional Session V-8(a) Tutorial for Go3R search engine

Location: Kamouraska (3rd floor)Tutors: B. Grüne, Berlin, Germany U. G. Sauer, Dresden, Germany Michael R. Alvers, Dresden, Germany

Additional Session IV-8 Ending severe pain and distress in animal experiments by 2025?

Location: Bersimis Co-Chairs: Coenraad Hendriksen, Bilthoven, Netherlands Gilly Griffin, Ottawa, Canada

• Introduction and frameworkC. HendriksenBilthoven, Netherlands

• Discussion on the opportunites, challenges and next steps towards ending severe pain and distress Moderators: C. Hendriksen and G. Griffin

2011S

CIE

NTI

FIC

SE

SS

ION

S


13:45 – 15:00

13:45 – 15:00

13:45 – 15:00

Session I-10 Safety testing for carcinogenicity and genetic toxicity: recent Three Rs advances

Location: Jolliet Co-Chairs: David Blakey, Ottawa, Canada Hajime Kojima, Tokyo, Japan

• I-10-670: In vitro versions of the Muta™Mouse Transgenic Rodent (TGR) Mutation Assay for hazard identification of chemicals P. WhiteOttawa, Canada

• I-10-134: In vivo Comet Assay: update on the ongoing international validation study coordinated by JaCVAMM. HayashiKisarazu, Japan

• I-10-265: ECVAM-coordinated pre-validation study of three cell transformation assays for the carcinogenicity testing of chemicals M. HalderIspra, Italy

Session I-12 Epigenetics and its increasing relevance in toxicology and risk assessment

Location: Duluth Co-Chairs: Matthieu Vinken, Brussels, Belgium Moshe Szyf, Montréal, Canada

• An introduction to epigeneticsM. VinkenBrussels, Belgium

• Stabilisation of primary hepatocyte cultures via interfering with epigenetic control mechanismsT. VanhaeckeBrussels, Belgium

• The environment and DDNA methylation: implication for toxicologyM. SzyfMontréal, Canada

WE

DN

ES

DAY

, AU

GU

ST

24, 2

011

SC

IEN

TIFIC S

ES

SIO

NS


13:45 – 16:15

13:45 – 15:00

WE

DN

ES

DAY, A

UG

US

T 24, 2011

Session II-6 Setting limits and resolving conflicts between the Rs

Location: Mackenzie Co-Chairs: Margaret Rose, Sydney, Australia Robert Hubrecht, Wheathampstead, UK

• II-6-533: The 3Rs principle – mind the ethical gap! A. OlssonPorto, Portugal

• II-6-140: A new approach to replacing primates in biomedical science: accessing the views of scientistsM. HudsonNottingham, UK

• II-6-108: Beastly bias and species choiceR. HubrechtWheathampstead, UK

• Discussion on setting limits on acceptable research — who judges and how.

Introduction: M. Jennings Horsham, UK

Session III-2 Innovative training in human and veterinary medicine

Location: Harricana Co-Chairs: Frauke Ohl, Utrecht, Netherlands Doug Morck, Calgary, Canada

• III-2-395: The potential of humane teaching methods within veterinary and other biomedical educationA. KnightLondon, UK

• III-2-398: A veterinary student’s perspective concerning educational animal use and the potential for humane alternatives S.-Y. WoonSydney, Australia

• III-2-508: Alternatives outreach and a new student movement for humane veterinary education and practice in EgyptS.I. ElzaabalawyCairo, Egypt

• III-2-516: Elimination of live terminal surgeries in Canadian veterinary practice: the case of the Veterinary Skills Training and Enhancement Program (VSTEP) curriculum change at the Ontario Veterinary College (OVC) A. YushchenkToronto, Canada

2011S

CIE

NTI

FIC

SE

SS

ION

S


WE

DN

ES

DAY

, AU

GU

ST

24, 2

011

13:45 – 15:00

13:45 – 16:15

• Panel Discussion:A. Knight, S.-Y Woon, S. I. Elzaabalawy, A. Yushchenk

Session IV-6 Broadening the application of Refinement

Location: Bersimis Co-Chairs: Hanno Würbel, Bern, Switzerland Kathryn Bayne, Rockville, USA

• Refinement through adequate enrichment and experimental designH. WürbelBern, Switzerland

• IV-6-078: Refined blood sampling of rodentsL.F. MikkelsenMaaloev, Denmark

• IV-6-126: Good welfare – good science: refining toxicological procedures for cynomolgus macaques (Macaca fascicularis) through enhanced socialisation with care-staffL. TaskerStirling, UK

• IV-6-404: Ways to advance laboratory animal welfare not only when it’s a regulatory mandate but whenever we recognize opportunities to enhance husbandry and/or research practicesL.V. MedinaAbbott Park, USA

• IV-6-418: Translating regulatory compliance into better animal welfare–are we making progess?N.H. FrancoPorto, Portugal

Session V-6 Animal reduction through the better use of mechanistically-based translational animal disease models

Location: Saint-Laurent Co-Chairs: Michel Tremblay, Montréal, Canada Andrew Bennett, Nottingham, UK

• V-6-654: Computational models for predicting human toxicities S. EkinsBurlingame, USA

• V-6-406: A model for inter-institutional 3Rs co-operation — sharing in vivo research resourcesR. BroomeMountain View, USA

SC

IEN

TIFIC S

ES

SIO

NS


WE

DN

ES

DAY, A

UG

US

T 24, 2011

13:45 – 15:00

• Development of a flow chamber test to replace animal research on arterial thrombosis and bleeding in vivo J. HeemskerkMaastricht, Netherlands

Additional Session I-19 Toxicity testing strategies – progress in skin sensitization testing: A COLIPA supported session

Location: Saint-François Co-Chairs: Monique Marrec-Fairley, Brussels, Belgium Pierre Aeby, Marly, Switzerland

• COLIPA (EU Cosmetics Industry) strategy for developing a non-animal risk assessment approach for skin sensitizationG. MaxwellBedford, UK

• Considerations for the development of an integrated testing strategy for skin sensitizationA. ShepkyHamburg, Germany

• Development of in vitro skin sensitization assay system in ShiseidoT. AsikagaTokyo, Japan

• Non-animal test battery optimized for detecting skin sensitizing potentialM. MiyazawaTochigi, Japan

• Towards an integrated testing strategy for skin sensitization: development, refinement and combination of non-animal methodsS. TessierAulnay-sous-Bois, France

• Skin sensitisation: modelling the human adverse responseG. MaxwellBedford, UK

2011S

CIE

NTI

FIC

SE

SS

ION

S


15:15 – 16:15

15:15 – 16:15

16:15 – 17:15

WE

DN

ES

DAY

, AU

GU

ST

24, 2

011

15:15 – 16:15

Additional Session II-11 The International Cooperation on Alternative Test Methods (ICATM)

Location: Duluth Chair: William S. Stokes, Research Triangle Park, USA

• NICEATM-ICCVAMW. StokesResearch Triangle Park, USA

• JaCVAMH. KojimaTokyo, Japan

• ECVAM J. KreysaIspra, Italy

• KoCVAMY.N. YumSeoul, Republic of Korea

• Health CanadaD. BlakeyOttawa, Canada

Additional Session V-8(b) Tutorial for Go3R search engine

Location: Kamouraska (3rd floor)Tutors: Barbara Grüne, Berlin, Germany Ursula G. Sauer, Dresden, Germany Michael R. Alvers, Dresden, Germany

16:15 – 17:15

Plenary Session 6 Pursuing Medawar’s challenge for full Replacement

Location: Le Grand Salon Chair: Robert Kavlock, Research Triangle Park, USA

• Plenary Speaker: Martin Stephens Washington DC, USA

2011P

OS

TER

SE

SS

ION

S


MO

ND

AY, A

UG

US

T 22

, 201

1

MONDAY, AUGUST 22, 2011POSTER SESSIONS

7:30 – 15:45

7:30 -15:45

Theme II Policy/law on animal use, public engagement and ethics review

Location: Hochelaga 4-6

• II-1-241: Meeting the deadline of the 2013 deadline for cosmetic testing: an opinion on the status of alternative methodsM. Thew, K. Taylor

London, UK

• II-1-333: Veterinarians play an important role in the promotion and education of the 3Rs S. Khan, M.K. McLean Urbana, USA

• II-1-367: Activities of Ethics Committee on Animal Use (CEUA) of Oswaldo Cruz Foundation, Brazil M. Mannaa, E.Molinaro, N. Labarthe, O. PresgraveRio de Janeiro, Brazil

• II-1-427: Effective and relative reduction of the use of animals in Sanofi PasteurJ.-M. Chapsal, T. Decelle Lyon, France

• II-1-471: Americans’ attitudes toward animal testing: 2001-2011 J.R. Goodman1, C.A. Borch2, E. Cherry3

1Washington DC, USA; 2Birmingham, USA; 3Purchase, USA

• II-2-135: The use of activity maps in project authorizationA. Brønstad Bergen, Norway

• II-2-164: Advancing ethics review in IACUC oversight of animal researchN. Mak Jenkintown, USA

• II-2-335: Incorporating ethics in the alternatives to animal use in scientific researchB.C. von Arcken Bogotá, Columbia

• II-2-348: Using language to find if Australian Animal Ethics Committees use emotion or ethics to assess animal experimentsM. Ciprian, L. D’Olimpio, A. Ram Pandit, D. Blache Perth, Australia

• II-2-485: Chimpanzees in US laboratoriesK. Conlee, J. Ball Washington DC, USA

PO

STE

R S

ES

SIO

NS


MO

ND

AY, AU

GU

ST 22, 2011

• II-2-527: Facilitating the role of lay members in ethics and animal care and use committeesM. Jennings1, P. Hawkins2

1Redhill, UK; 2Southsea, UK

• II-2-557: Guidance on the severity classification of procedures involving fishP. Hawkins1, K. Ryder2, N. Dennison2, G. Goodman3, S. Hetherington4, S. Llywelyn-Jones5, A. J. Smith6

1West Sussex, UK; 2Dundee, UK; 3Edinburgh, UK; 4Lowestoft, UK; 5London, UK; 6Oslo, Norway

• II-3-188: New EU Directive 2010/63/EU on the protection of animals used for scientific purposes: animal welfare aspects of the transposition into national lawR. Kolar, I. Ruhdel Neubiberg, Germany

• II-3-191: Analysis of EU-legislation in terms of consistency and state-of-the-art regarding the implementation of the 3Rs in the data requirements to identify potential for further improvement K. Wagner, B. Fach, R. Kolar Neubiberg, Germany

• II-3-298: Regulatory changes and the resultant effect on alternatives consideration in the United States M.W. Wood, L.A. Hart Davis, USA

• II-3-359: The Brazilian law that regulates animal use does not improve the reduction concept of 3Rs O. Presgrave, C. Caldeira, E. Alves, R. Silva, I. Gimenes, J.C. de Freitas, R. Presgrave Rio de Janeiro, Brazil

• II-3-362: Comparison of the pyrogen in vivo methods described in Brazilian and European pharmacopoeias: which one contributes to animal reduction? I. Gimenes, O. Presgrave, C. Caldeira Rio de Janeiro, Brazil

• II-3-369: The need of establishing a training and educational system for animal use and care personnel in Brazil E. Molinaro, N. Labarthe, O. Presgrave Rio de Janeiro, Brazil

• II-3-374: Does Brazilian Animal Law really regulate animal use and improve the development of alternative methods? N. Labarthe, E. Molinaro, O. Presgrave Rio de Janeiro, Brazil

• II-3-441: Animal suffering in US laboratories: efforts to tackle this critical issue L. Gomez, K. Conlee Washington DC, USA

• II-3-493: Exclusion of birds, rats, and mice from legal protection in the U.S.: a science policy case study S.A. Leary, C. Schaeffer, V. Katrinak Jenkintown, USA

2011P

OS

TER

SE

SS

ION

S


MO

ND

AY, A

UG

US

T 22

, 201

1

• II-4-103: An advisory center for the 3RS. Schindler Zurich, Switzerland

• II-4-143: Benefits of post-approval monitoringG. Lauzon, C. DemersMontréal, Canada

• II-4-183: Nanoparticles in cosmetics: does EU legislation allow animal testing — or not?U.G. Sauer Neubiberg, Germany

• II-4-224: The industrial applicability of in vitro methods: the role of the In Vitro Testing Industrial Platform (IVTIP)B. De Wever1, E. Roggen2, C. Krul3, A. Poth4, S. Mikulowski51Monte Carlo, Monaco; 2Kongens Lynghy, Denmark; 3Zeist, Netherlands; 4Rossdorf, Germany; 5Stockholm, Sweden

• II-4-282: Bridging the gap between validation and implementation: replacing animal use in vaccine batch potency testingS. Dozier1, J. Brown2, A. Currie3

1Ithaca, USA; 2Los Angeles, USA; 3London, UK

• II-4-299: Animal protection through participation in the Organisation for Economic Co-operation and Development: the ICAPO modelK. Sullivan1, C. Sandusky1, K. Taylor2, T. Seidle3, C. Willett4

1Washington DC, USA; 2London, UK; 3Brussels, Belgium; 4Norfolk, USA

• II-4-344: The use of nonhuman primates in research: The Association of Primate Veterinarians as an educational resource for enhancing primate welfareA. Winterborn1, C.J. Doane2, J. Hasenau3, S. Kuhlman4, P. V. Turner5

1Kingston, Canada; 2Beaverton, USA; 3Reno, USA; 4Summit, USA; 5Guelph, Canada

• II-4-373: An application of alternative toxicological methods in safety testing of perfumery and cosmetic products in RussiaN.V. Zavyalov, E.L.SkvortsovaMoscow, Russia

• II-4-387: Implementation of in vitro replacement technologies in regulatory drug testing — an innovation systems perspectiveM. Kooijman, P.J.K. van Meer, E.H.M. Moors, M.P. Hekkert, H. SchellekensUtrecht, Netherlands

• II-4-451: Enhancing implementation of the 3Rs in daily practice — which way to go?J. van Luijk1, Y. Cuijpers2, L. van der Vaart3, M. Leenaars1, M. Ritskes-Hoitinga1

1Nijmegen, Netherlands; 2Utrecht, Netherlands; 3Oisterwijk, Netherlands

• II-4-469: Prioritising promising 3R research, a helpful classification schemeM. van Boxel1, D.Lankveld2, S. Deleu1

1Utrecht, Netherlands; 2Bilthoven, Netherlands

PO

STE

R S

ES

SIO

NS


MO

ND

AY, AU

GU

ST 22, 2011

• II-4-476: Animal welfare and Three R’s education: filling the gap in interdisciplinary studiesP.D. Frasch1, K. Hessler1, J. Tischler2

1Portland, USA; 2Cotati, USA

• II-4-482: Improving 3Rs information in research publicationsD.J. Fry Manchester, UK

• II-4-519: The American Veterinary Medical Association’s Animal Welfare Committee: educating veterinarians and the public regarding best practices for animal welfareD. Marsman1, G. Golab2, J. Dinnage3, P.V. Turner4

1Mason, USA; 2Schaumberg, USA; 3Scottsdale, AZ; 4Guelph, Canada

• II-4-524: AltTox.org: communication platform for 21st century toxicologyM. Stephens1, H. Kojima2, G. Patlewicz-Tier3, H. Spielmann4, L. Talley1

1Washington DC, USA; 2Tokyo, Japan; 3Newark, USA; 4Berlin, Germany

• II-4-549: Programming study on 3R alternatives; how to focus 3R efforts in the NetherlandsM. van Boxel1, S. Deleu2


• II-4-593: A new class of biomimetic, in silico models designed for increasing research efficiency while reducing animal use C.A. Hunt San Francisco, USA

• II-4-596: Effecting change in animal welfare at a national level – the role of the Canadian Veterinary Medical AssociationP.V. Turner1, T.L. Whiting2, W. Skippon3

1Guelph, Canada; 2Winnipeg, Canada; 3Ottawa, Canada

• II-4-605: Canadian Association for Laboratory Animal Medicine: promoting research animal welfare coast-to-coastA. Winterborn1, P.V. Turner2

1Kingston, Canada; 2Guelph, Canada

• II-4-713: REACH regulation: Ensuring safety of industrial enzymes – is animal testing necessary?U. Festersen, E.L. Roggen, N.W. Berg, F.K. Birkved, D.S. Brinch Kongens Lynghy, Denmark

• II-5-192: Developing regulatory acceptable in vitro alternatives to established in vivo assaysS. Madden, C. Roper Edinburgh, UK

• II-5-321: InVitroJobs — communication network and job platform presents “Working Group - a Portrait” C. Hohensee1, A. Schmidt2, A. Schmidt2, C. Ledermann2, C. Baumgartl-Simons2

1Berlin, Germany; 2Aachen, Germany

2011P

OS

TER

SE

SS

ION

S


7:30 – 15:45

MO

ND

AY, A

UG

US

T 22

, 201

1

• II-5-371: An evaluation of the Reconstructed Human Epidermis (RhE) method for predicting skin corrosivity of chemical products with extreme acid pHS.S. Willems1, A.M. Sheppard1, H. Raabe2, R. Curren2

1Sturtevant, USA; 2Gaithersburg, USA

• II-5-534: Update on validation status and industry utilization of Normal Human 3D (NHu-3D) tissue models in toxicologyH. Kandarova1,2, M. Klausner1, J. Kubilus1, S. Ayehunie1, P. Hayden1, Y. Kaluzhny1, S. Letasiova2, J. Sheasgreen1

1Ashland, USA; 2Bratislava, Slovak Republic

• II-5-645: Multi-study validation trial for cytochrome P450 induction providing a reliable human-metabolic competent standard model or method using the human cryoHepaRG® cell line and cryopreserved human hepatocytesS. Coecke, I. Langezaal Ispra, Italy

• II-6-497: Endpoints for humane sacrifice in non-clinical safety studiesB. Altmann, M. Bellot, A. Eichinger-Chapelon, M. Festag, G. Schmitt Basel, Switzerland

• II-6-558: What can regulatory toxicology and other scientific disciplines learn from Three Rs approaches used in the shellfish toxin testing arena?N. Dennison1, D.B. Anderson1, J.A. MacArthur Clark2, K. Ryder1

1Dundee, UK; 2London, UK

Theme III Incorporation of the Three Rs in education and training

Monday, August 22, 2011 Location: Hochelaga 4-6

• III-1-250: Live zoology and digital technologies as effective alternatives for animal use in zoology curriculum: a success story from MDS University Ajmer, IndiaK.K. Sharma1, M.A. Akbarsha2, V. Sharma1, N. Sharma3, N. Sharma4

1Ajmer, India; 2Tiruchirapalli, India; 3Ajmer, India; 4Dehradun, India

• III-1-307: In vitro toxicology training programs at Mahatma Gandhi-Doerenkamp Center (MGDC), India: a status report and a review M.D. Zeeshan, A. Riyasdeen, A. Radha, F. Kunnathodi, M.A. Akbarsha Tiruchirappalli, India

• III-1-385: First ethics ranking of universities in GermanyA. Schmidt, C. Hohensee, U. Teichgràber, C. Baumgartl-Simons Aachen, Germany

PO

STE

R S

ES

SIO

NS


• III-1-507: Master students’ feedback on 3Rs education approach F. Caloni, V. Alberizzi, A. Costa, M. Loiacono, M.G. Morselli, A. Pasotti, C. Cortinovis Milan, Italy

• III-1-509: Investing in humane education: provision of alternatives across IndiaN. Jukes1, S. Bhavsar2, L. Ward3, J. Marchig3

1Leicester, UK; 2Baroda, India; 3Edinburgh, UK

• III-2-113: Course on alternative methods to animal use in toxicology in the Veterinary Faculty of MilanF. Caloni Milan, Italy

• III-2-128: Ophthalmic artery super-selective catheterization of the pig as a training model with possible implications in retinoblastoma treatmentM. Asprea, P. Schaiquevich, F. Requejo, E. Buitrago, G. Chantada Buenos Aires, Argentina

• III-2-434: New replacement alternatives used for training students in veterinary medicine in the NetherlandsH. Blom1, C. Wolschrijn1, I. den Hartog2, C. Wittevrongel21Utrecht, Netherlands; 2The Hague, Netherlands

• III-2-488: Implementation of a body donation program and use of software: Replacement in veterinary anatomy in PeruM. Navarrete, J. Cisneros, A. Sato, M. Quevedo, M. Ramos Lima, Peru

• III-2-492: Curricular transformation at St Petersburg State Veterinary AcademyT. Novosaduk1, N. Jukes2, E. Maroueva3

1St Petersburg, Russia; 2Leicester, UK; 3Moscow, Russia

• III-2-510: The use of formal agreements to achieve replacement in education: the experience of Russia and UkraineN. Jukes1, E. Maroueva2, D. Leporsky3, C. Gericke4

1Leicester, UK; 2Moscow, Russia; 3Kharkov, Ukraine; 4Braunschweig, Germany

• III-2-517: International harmonization of education and training standards for laboratory animal veterinariansK. Bayne1, T.M. Kurosawa2, J. MacArthur Clark3, P.V. Turner4

1Frederick, USA; 2Osaka, Japan; 3London, UK; 4Guelph, Canada

• III-2-521: How formal training influences researchers’ awareness and attitudes to animal use in biomedical researchN.H. Franco1,2, J.A. Nunes2, I.A.S. Olsson1

1Porto, Portugal; 2Coimbra, Portugal

• III-3-215: Outcomes of efforts of Mahatma Gandhi-Doerenkamp Center (MGDC), India, to replace animal dissections in life science and biomedical science educationG.G.H.A. Shadab1, M.D. Zeeshan2, F. Kunnathodi2, M.A. Akbarsha2

1Aligarh, India; 2Tiruchirappalli, India

MO

ND

AY, AU

GU

ST 22, 2011

2011P

OS

TER

SE

SS

ION

S


• III-3-465: Replacement of animal use in medical physiology B. Dejanova1, D. Dewhurst2, S. Mancevska1, S. Petrovska1, V. Antevska1

1Skopje, Macedonia; 2Edinburgh, UK

• III-3-487: Strategies for replacement in the medical physiology laboratory in Centro Universitario de la Costa (Puerto, Vallarta) of Universidad de GuadalajaraS.A. Viruete Cisneros, C.T. Murillo Dueñas, O.S. Guerrero, D.M.L. Rubio, H.R. GomezPuerto Vallarta, México

• III-3-496: International practical trainings on in vitro methods E. Hill1, C. Eskes2

1Gaithersburg, USA; 2Agno, Switzerland

• III-4-117: Perception of animals used in education and research in Brazil by students and professorsP.R. Tamioso, V.C. Bones, C.F.M. Molento, M.L. Fischer Curitiba, Brazil

• III-4-136: The opinion on the use of animals in higher education in Brazil: comparison across programs and between first and last year studentsB.G.F. Deguchi, C.F.M. Molento, C.E.P. de Souza Curitiba, Brazil

• III-4-383: Teaching in pharmacology and 3R: problems and ways forward S. Gorzalczany, M. Rubio, G. Bramuglia, C.M. Baratti, C. Taira Buenos Aires, Argentina

• III-4-407: Education and animal experimentation, ethics in higher educationE.E. Zöñiga, C.G. Iglesias, L.R. Torres Mexico City, Mexico

• III-4-603: Training for reductionM. Hudson, D. Fry Nottingham, UK

• III-5-086: The new alternative laboratory for training and teaching J.G. StormarkBergen, Norway

• III-5-435: Teaching human biology and health in pre-collegeL.J. Ducceschi1, L.A. Hart2, W.A. Storm2, M.W. Wood2

1Jenkintown, USA; 2Davis, USA

• III-5-505: The impact of decentralised alternatives libraries on campaigning for replacementN. Jukes1, S. Bhavsar2, D. Leporsky3, E. Maroueva4, S. Ponce5, M. Ramos6, A. Schmidt7

1Leicester, UK; 2Baroda, India; 3Kharkov, Ukraine; 4Moscow, Russia; 5Guadalajara, Mexico; 6Lima, Peru; 7Jena, Germany

MO

ND

AY, A

UG

US

T 22

, 201

1

PO

STE

R S

ES

SIO

NS


• III-5-506: Alternatives seminars and multimedia exhibitions: global outreach and support for humane education initiativesN. Jukes1, R. Bhavsar2, S. Bhavsar2, E. Maroueva3, J. Ngonyo4, S. Ponce5, C. Schirmer6, A. Schmidt7

1Leicester, UK; 2Baroda, India; 3Moscow, Russia; 4Nairobi, Kenya; 5Guadalajara, Mexico; 6Lima, Peru; 7Jena, Germany

• III-6-046: Refinement in practical works in FELASA accredited course at ENVTM. Kolf-Clauw, R. Letron, B. Abella, Y. Barreira Toulouse, France

• III-6-421: las-online.eu — a trilingual approach to refinement through laboratory animal science (LAS) educationN. Linklater1, J. Weiss2, G. Heldmaier1, C. Exner1

1Marburg, Germany; 2Heildelberg, Germany

MO

ND

AY, AU

GU

ST 22, 2011

2011P

OS

TER

SE

SS

ION

S


TUE

SD

AY, A

UG

US

T 23

, 201

1

TUESDAY, AUGUST 23, 2011POSTER SESSIONS

7:30 – 15:15

7:30 -15:15

Theme I Safety and efficacy testing of chemicals, pharmaceuticals and biologicals


• I-1-060: Monocyte Activation Test (MAT) is a reliable choice for pyrogenicity test in parenteral formulations of human serum albuminZ.P. Ruiz1, R.P. Morales1, I. Spreitzer2, A. Lagarto1, T. Montag2

1Havana, Cuba; 2Langen, Germany

• I-1-106: Comparison of the bioactivity for pertussis toxin by the histamine sensitization test and in vitro assaysH. Oh, J. Joung, B. Kim, S. Hong, H. Lee Chungcheongbuk-do, Republic of Korea

• I-1-138: Endotoxin and non-endotoxin pyrogens trigger inflammatory cytokine release in the Monocyte-Activation Test with cryopreserved human bloodB. Holtkamp, G. Schmitz Dreieich, Germany

• I-1-149: Characterization of binding assay components used to detect residual pertusssis toxin in vaccine preparationsF. Cornel, R. Isbrucker Ottawa, Canada

• I-1-222: Alternate in vitro methods for detection of pertussis toxin in component pertussis vaccinesR. Maharajh, J.Menon, D. Kemp, J. Yip, S. Nelson Toronto, Canada

• I-1-229: Interferon genes regulated by pertussis toxin: potential for an in vitro pertussis vaccine safety assay S.F. Vaessen1, R.J. Vandebriel2, M.W.P. Bruysters2, S. Verkoeijen1, A.M. Akkermans2


• I-1-260: Immunological response of MUTZ-3 dendritic cells to the different components of conjugated haemophilus influenzae type B vaccine: potential in vitro assay for vaccine immunogenicityM.H.N. Hoefnagel1, J.P. Vermeulen1, R. J. Scheper2, R. J. Vandebriel11Bilthoven, Netherlands; 2 Amsterdam, Netherlands

• I-1-327: The Pertussis-ATP-Test to replace the animal experiments for testing acellular pertussis vaccinesC. Bache, I. Spreitzer, B. Becker, C. K. Schneider, M. Schwanig, T. Montag Langen, Germany

• I-1-328: Improved Monocyte Activation Test (MAT) for accelerated and sensitive pyrogen detection J. Hermanns, I. Spreitzer, C. Bache, B. Loeschner, B. Becker, C.K. Schneider, T. MontagLangen, Germany

PO

STE

R S

ES

SIO

NS


• I-1-346: Application of 454 pyrosequencing technology on the detection of adventitious agents in vaccinesC.-F. Yang, E. Song, J. Hong Mountain View, USA

• I-1-361: Comparison between Rabbit Pyrogen Test (RPT) and human whole blood cytokine release assay (IPT) C. Caldeira, I. Gimenes, S. Nogueira, J.C. de Freitas, O. Presgrave Rio de Janeiro, Brazil

• I-1-379: The re-use of rabbits in pyrogen test (RPT) of hiperimmune sera and vaccines contributes to the reduction of animal useJ.C. de Freitas, S. Nogueira, I. Gimenes, C. Caldeira, O. Presgrave Rio de Janeiro, Brazil

• I-1-443: Development of xMAP technology for the control of multicomponent vaccines bioactivityC. Mourton-Gilles, M. Girard, M. Akhoubzi, D. Sauvaire Vendargues, France

• I-1-462: Identification and characterization of monoclonal antibodies for use in S. pneumoniae vaccine characterization assaysT. Chen, K. Williams, D. Salha, B. Gajewska, S. Gallichan Toronto, Canada

• I-1-504: International validation and evaluation of an alternative to HIST for pertussis containing vaccinesD. Xing1, C. T-Yuen1, C. Asokanathan1, Y. Horiuchi21Potter’s Bar, UK; 2Tokyo, Japan

• I-1-569: International workshop on alternative methods to reduce, refine, and replace the use of animals in human vaccine potency and safety testingR. McFarland1, J. Kulpa-Eddy2, R. Isbrucker3, M. Halder4, H. Kojima5, D. Verthelyi1, M. Schmitt1, R. Lewis1, N. Johnson6, B. Jones6, D. Allen6, W. Casey6, W. Stokes6

1Rockville, USA; 2Riverdale, USA; 3Ottawa, Canada; 4Ispra, Italy; 5Tokyo, Japan; 6Research Triangle Park, USA

• I-1-592: Implementation of the In Vitro Pyrogen Test (IPT) for replacement of the rabbitS. Fennrich, S. Schindler Tübingen, Germany

• I-1-675: Characterisation of antigen adsorbed to aluminium salts M. Regnier, G. Kersten, W. Tilstra, C. Hendriksen, B. Metz Bilthoven, Netherlands

• I-1-676: Pertussis toxin content of acellular vaccines assessed by in vitro cAMP responsesM.E. Hoonakker1,2, N. Ruiterkamp1, C.F.M. Hendriksen1,2

1Bilthoven, Netherlands; 2Utrecht, Netherlands

• I-1-698: The consistency approach for diphtheria and tetanus toxoid vaccinesJ. van der Gun, M. Thielen, N. Ruiterkamp, C. HendriksenBilthoven, Netherlands

TUE

SD

AY, AU

GU

ST 23, 2011

2011P

OS

TER

SE

SS

ION

S


• I-2-049: Development of in vitro panel of assays for rapid toxicological assessment of novel munition compounds C.J. Cao, M.S. Johnson Aberdeen Proving Ground, USA

• I-2-076: Preliminary study of the revision of Japanese Pharmacopoeia test for rubber closure for aqueous infusions H. Kojima1, K. Yamakage2, S. Oba1, H. Tsuge1, M. Aoki31Tokyo, Japan; 2Hatano, Japan; 3Osaka, Japan

• I-2-082: Toxicogenomics to assess pesticide mixture toxicityA. Menache Perpignan, France

• I-2-089: Non-animal approaches for consumer safety risk assessments: Unilever’s scientific research programmeC. Westmoreland, P. Carmichael, B. Cochrane, M. Dent, J. Fentem, C. MacKay, G. Maxwell, F. Reynolds, R. Zazzeroni Bedford, UK

• I-2-098: Accelerating the transition to 21st century toxicology: outcomes of a workshop organized by Human Toxicology Project ConsortiumM. Stephens1, M. Andersen2, K. Boekelheide3, P. Carmichael4, M. Holsapple5

1Washington DC, USA; 2Research Triangle Park, USA; 3Providence, USA; 4Sharnbrook, UK; 5Washington DC, USA

• I-2-099: Assesment of cardiac toxicity of doxorubicin on the rat electrocardiogram and its prevention by drugsE.M. Ammar, S.A. Said, G.M. Suddek, S.L. El-DamarawMansoura, Egypt

• I-2-102: Prototype pathway research for Toxicity Testing in the 21st Century (TT21C) — a case study using DNA damage characterisationP. Carmichael Sharnbrook, UK

• I-2-175: Comparative cytotoxicity evaluation of essential oil from Minthostachys setosa in CHO-K1 cells, NIH/3T3 cells and human keratinocytes N.M. Esteves-Pedro, A.C. Dorion Rodas, D.M.L. Pinto, M.B. Mathor, T.M. Kaneko São Paulo, Brazil

• I-2-195: Alternative in-vitro phototoxicity test using reconstructed skin model, KeraSkinTM Y.-H. Ryu, H.-S. Jung, S.-H. Lee Seoul, Republic of Korea

• I-2-232: Comparison of xenobiotic metabolizing enzyme activities in normal human skin and reconstructed human skin models from skinethic laboratories D. Duché1, J. Eilstein1, G. Lereaux1, J.R. Meunier1, J. Leclaire2

1Aulnay-sous-Bois, France; 2Clichy, FranceTUE

SD

AY, A

UG

US

T 23

, 201

1

PO

STE

R S

ES

SIO

NS


• I-2-233: Skin metabolismJ. Eilstein, G. Léreaux, J.R. Meunier, J. Leclaire, D. DucheAulnay-sous-Bois, France

• I-2-238: Deciphering the mechanisms of action of potassium bromate in human and rat renal proximal tubular cellsA. Wilmes1, A. Limonciel1, L. Aschauer1, R. Radford2, K. Bloch3, W. Pfaller1, C. Slattery2, E. Lock3, M.P. Ryan2, P. Jennings1

1Innsbruck, Austria; 2Dublin, Ireland; 3Liverpool, UK

• I-2-262: Alternative approaches for the evaluation of repeated dose toxicity and its use for quantitative risk assessment of cosmetic ingredients P. Prieto1, S. Creton2, A. Boobis2, W.Dekant3, J. Kleinjans4, H. Komulainen5, P. Mazzatorta6, A. Bal-Price1, V. Rogiers7, G. Schoeters8, M. Vinken7

1Ispra, Italy; 2London, UK; 3Würzburg, Germany; 4Maastricht, Netherlands; 5Kuopio, Finland; 6Lausanne, Switzerland; 7Brussel, Belgium; 8Antwerp, Belgium

• I-2-273: Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches S. Coecke1, O. Pelkonen2, S. Batista Leite1 Working Group Toxicokinetics1Ispra, Italy; 2Oulu, Finland

• I-2-290: The Integrated Discrete Multiple Organ Co-culture (IdMOC) technology as an in vitro model for systems toxicologyA.P. Li, A. Uzgare, Q. Yang, U. DoshiColumbia, USA

• I-2-294: Implementation of a redesigned preclinical biocompatibility testing program to support personal lubricant medical device products L. Bernhofer, P. Sterchele, T. McCarthy, W. Powers Skillman, USA

• I-2-310: Taking a mode-of-action approach to designing a hepatotoxicity screening strategy using the HepaRG cell model and high content imaging M. Mennecozzi, B. Landesmann, M. Whelan Ispra, Italy

• I-2-325: Toxicity of unfiltered and filtered diesel exhaust under various loadsL. Joeng1, A. Hayes1, S. Kook1, S. Bakand2

1Sydney, Australia; 2Tehran, Iran

• I-2-339: A virtual liver for pharmacological and toxicological investigations: multiscale, location dependent, xenobiotic hepatocyte response mechanismsC.A. Hunt San Francisco, USA

• I-2-368: COSMOS — a new European project to develop computational models for the repeat dose toxicity of cosmetic ingredients to humans A.N. Richarz1, M.T.D. Cronin1, D.C. Neagu2, C. Yang3, J.M. Zaldivar-Comenges4, M. Berthold5

1Liverpool, UK; 2Bradford, UK; 3Columbus, USA; 4Ispra, Italy; 5Zurich, Switzerland

TUE

SD

AY, AU

GU

ST 23, 2011

2011P

OS

TER

SE

SS

ION

S


• I-2-426: The platform on science within the European Partnership for Alternative Approaches to Animal Testing (EPAA) K.-D. Bremm1, W. Diembeck2, S. Bremer3, S. Coecke3, I. Manou4

1Wuppertal, Germany; 2 Hamburg, Germany; 3Ispra, Italy; 4Brussels, Belgium

• I-2-450: Data integration and analysis approaches for toxicogenomics applications in the 3Rs: McDSA, ConXbase and ToxProfilerE. van Someren, A. Boorsma, D. Kroese, R. StierumZeist, Netherlands

• I-2-470: The FP7 Project AXLR8 — accelerating the transition to a toxicity pathway-based paradigm for chemical safety assessment through internationally coordinated research and technology development V. Kral1, H. Spielmann1, M. Schäfer-Korting1, T. Seidle2, E. McIvor2, A. Rowan2, G. Schoeters3

1Berlin, Germany; 2 London, UK; 3Mol, Belgium

• I-2-545: Displacement of test chemicals from serum constituents in mixtures and possible effects on free concentrations and in vitro assay results N.I. Kramer, C.A.G. van Daele, B.J. Blaauboer Utrecht, Netherlands

• I-2-546: In vitro kinetics of chlorpromazine after repeated exposure in primary rat hepatocytes and human HepaRG cells J.J.W. Broeders1, B.Lauer2, G.L. Truisi2, R. Jossé3, J.L.M. Hermens1, B.J. Blaauboer1

1Utrecht, Netherlands; 2Darmstadt, Germany; 3Rennes, France

• I-2-577: Experiences with cytotoxicity assays to select starting doses for acute oral toxicity testing A. Schrage, K. Hempel, S.N. Kolle, M. Schulz, T. Ramirez, B. van Ravenzwaay, R. Landsiedel Ludwigshafen, Germany

• I-2-594: Autonomous virtual hepatocyte micromechanisms learn to respond to compound physicochemical properties (PCPs): clearance from simulation experiments, given new compound PCPs, predicts in vitro clearance C.A. Hunt, S. Sheikh-Bahaei San Francisco, USA

• I-2-639: Effect of Trichostatin A on miRNA expression in cultures of primary rat hepatocytes J. Bolleyn1, J. Fraczek1, M. Vinken1, D. Lizarraga2, S. Gaj2, J.H.M. van Delft2, V. Rogiers1, T. Vanhaecke1

1Brussels, Belgium; 2Maastricht, Netherlands

• I-2-642: Detection of endpoints and biomarkers of repeated dose toxicity using in vitro systems J. Hescheler1, S. Bremer2, J. Kleinjans3, M. Watzele4, V. Rogiers5, A. Schrattenholz6, J. Hengstler7, H. Keun8, A. Kopp-Schneider9, A. Ringwald10, J. Vilo11, P. Jennings12, A. Sickmann7, I. Mangelsdorf13, B. van der Water14

1Cologne, Germany; 2Ispra, Italy; 3Maastricht, Netherlands; 4Penzburg, Germany; 5Brussels, Belgium; 6Mainz, Germany; 7Dortmund, Germany; 8London, UK; 9Heidelberg, Germany; 10Paris, France; 11Tartu, Estonia; 12Innsbruck, Austria; 13Hannover, Germany; 14Leiden, Netherlands

TUE

SD

AY, A

UG

US

T 23

, 201

1

PO

STE

R S

ES

SIO

NS


• I-2-722: Coordination of projects on new approaches to replace current repeated dose systemic toxicity testing of cosmetics and chemicals — COACH B. Cucinelli1, M. Schwarz2, M. Whelan3

1Paris, France; 2Tuebingen,Germany; 3Ispra, Italy

• I-3-050: Critical selection of reliable reference genes for gene expression study in the HepaRG cell line L.M. Ceelen, W. De Spiegelaere, M. David, J. De Craene, M. Vinken Brussels, Belgium

• I-3-178: The effect of three different types of extract of Viscum album in two squamous cell carcinoma cell line of the tongue M.F. Guarizo Klingbeil, M.B. Mathor, L.R. Sardinha, P. Severino, D. dos Santos Pinto Jr.São Paulo, Brazil

• I-3-219: Reduction in the number of animals needed for immunogenicity studies, by improved analysis of biopharmaceutical-specific antibody responses B. Granath1, J. Holgersson2, N. Brenden1

1Södertälje, Sweden; 2 Gothenburg, Sweden

• I-3-364: Correlation of Erythrina velutina biological activities: behavior in vivo and toxicity in vitro L.P. Correia1, R. Nobrega de Almeida1, S.L. Dalmora2, H.M. de Medeiros Cavalcante1, R.O. Macedo1

1Joao Pessoa, Brazil; 2Santa Maria, Brazil

• I-3-412: A single dose subcutaneous injection efficacy study followed by a 14-day observation period for reduction of subcutaneous fat in female Gӧttingen minipigs C. Julius Frankfurt am Main, Germany

• I-3-420: The value of non-human primates in the development of therapeutic monoclonal antibodiesP.J.K. van Meer1, M. Kooijman1, J.W. van der Laan2, E.H.M. Moors1, H. Schellekens1

1Utrecht, Netherlands; 2Den Haag, Netherlands

• I-4-288: Identification of endocrine disruptors using an organotypic normal human cell based vaginal tissue model S. Ayehunie, M. Klausner, P. Hayden, H. Kandarova Ashland, USA

• I-4-454: Results of the validation study of the stably-transfected estrogen receptor alpha transcriptional activation antagonist assay using the HeLa9903 cell line A. Ono1, M. Takeyoshi2, S. Bremer3, M. Jacobs4, S.C. Laws5, T. Sozu6, H. Kojima1

1Tokyo, Japan; 2Saitama, Japan; 3Ispra, Italy; 4Parma, Italy; 5North Carolina, USA; 6Kyoto, Japan

• I-6-095: Statistical power of the OECD 210 chronic fish early life stage test and what this suggests for future animal alternative approaches S.E. Belanger1, J.T. Oris2, A.J. Bailer2

1Cincinnati, USA; 2Oxford, USA

TUE

SD

AY, AU

GU

ST 23, 2011

2011P

OS

TER

SE

SS

ION

S


• I-6-161: Development of a mechanistically informative genome-wide, in vitro chemicals screening technology M. Knöbel1, A.D. Sawle2, A.R. Cossins2, K. Schirmer1

1Dübendorf, Switzerland; 2Liverpool, UK

• I-6-197: Predicting acute toxicity in fish using the rainbow trout gill cell line, RTgill-W1 K. Tanneberger1, M. Knöbel1, F.J.M. Busser2, J.L.M. Hermens2, K. Schirmer1

1Dübendorf, Switzerland; 2Utrecht, Netherlands

• I-6-382: Transepithelial electrical resistance to monitor epithelial cell integrity for in vitro toxicity testing of water samples S. Ahmed1, M. Favre1, M. Giazzon1, B. Rothen-Rutishauser2, M. Liley1

1Neuchatel, Switzerland; 2Bern, Switzerland

• I-6-478: Assessment of mitochondrial toxicity of environmental chemicals using a quantitative high-throughput screening approach M.S. Attene-Ramos1, R. Huang1, S. Sakamuru1, S. Shahane 1, L. Shou1, K.L. Witt2, R.R. Tice2, C.P. Austin1, M. Xia1

1Bethesda, USA; 2Research Triangle Park, USA

• I-6-537: EUROECOTOX – European Network for Alternative Testing Strategies in Ecotoxicology S. Scholz1, E. Sela2, M. Garcia-Franco2, M. Galay-Burgos3, T. Braunbeck4, N. Klüver1, L. Blaha5, I. Sovadinova5, K. Schirmer6, K. Tanneberger6, M. Tabor-Kaplon7, M. Michelsen7, H. Witters8, J. Guinea2

1Leipzig, Germany; 2Madrid, Spain; 3Brussels, Belgium; 4Heidelberg, Germany; 5Brno, Czech Republic; 6Dübendorf, Switzerland; 7s’Hertogenbosch, Netherlands; 8Mol, Belgium

• I-6-585: An educational program for the use of alternative methods to animal experimentation and testingM. Daneshian1, T. Hartung1,2, M. Leist1

1Konstanz, Germany; 2Baltimore, USA

• I-6-586: Center for Alternatives to Animal Testing – Europe (CAAT-Europe)M. Daneshian1, T. Hartung1,2, M. Leist1

1Konstanz, Germany; 2Baltimore, USA

• I-6-591: Application of the 3Rs in the field of ecotoxicology S.F. Owen1, G.H. Panter1, G.D. Readman1, N. Watts2, M.J. Winter1

1Devon, UK; 2Macclesfield, UK

• I-6-599: OECD validation study on the transferability, intra- and inter-laboratory reproducibility of the zebrafish embryo toxicity test F. Busquet1, T. Braunbeck2, R. Strecker2, S. Belanger3, G. Carr3, J. Rawlings3, M. Halder1, A. Lillicrap4, S. Walter-Rohde5, P. Amcoff6

1Ispra, Italy; 2Heidelberg, Germany; 3Cincinnati, USA; 4 Oslo, Norway; 5Dessau-Roßlau, Germany; 6Paris, France

• I-7-354: Preliminary study of development of an in vitro potency test for black disease vaccine using vero cells A. Emadi, V. Malja, E. Hasannia, S. Ataei, M. Mirshahmohamad Karaj, IranTU

ES

DAY

, AU

GU

ST

23, 2

011

PO

STE

R S

ES

SIO

NS


• I-7-457: Application of the Three Rs to challenge assays used in vaccine testing: Tenth report of the BVAAWF/FRAME/RCPSA/UFAW Joint Working Group on RefinementM. Jennings1 given on behalf of the JWGR authors2

Horsham, UK

• I-8-057: Comparative study of five in vitro tests as an alternative method for eye irritation test Y. Xingfen, Y. Ying, W. Zhang, J. Huang, X. Xiong Guangzhou, China

• I-8-091: Extracellular acidification and changes in bioimpedance of L929 cellsJ. Wiest Munich, Germany

• I-8-127: In vitro eye irritation assessment using the SkinEthic HCE test method applied to ingredients used in cosmetics J. Cotovio, N. Alépée, M.H. Grandidier, D. Lelièvre, J.R. Meunier Aulnay-sous-Bois, France

• I-8-150: Assessment of eye irritation potential using the reconstructed human corneal tissue, LabCyte CORNEA-MODEL M. Katoh, N. Uemura, F. Hamajima, T. Ogasawara, K.-I. Hata Gamagori, Japan

• I-8-151: A tiered approach combining the STE test, the EpiOcular assay, the HET-CAM assay and the BCOP assay for predicting eye irritation potential of chemicals T. Abo1, T. Komano2, R. Fautz3, T. Simion4, K. Hayashi11Tochigi, Japan; 2Kanagawa, Japan; 3Darmstadt, Germany; 4Ohio, USA

• I-8-180: Inter-laboratory phase II validation study of in vitro eye irritation test; Short Time Exposure (STE) test K. Hayashi1, T. Hayashi2, M. Sakaguchi2, S. Watanabe2, H. Kojima3

1Tochigi, Japan; 2Kanagawa, Japan; 3Tokyo, Japan

• I-8-302: Development of IRR-IS®, an Episkin® based model for quantifying chemical irritation potency using an algorithm based on analysis of magnitude of gene expression of selected biomarkers F. Cottrez, C. Auriault, H. Groux Grasse, France

• I-8-314: Comparative studies for three in vitro methods to evaluate the eye irritation potential of disinfectants R.S. Silva, A.G.L. Oliveira, E.N. Alves, O.A.F. Presgrave, R.F. Presgrave Rio de Janeiro, Brazil

• I-8-324: Proposal of a mechanism-based selection of reference chemicals for development/evaluation of in vitro eye irritation methods P. McNamee1, B. De Wever2 A. De Smedt3, B. Le Varlet4, N. Alépée5

1Egham, UK; 2Düsseldorf, Germany; 3Beerse, Belgium; 4Valence, France; 5Aulnay-sous-Bois, France

• I-8-345: A novel rapid assay useful for eye irritation test using human corneal epithelium model reconstructed in a collagen vitrigel membrane chamber T. Takezawa1, H. Yamaguchi21Tsukuba, Japan; 2Isehara, Japan

TUE

SD

AY, AU

GU

ST 23, 2011

2011P

OS

TER

SE

SS

ION

S


• I-8-388: In-house validation of the EpiOcular™ eye irritation test (EpiOcular-EIT) with 60 test substances and its implementation into the tiered testing strategy for assessment of ocular irritation according to the GHSS.N. Kolle1, H. Kandarova2; B. van Ravenzwaay1, R. Landsiedel11Ludwigshafen, Germany; 2 Ashland, USA

• I-8-394: COLIPA eye irritation task force strategy and programme for development of In vitro methods: continued developments and status S. Bessou-Touya1, N. Alépée2, A. De Smedt3, B. De Wevert4, P. Jones5, P. McNamee6, M. Marrec-Fairley7, U. Pfannenbecker8, M. Tailhardat9, F. Van Goethem3

1Castres, France; 2Aulnay-sous-Bois, France; 3Beerse, Belgium; 4Düsseldorf, Germany; 5Sharnbrook, UK; 6Egham, UK; 7Brussels, Belgium; 8Hamburg, Germany; 9St. Jean de Braye, France

• I-8-408: Eye irritation of eye make-up removers assessed by methods in vitro and a clinical studyD. Jírová1, K. Kejlová1, R. Čihák 2, S. Janoušek, H. Bendová1, P. Plodíková2

1Prague, Czech Republic; 2Rybitví, Czech Republic

• I-8-428: Inter-laboratorial validation of the alternative HET-CAM test T.P. Victorio1, J. Lago2, S.F. Hengeltraub2

1São Paulo, Brazil; 2Cajamar, Brazil

• I-8-433: Development of a new opacitometer for the Bovine Corneal Opacity and Permeability (BCOP) assay S. Verstraelen1, H. Leppens1, E. Hansen2, B. De Wever1, P.Vanparys1

1Mol, Belgium; 2Beerse, Belgium

• I-8-438: Validation study on the Occular Irritection® assay D. Facchini1, C. Eskes2, M. Bufo1, S. Hoffmann3, M. Vassallo4, A. Wang5, F. d’Abrosca1, R. Ulmer5

1Suisio, Italy; 2Agno, Switzerland; 3Koln, Germany; 4Garbagnate Milanese, Italy; 5Irvine, USA

• I-8-532: Considerations for demonstrating the inter-laboratory reliability of Chorioallantoic Membrane Vascular Assay (CAMVA) and the Bovine Corneal Opacity and Permeability Assay (BCOP) G. Mun1, N. Wilt1, D.A. Donahue2, J. Avalos2, K. Norman1, A. Hilberer1, F.A. Simion2, H. Raabe1

1Gaithersburg, USA; 2Cincinnati, USA

• I-8-541: Prospective validation study of reconstructed human tissue models for eye irritation testing P. McNamee1, N. Alépée2, J. Barroso3, T. Cole3, C. de Jong-Rubingh4, C. Eskes5, S.J. Freeman6, G. Kirmizidis3, J. Lammers4, U. Pfannenbecker7, V. Zuang3

1Egham, UK; 2Aulnay-sous-Bois, France; 3 Ispra, Italy; 4Utrecht, Netherlands; 5Agno, Switzerland; 6Surrey, UK; 7Beiersdorf, Germany

• I-8-576: Usefulness and limitations of the Cytosensor Microphysiometer (CM) test method for ocular safety testing W. Stokes1, D. Lowther2, A. Layton3, J. Redden4, E. Lipscomb5, J. Truax5, N. Johnson5, D. Allen1

1Research Triangle Park, USA; 2College Park, USA; 3Bethesda, USA; 4Washington DC, USA

• I-8-598: The impact of US adoption of the UN Globally Harmonized System on the use of in vitro methods for ocular and dermal irritation and corrosionC. Willett1, K. Sullivan2

1Norfolk, USA, 2Washington DC, USA TUE

SD

AY, A

UG

US

T 23

, 201

1

PO

STE

R S

ES

SIO

NS


• I-8-629: The eyes have it: calf versus adult eyes in the Bovine Corneal Opacity and Permeability (BCOP) assay D.A. Donahue1, D. Hall2, D.R. Cerven2, G. DeGeorge2, J. Avalos1, F.A. Simion1

1Cincinnati, USA; 2Spinnerstown, USA

• I-8-630: PorCORA ocular reversibility assay testing with personal care products D.R.Cerven1, M. Piehl1, G. DeGeorge1, D.A. Donahue2, J. Avalos2

1Spinnerstown, USA; 2Cincinnati, USA

• I-8-631: Porcine Corneal Ocular Reversibility Assay (PorCORA) predicts EU R41 and GHS Category 1 M. Piehl, R. Soda, M.R. Carathers, G. DeGeorge, D. Cerven Spinnerstown, USA

• I-8-632: PorFocal, for your eyes only! M.R. Carathers, M. Piehl, R.C. Soda, D.R. Cerven Spinnerstown, USA

• I-8-633: Historical data on personal care products over fourteen years using the Chorioallantoic Vascular Membrane Assay (CAMVA) and the Bovine Cornea Opacity/Permeability Assay (BCOP) D.A. Donahue1, W. Newhard2, L. Kaufman3, J. Avalos1, D. Cerven3

1Cincinnati, USA; 2Spinnerstown, USA; 3 Wooster, USA

• I-8-634: Development of the Replacement Ocular Battery – tiered testing strategy of alternative toxicology tests to replace the need for rabbit eye tests D.R. Cerven, M. Piehl, G. DeGeorge Spinnerstown, USA

• I-9-201: Testing REACH - responding to the testing proposals system to reduce animal testing K. Taylor1, C. Casalegno1, W. Stengel21London, UK; 2Munich, Germany

• I-9-261: Effects of developmental toxicants on microRNA expression during neural differentiation of murine embryonic stem cells L. Smirnova, A. Sittka, A. Seiler, K. Hayess, A. LuchBerlin, Germany

• I-9-330: The developmental neurotoxicity of lead in rat primary aggregating brain cell cultures using transcriptomics and metabolomics approaches H.T. Hogberg, E. van Vliet, S. Nolan, T. Fonong, T. Hartung Baltimore, USA

• I-9-376: Towards automation of the Embryonic Stem Cell Test S. Stroebel, J. Lichtenberg, W. Moritz, J.M. KelmZurich, Switzerland

• I-9-523: Zebrafish embryo: an alternative model system for embryo toxicity and developmental neurotoxicity I. Selderslaghs, J. Hooyberghs, H. Witters Mol, Belgium

TUE

SD

AY, AU

GU

ST 23, 2011

2011P

OS

TER

SE

SS

ION

S


• I-9-538: Using molecular signatures for identification of teratogenic compounds in the zebrafish embryo assay A. Büttner, N. Klüver, W. Busch, A. Giannis, S. Scholz Leipzig, Germany

• I-9-550: Integrated testing strategy for reproductive toxicity A. Wolterbeek1, C. Krul1, B. van der Burg2, D. Kroese1

1Zeist, Netherlands; 2Amsterdam, Netherlands

• I-9-588: Assessment of impaired neurite outgrowth in live human neurons as functional readout for potential developmental neurotoxicants A. Krug, N. Stiegler, M. Leist Konstanz, Germany

• I-9-590: Migration assays in human embryonic stem cell-derived neural crest cells to detect neurodevelopmental toxicants B. Zimmer, S. Kadereit, M. Leist Konstanz, Germany

• I-9-627: Embryonic stem vs. embryonic carcinoma cells: a miRNA perspective on developmental toxicology S. Bremer-Hoffman, A. Compagnoni, M. Fabbri, L. Gribaldo, I. Laurenza, M. Mennecozzi, D. Pamies-Aubalat, S. Nerini-Molteni, M. Grazia Sacco, K. Voinits, M. Whelan Ispra, Italy

• I-9-628: A human embryonic stem cell approach for toxicity assessment in human early neural development/neurulation K. Vojnits, M. Klaric, S. Bremer, R. Ensenat-Waser Ispra, Italy

• I-10-170: Using high content imaging to automate the in vitro micronucleus assay: analysis of CHO-K1 and Balb/3T3 in the presence and absence of cytochalasin BD.M. Miller, A.M. Peters, J.R. HaskinsPittsburgh, USA

• I-10-185: A validation study on a Bhas 42 cell transformation assay using 96-well micro-plates A. Sakai1, S. Arai, K. Sasaki1, D. Muramatsu1, N. Endou1, F. Mizuhashi2, S. Kasamoto2, M. Nagai2, M. Takai2 M. Asakura1, N. Tashiro4, N. Ishii3, S. Yamazaki1, M. Umeda1, N. Tanaka1

1Hadano, Japan; 2Iwata, Japan; 3Kamisu, Japan

• I-10-207: The use of human 3D epidermal models for genotoxicity testing: results with the Comet assay A. Reus1, K. Reisinger2, T. Downs3, S. Pfuhler3, C. Krul11Zeist, Netherlands; 2Düsseldorf Germany; 3Cincinnati, USA

• I-10-214: Novel in vitro genotoxicity assays using reconstructed human tissues G. Ouédraogo1, N. Flamand1, F. Nesslany2, S. Simar2, D. Marzin2

1Aulnay-sous-Bois, France; 2Lille, France

• I-10-223: Comparable metabolite patterns of benzo[a]pyrene and cinnamic aldehyde in human skin ex vivo and human skin models in vitro indicate comparable metabolic capacitiesJ. Brinkmann1, C. Hutzler, S. Trappe1, U. Bock2, M. Liebsch1, F. Henkler, A. Luch1

1Berlin, Germany; 2Saarbrücken, Germany

TUE

SD

AY, A

UG

US

T 23

, 201

1

PO

STE

R S

ES

SIO

NS


• I-10-239: The application and use of cell transformation assays in hazard and risk assessment — experience at a CROA. Poth Rossdorf, Germany

• I-10-242: Development and validation of mechanism-based in vitro transformation assays for carcinogen screeningH. Yasaei1, J.C. Pickles1, M. O’Donovan2, R.F. Newbold1

1Uxbridge, UK; 2Macclesfield, UK

• I-10-252: Reconstructed Human Epidermis (RHE) use for genotoxicity testing with less false positive results E. Andres1, J. Molinari1, V. Moura Sa-Rocha2, S. Hurtado2, C. Barrichello1

1Paris, France; 2Cajamar, Brazil

• I-10-256: Genotoxicity evaluation of molecules possessing antifertility potential: testing in microorganisms as an alternative to animal testingN. Sharma1, V. Sharma1, M.A. Akbarsha2, K.K. Sharma1

1Ajmer, India; 2Tiruchirappalli, India

• I-10-264: Comparison of in vitro versus in vivo transcriptomics data of hepatocarcinogensT. Y. Doktorova1, H. Ellinger-Ziegelbauer2, M. Vinken1, T. Vanhaecke1, H.-J. Ahr2, V. Rogiers1

1Brussels, Belgium; 2Wuppertal, Germany

• I-10-271: Alternative approaches for the evaluation of carcinogenicity and its use for quantitative risk assessment of cosmetic ingredients J. van Benthem1, S. Felter2, S. Pfuhler2, T. Heinonen3, A. Poth4, R. Serafimova5, J. van Delft6, E. Benfenati7, P. Phrakonkham5, A. Worth5, R. Corvi51Bilthoven, Netherlands; 2Cincinnati, USA; 3 Tampere, Finland; 4Roßdorf, Germany; 5Ispra, Italy; 6Maastricht, Netherlands; 7Milan, Italy

• I-10-286: Genotoxicity testing using the micronucleus and Comet assays in normal human cell-based 3D epithelial models Y. Kaluzhny, M. Klausner, P. Hayden, H. Kandarova Ashland, USA

• I-10-315: Effects of the genotoxic compounds, benzo[a]pyrene and cyclophosphamide on phase 1 and 2 activities in EpiDermTM models N.J. Hewitt1, C. Götz2, E. Jermann2, J. Tigges2, Z. Kohne2, U. Hübenthal2, J. Krutmann2, H.F. Merk3, E. Fritsche2,3

1Erzhausen, Germany; 2Düsseldorf, Germany; 3 Aachen, Germany

• I-10-316: COLIPA validation of the Reconstructed Human Skin Micronucleus Assay (RSMN): further pre-validation studies and investigations into increasing time efficiency R. Fautz1, G. Ouédraogo2, K. Reisinger3, M. Aardema4, B. Barnett4, B. Faquet2, G. Mun5, E. Dahl5, R. Curren5, N. Hewitt6, S. Pfuhler4

1Darmstadt, Germany; 2Aulnay-sous-Bois, France; 3Düsseldorf, Germany; 4Cincinnati, USA; 5Gaithersburg, USA; 6Erzhausen, Germany

TUE

SD

AY, AU

GU

ST 23, 2011

2011P

OS

TER

SE

SS

ION

S


• I-10-322: Characterization of molecular events underlying induced morphologically transformed (MT) phenotypes in the Syrian Hamster Embryo (SHE-MT) assay J.C. Pickles1, H. Yasaei1, M. O’Donovan2, R.F. Newbold1

1London, UK; 2Cheshire, UK

• I-10-352: Applicability and robustness of the Hen’s Egg Test for Micronucleus Induction (HET-MN): results from an interlaboratory trial K. Reisinger1, D. Greywe2, N. Banduhn1, J. Scheel1, T. Wolf2

1Düsseldorf, Germany; 2Osnabruck, Germany

• I-10-366: Electrophilic reaction chemistry to predict genotoxicity through mechanistically derived grouping and read-across: links to adverse outcome pathwaysM.T.D. Cronin, C.M. Ellison, S.J. Enoch, M. Hewitt, J.C. Madden, K.R. Przbylak, J.A.H. SchwöbelLiverpool, UK

• I-10-384: Opportunities to minimise animal use in regulatory toxicology; a cross-company review K. Chapman1, S. Sparrow2, S. Robinson3, C. Bruce4, A. Danks5, D. Everett6, R. Hill7, H. Palmer8

1London, UK; 2Ware, UK; 3Macclesfield, UK; 4Sandwich, UK; 5Tranent, UK; 6Harrogate, UK; 7Ledbury, UK; 8Huntingdon, UK

• I-10-391: In vitro genotoxicity testing using a metabolic competent human 3D bronchial epithelial modelC. Krul1, B. Klein2, A. Reus1, J. van Triel1, J. Boei21Zeist, Netherlands; 2Leiden, Netherlands

• I-10-403: The COLIPA strategy for animal-free genotoxicity testingS. Pfuhler1, P. Carmichael2, R. Fautz3, G. Ouedraogo4, K. Reisinger5

1Cincinnati, USA; 2Bedford, UK; 3Darmstadt, Germany; 4Asnières-sur-Seine, France; 5Düsseldorf, Germany

• I-10-414: Spectrophotometric measurements of transformation frequency in Bhas 42 cells using hydrogen peroxide K. Sasaki, D. Muramatsu, S. Arai, N. Endou, A. Sakai, S. Yamazaki, M. Umeda, N. Tanaka Hadano, Japan

• I-10-452: Development of a new genotoxicity assay using proliferating and metabolically active upcyte® hepatocytesA. Nörenberg, N.J. Hewitt, S. Heinz, A. Nussher, J. BraspenningHeidelberg, Germany

• I-10-464: An efficient approach to carcinogenicity prediction through in vitro mutagenicity and cell transformation assays R. Benigni, C. Bossa, O. Tcheremenskaia, A. GiulianiRome, Italy

• I-10-484: Quantitative assessment of the effects of low dose ionizing radiation using a human hybrid cell transformation assayE. Elmore, J.L. RedpathIrvine, USA

TUE

SD

AY, A

UG

US

T 23

, 201

1

PO

STE

R S

ES

SIO

NS


• I-10-565: Application of the threshold of toxicological concern-concept in safety assessment of chemically complex matricesM.A.J. Rennen, S. Koster, P.L.P. van Loo, C.A.M. Krul, G.F. Houben Zeist, Netherlands

• I-10-597: Air/liquid interphase technique as an alternative in-vitro testing strategy for detecting biological effects of volatile compounds. First results and future perspectives of an ongoing prevalidation studyL. Smirnova1, R. Pirow1, M. Liebsch1, J. Tharmann1, A. Luch1, M. Bauer2, C. Graebsch2, G. Linsel1, R. Siemers1, C. Otto1, S. Tröller1, N. Müller1, E. Berger-Preiß3, H. Kock3, A. Oertel3, D. Ritter3, J. Knebel 31Berlin, Germany; 2Leipzig, Germany; 3Hannover, Germany

• I-10-629: Comet assay atlasJ. Tanaka, M. Ueda, S. Masumori, M. Nakajima, M. Hayashi Shizuoka, Japan

• I-11-083: Role of AU-rich element binding proteins in mRNA stability and potency of chemical allergensE. Corsini1, V. Galbiati1, C.L. Galli1, M. Marinovich1, M. Racchi21Milan, Italy; 2Pavia, Italy

• I-11-088: SenCeeTox®: a new in vitro method for predicting photosensitizationJ.M. McKim Jr.1, D. Keller1, P. Rao2, J. SaNogueira2, L. Spaulding2

1Kalamazoo, USA; 2Allendale, USA

• I-11-111: Prediction of skin sensitization potential of preservatives using CD54 and/or CD86 on THP-1 cellsS. Kim, S. An, K. Shin, T. Lee, H. KimYongin, Republic of Korea

• I-11-112: Validation of a skin irritation study using a Japanese model; LabCyte EPI-MODEL24, additional study M. Nakamura 1, T. Suzuki 2, S. Shinoda3, M. Kato4, H. Kojima5

1Osaka, Japan; 2Kanagawa, Japan; 3Saitama, Japan; 4Aichi, Japan; 5Tokyo, Japan

• I-11-116: Application of the TTC and weight of evidence for the safety assessment of botanicals: Calendula and Juniper T. Re1, V. Srinivasan1, R. Persaud1, E. Antignac2

1Clark, USA; 2Asnières-sur-Seine, France

• I-11-123: Acute dermal toxicity using the OECD TG 404 integrated testing strategy combining the use of the EpiSkin test methodsN. Alépée, M.H. Grandidier, F. Soler, J. Cotovio, J.R. MeunierAulnay-sous-Bois, France

• I-11-137: Signature biomarker analysis for prediction of skin sensitizers using a cell-based in vitro alternative to animal experimentationM. Lindstedt, H. Johansson, A.-S. Albrekt, C. BorrebaeckLund, Sweden

TUE

SD

AY, AU

GU

ST 23, 2011

2011P

OS

TER

SE

SS

ION

S


• I-11-142: Evaluating the sensitization potential of surfactants: using in vitro methods in a weight of evidence approach D. Hart1, N. Ball2, S. Cagen3, J.-C. Carrillo4, D. Eigler5, F. Faulhammer6, N. Frijus-Plessen7, C. Graham8, C. Haux1, S.N. Kolle6, R. Kreiling9, A. Natsch10, D. Penney11, A. Traore12, A. Mehling13

1Slough, UK; 2Horgen, Switzerland; 3Houston, USA; 4The Hague, Netherlands; 5Essen, Germany; 6Ludwigshafen, Germany; 7Marl, Germany; 8The Woodlands, USA; 9Sulzbach, Germany; 10Dübendorf, Switzerland; 11Houston, Texas; 12Paris, France; 13Düsseldorf, Germany

• I-11-145: The Myeloid U937 Skin Sensitization Test (MUSST) for the prediction of skin sensitization potentialJ.-M. Ovigne, C. Piroird, F. Rousset, S. Martinozzi-Teissier, J.R. MeunierAulnay-sous-Bois, France

• I-11-152: Development of a skin sensitization test using a three-dimensional human skin model consisting of dendritic cells, keratinocytes and fibroblasts on collagen vitrigel membrane for applying to cosmetic products T. Uchino1, T. Takezawa2, Y. Ikarashi1, T. Nishimura1

1Tokyo, Japan; 2Tsukuba, Japan

• I-11-153: Statistical prediction model for skin sensitization potential using an integrated dataset from h-CLAT, DPRA, and DEREK.K. Okamoto1, Y. Nukada2, M. Miyazawa2, H. Sakaguchi2, A. Takatsu1

1Odawara, Japan; 2Tochigi, Japan

• I-11-169: Papain characterization: an approach to the cytotoxicity profileP.S. Lopes, N.M. Esteves-Pedro, G.H.C. Varca, C.C. Ferraz, M.B. Mathor São Paulo, Brazil

• I-11-173: Towards the 21st Century, advances and refinements in the prediction of sensitisation potential using the TIMES platformG. Patlewicz1, G. Dimitrova2, C. Kuseva2, G. Ellis3, R. Hunziker4

1Newark, USA; 2Bourgas, Bulgaria; 3Vernier, Switzerland; 4Horgen, Switzerland

• I-11-176: Evaluation of KeraSkinTM — VM, a new reconstructed human epidermis model as an alternative to skin irritation test method according to the OECD TG439 K.-M. Jung1, W.-H. Jang1, S.-H. Lee2, H.-S. Jung2, K.-M. Lim1

1Yongin, Republic of Korea; 2Seoul, Republic of Korea

• I-11-177: Development of Fluorescence Intensity Increased Method (FIM) to evaluate the skin photosensitization potential of chemicals.M. Ishikawa, M. Hirota, T. Ashikaga, H. Kouzuki, T. IwabuchiYokohama, Japan

• I-11-182: Evaluation of photosensitizer by non-radioactive local lymph node assay (LLNA)W.-H. Jang1, K.-M. Jung1, Y.-H. Park1, B.-H. Kim2, K.-M. Lim1

1Yongin, Republic of Korea; 2Daegu, Republic of Korea

TUE

SD

AY, A

UG

US

T 23

, 201

1

PO

STE

R S

ES

SIO

NS


• I-11-186: An in vitro test to screen skin sensitizers using a stable THP-1-derived IL-8 reporter cell line, THP-G8S. Aiba1, Y. Kimura1, T. Takahasi1, S. Nishii2, Y. Ohmiya3

1Sendai, Japan; 2Fukui, Japan; 3Tsukuba, Japan

• I-11-187: CEFIC-LRI workshop on skin sensitisation methods J.-C. Carrillo1, N. Ball2, S. Cagen1, H. Certa3, D. Eigler4, F. Faulhammer5, C. Garcia6, C. Graham7, C. Haux8, R. Kreiling9, P. Kern10, A. Mehling11, M. Woolhiser12, B. Hubesch13

1The Hague, Netherlands; 2Horgen, Switzerland; 3Marl, Germany; 4Essen, Germany; 5Ludwigshafen, Germany; 6Porteaux, France; 7The Woodlands, USA; 8Stenungsund, Sweden; 9Sulzbach, Germany; 10Brussels, Belgium; 11Düsseldorf, Germany; 12Midland, USA; 13Brussels, Belgium

• I-11-189: A strategy for the hazard identification and potency categorization of skin sensitization using a combination of non-animal testingsY. Nukada, M. Miyazawa, K. Saito, H. Sakaguchi, N. NishiyamaTochigi, Japan

• I-11-190: ECVAM prevalidation study on skin sensitisation alternatives: progress updateD. Basketter1, P. Aeby2, S. Aiba3, N. Alepee4, A. Angers-Loustau5

1Sharnbrook, UK; 2Brussels, Belgium; 3Sendai, Japan; 4Paris, France; 5Ispra, Italy

• I-11-194: Implementation of non-animal approaches for cosmetic safety assessments for skin sensitisation C. Goebel1, P. Aeby2, N. Ade3, N. Alépée3, A. Aptula4, D. Araki5, E. Dufour3, N. Gilmour4, J. Hibatallah6, D. Keller7, P. Kern8, A. Kirst9, M. Marrec-Fairley10, G. Maxwell4, J. Rowland11, B. Safford4, F. Schellauf10, A. Schepky12, C. Seaman13, T. Teichert12, N. Tessier14, S. Teissier15, H. Ulrich Weltzien16, P. Winkler17, J. Scheel71Darmstadt, Germany; 2Marly, Switzerland; 3Asnières-sur-Seine, France; 4Bedford, UK; 5Paris, France; 6Neuilly sur Seine, France; 7Düsseldorf, Germany; 8Stroombeek Bever, Belgium; 9Darmstadt, Germany; 10Brussels, Belgium; 11Surrey, UK; 12Hamburg, Germany; 13Hertfordshire, UK; 14 Tours, France; 15Aulnay-sous-Bois, France; 16Freiburg, Germany; 17Neuss, Germany

• I-11-198: The molecular mechanisms of IL-8 production by hapten-stimulated monocytes: the analysis using a stable THP-1-derived IL-8 reporter cell line, THP-G8Y. Kimura1, T. Takahashi1, S. Nishii2, Y. Ohmiya3, S. Aiba1

1Sendai, Japan; 2Tsuruga, Japan; 3Tsukuba, Japan

• I-11-200: Study on development of in vitro photosensitization test using human-derived monocyteY.K. Lee, Y.N. Yum, J.H. Park, S.Y. Han, S. Sohn Cheongwon-gun, Republic of Korea

• I-11-202: In vitro skin sensitization test; human cell line activation test (h-CLAT)T. Ashikaga1, Y. Nukada2, S. Sono1, M. Miyazawa2, H. Sakaguchi21Yokohama, Japan; 2Tochigi, Japan

• I-11-206: Evaluation of SensCeeTox® an integrative model for identifying chemical sensitizersC. Gomes, A. Del Bufalo, R. Note, S. Teissier, C. PiroirdAulnay-sous-Bois, France

TUE

SD

AY, AU

GU

ST 23, 2011

2011P

OS

TER

SE

SS

ION

S


• I-11-217: A combined model of sebocytes with human epidermal-dermal equivalents for evaluating the effect of topical application of sebum inhibitorsL. Zhang1, A. Pappas1, P. Winkler2, M. Eisinger1, W.-H. Li11Skillman, USA; 2Neuss, Germany

• I-11-226: Methods development through recognition in 3Rs: L’Oréal commitment J.R. Meunier, G. Ouedraogo, S. Ringeissen, J.-M. Ovigne, N. Alepée Aulnay-sous-Bois, France

• I-11-230: Contact sensitizers modulate the arachidonic acid metabolism of PMA-differentiated U-937 monocytic cells activated by LPSA. Del Bufalo1, S. Martinozzi-Teissier1, J. Bernad2, J.R. Meunier1, B. Pipy2

1Aulnay-sous-Bois, France; 2Toulouse, France

• I-11-234: Computational system for predicting chemical reactivity towards macromolecules and subsequent adverse effectsS. Ringeissen1, G. Dimitrova2, O. Mekenyan2, D. Duche1, J. Eilstein1

1Aulnay-sous-Bois, France; 2Bourgas, Bulgaria

• I-11-243: Use of melanocytes and keratinocytes in co-culture for the assessment of the potential of a Brazilian flora nut as a de-pigmentation agent B. da Silva Sufi, P. Santos Lopes, C. Isaac, D. Yoshito, M. B. Mathor São Paulo, Brazil

• I-11-245: Use of fresh, functional human skin tissue in assessing anti-inflammatory effects of human pharmaceuticalsC. Miller, S. Lynagh Glasgow, UK

• I-11-259: Peptide reactivity assay using spectrophotometric analysis for screening of skin sensitizerY.H. Jeong, S. An, S. Kim, K.H. Shin, H.K. KimYongin, Republic of Korea

• I-11-274: Human hair follicle equivalents in vitro for substance testingI. Wagner, R. Horland, G. Lindner, R. Lauster, U. MarxBerlin, Germany

• I-11-276: A new perspective to evaluate sensitizing agents using microarray analysesV. de Moura Sà-Rocha1, T. Haline-Vaz1, C. Alves Pinto1, J.L. Gesztesi1, N.I.T. Zanchin2

1Cajamar, Brazil; 2Limeira, Brazil

• I-11-280: Evaluation of SENS-IS®, an Episkin® based model for Identifying Chemical SensitizersS. Martinozzi-Teissier1, F. Cottrez2, F. Tourneix1, H. Groux2, J.R. Meunier1

1Aulnay-sous-Bois, France; 2Grasse, France• I-11-281: Enterprise and university joined efforts to develop in vitro alternative methods in Brazil

C.B. Parise1, V.M. Sà-Rocha2, J.-L. Gesztesi2, J.Z. Moraes1

1São Paulo, Brazil; 2Cajamar, Brazil

TUE

SD

AY, A

UG

US

T 23

, 201

1

PO

STE

R S

ES

SIO

NS


• I-11-293: Development of SENS-IS®, an Episkin® based model for measuring chemical sensitizers potencyF. Cottrez, C. Auriault, H. GrouxGrasse, France

• I-11-301: Characterization of alcohol- and aldehyde- deshydrogenase activities in normal human skin compared with reconstructed human skin models G. Léreaux, J. Eilstein, J.-R. Meunier, J. Leclaire, D. Duché Aulnay-sous-Bois, France

• I-11-304: In vitro alternative for chemical allergenicity screening using plasmacytoid dendritic cellsS. Ayehunie, M. Child, M. Spratt, M. Klausner, J. SheasgreenAshland, USA

• I-11-313: In vitro testing of contact allergens: which cell types are suitable?M. Hitzler, A. Bergert, A. Luch, M. PeiserBerlin, Germany

• I-11-329: Skin-sensitizing capacity and potency: pre-validation of an alternative two-tiered in vitro assayM. Teunis1, M. Smits1, E. Corsini2, S. Gibbs3, E. Roggen4

1Utrecht, Netherlands; 2Milan, Italy; 3Amsterdam, Netherlands; 4Bagsvaerd, Denmark

• I-11-332: VITOSENS: a mechanism-based in vitro assay for chemical-induced skin sensitizationJ. Hooyberghs1,3, N. Lambrechts1, I. Nelissen1, H. Witters1, R. Van Den Heuvel1, G. Schoeters1,2

1Mol, Belgium; 2Antwerp, Belgium; 3Diepenbeek, Belgium

• I-11-334: Development of PEPT-IS®, a peptide-binding based assay for assessing chemical sensitization using lipocalin derived peptidesC. Auriault1, L. Mouhat2 J.-M. Sabatier2, H.Groux1

1Grasse, France; 2Marseille, France

• I-11-338: Gene profiles of a bronchial epithelial cell line (BEAS-2B) induced by exposure to low-molecular weight chemicalsS. Remy, I. Nelissen, J. Hooyberghs, S. Verstraelen, G. SchoetersMol, Belgium

• I-11-386: Integrated adaptive testing strategy for skin sensitization assessmentJ. Jaworska1, Y. Dancik1, P. Kern1, F. Gerberick1, A. Natsch2

1Strombeek-Bever, Belgium; 2Basel, Switzerland

• I-11-397: Predicting sensitizing potential of cosmetic ingredients: enlargement of the applicability domain of the MUSST assay by using complementary U937-based assaysS. Martinozzi-Teissier, C. Piroird, D Verda, A. Staropoli, J.M. OvigneAulnay-sous-Bois, France

• I-11-439: In vitro skin irritation testing of greasy and sticky substances J. Molinari1, N. Remoué 1, E. Andrés1, V. Rocha2, C. Barrichello1

1Paris, France; 2Cajamar, Brazil

TUE

SD

AY, AU

GU

ST 23, 2011

2011P

OS

TER

SE

SS

ION

S


• I-11-446: Updated NICEATM evaluation and international acceptance of the reduced murine local Lymph Node AssayD. Allen, T. Burns, J. Strickland, E. Salicru, W. StokesResearch Triangle Park, USA

• I-11-456: Effect of skin barrier function and metabolic ability on the concentration-distance profiles of chemical compounds in reconstituted cultured human skin models H.Todo, K. Sugibayashi Sakado, Japan

• I-11-458: Establishment and characterization of in vitro skin models mimicking hallmarks of atopic skin D. Henkes1, K.M. Eckl2, J. Phendl1, C.H. Korting3, C.H. Hennies2 , M. Schäfer-Korting1, S. Küchler1

1Berlin, Germany; 2Cologne, Germany; 3Munich, Germany

• I-11-535: Retrospective analysis of the EpiDerm 3-Minute Prediction Model for assessment of GHS skin corrosion packing group sub-category 1AH. Kandarova, Y. Kaluzhny, J. Kubilus, P. Hayden, J. Sheasgreen, M. Klausner Ashland, USA

• I-11-542: Functionality and specificity of gene markers for skin sensitization in dendritic cellsN. Lambrechts1, I. Nelissen1, V. Van Tendeloo2, H. Witters1, R. Van Den Heuvel1, J. Hooyberghs1,3, G. Schoeters1,2

1Mol, Belgium; 2Antwerp, Belgium; 3Diepenbeek, Belgium

• I-11-548: In vitro assessment of skin irritation potential of surfactant-based formulations using 3-D skin-reconstructed tissues and cytokine expression analysisR.M. Walters1, L. Gandolfi1, N. Tierney1, E. Gunn1, K. Martin1, A. Kong2, A. Hilberer2, N. Barnes2, N. Wilt2, J.R. Nash2, H. Inglis2, H. Raabe2, G.-E. Costin2

1Skillman, USA; 2Gaithersburg, USA

• I-11-567: Evaluation of the Murine Local Lymph Node Assay (LLNA) for potency categorization of chemicals causing allergic contact dermatitis in humansJ. Strickland1, P. Brown2, J. Matheson3, A. Jacobs2, T. McMahon1, D. Germolec1, D. Allen1, E. Salicru1, T. Burns1, F. Stack1, W. Stokes1

1Research Triangle Park, USA; 2Silver Spring, USA; 3Bethesda, USA

• I-11-568: Evaluation of the murine local lymph node assay (LLNA) for assessing the allergic contact dermatitis hazard potential of pesticide formulationsT. McMahon1, D. McCall1, J. Matheson2, A. Jacobs3, T. Burns4, D. Allen4, W. Stokes4

1Washington DC, USA; 2Bethesda, USA; 3Silver Spring, USA; 4Research Triangle Park, USA

• I-11-574: International acceptance of the nonradioactive LLNA: BrdU-ELISA for evaluating allergic contact dermatitis hazardsA. Jacobs1, J. Matheson2, V. Malshet1, J. Toy1, J. Strickland3, D. Allen3, T. Burns3, F. Stack3, W. Stokes3

1Silver Spring, USA; 2Bethesda, USA; 3Research Triangle Park, USA

TUE

SD

AY, A

UG

US

T 23

, 201

1

PO

STE

R S

ES

SIO

NS


• I-11-575: International acceptance of the nonradioactive LLNA: DA for evaluating allergic contact dermatitis hazardsP. Brown1, J. Matheson2, A. Jacobs1, R. Ward3, E. Margosches3, E. Salicru4, D. Allen4, F. Stack4, W. Stokes4

1Silver Spring, USA; 2Bethesda, USA; 3Washington DC, USA; 4 Research Triangle Park, USA

• I-11-579: Towards animal-free testing for skin sensitization: in-house validation of four methods: MUSST, h-CLAT, KeratinoSens and DPRAC. Bauch1,2, T. Ramirez1, T. Eltze1, E. Fabian1, S.N. Kolle1, C. Pachel1,3, B. Wiench1,4, C.J. Wruck2, B. van Ravenzwaay1, R. Landsiedel11Ludwigshafen am Rhein, Germany; 2Aachen, Germany; 3Kaiserslautern, Germany; 4Mainz, Germany

• I-11-580: Determination of dimethylfumarate and analogues sensitization potential in in vivo and in vitro models C. Mourton-Gilles1, J.-C. Ourlin1, C. Rousselle2, B. Lauret1, C. Megy1, J. Maurin1, J.-L. Peiffer1,E. Intsaby-Chabert1, P. Chabert1, I. Fabre1, D. Sauvaire1

1Vendargues, France; 2Maisons-Alfort, France

• I-12-129: Computational modelling and the reduction of animal testing in toxicology studies G. Edmund, B. Howlin Guildford, UK

• I-12-589: A test strategy to detect developmental toxicants that affect neural development using human embryonic stem cells N. Stiegler, B. Zimmer, M. Wenig, T. Waldmann, S. Kadereit, M. Leist Konstanz, Germany

TUE

SD

AY, AU

GU

ST 23, 2011

2011P

OS

TER

SE

SS

ION

S


WE

DN

ES

DAY

, AU

GU

ST

24, 2

011

WEDNESDAY, AUGUST 24, 2011POSTER SESSIONS

7:30 – 15:15

7:30-15:15

Theme IV Animal welfare for Refinement and high quality science


• IV-1-061: Assessment of post-surgical pain in mice using species-typical burrowing behaviorP. Jirkof, N. Cesarovic, A. Rettich, M. Arras Zurich, Switzerland

• IV-1-120: Defining metrics to measure and communicate progress of 3Rs investments and activities — European Federation of Pharmaceutical Industries and Associations (EFPIA)T. Decelle1, M. Chlebus2, S. Robinson3

1Marcy-L’Étoile, France; 2Brussels, Belgium; 3Macclesfield, UK

• IV-1-144: Assessment of intraplantar FCA-induced mechanical hypersensitivity using dynamic weight bearingI. Robinson, C.S. Traher, J. Hatcher Cambridge, UK

• IV-1-160: CO2 and inhalent anaesthetics for the induction of euthanasia in mice: a comparative studyN. Marquardt, H. Fink, B. Bert Berlin, Germany

• IV-1-236: The effect of transportation on the physiology and behaviour of rats J.W.M. Arts1, K. Kramer2, F. Ohl11Utrecht, Netherlands; 2Amsterdam, Netherlands

• IV-1-270: An interactive tool used to improve early recognition of health problems in miceS. Vincent, G. Lauzon, L. Thibault, H. Héon Montréal, Canada

• IV-1-292: Eliminating pain and distress in ocular safety testing: use of topical anesthetics, systemic analgesics, and humane endpoints W. Stokes1, J. Merrill2, D. Lowther2, T. McMahon3, J. Chen3, M. Hashim3, M. Lewis3, B. Jones1

1Research Triangle Park, USA; 2Silver Spring, USA; 3Washington DC, USA

• IV-1-296: Assessment of the effects of meloxicam on polyclonal antibody production and related adjuvant-induced inflammation in New Zealand White rabbitsN. Bratcher, W. Buck, B. Hess, C. Medina, L. Medina Abbott Park, USA

• IV-1-309: Refinements in dog housing and husbandry, and the link with quality of science L. Hall1, S. Robinson2, S. — Crimes2, H. Buchanan-Smith1

1Stirling, UK; 2Alderley Edge, UK

PO

STE

R S

ES

SIO

NS


• IV-1-360: The effect of behavioural state and cage environment on responses to euthanasia with isoflurane or carbon dioxide in BALB/c miceH. Golledge, J. Lukic, P. Flecknell Newcastle upon Tyne, UK

• IV-1-393: Environmental enrichment influences the results in behavioral testsK. Gilbert, P. Fortier, T.M. Bah, G. Rousseau, N. LeMarec, R. Godbout Montréal, Canada

• IV-1-461: Welfare assessment in swine in biomedical research — suggestion for a welfare assessment standard for research facilitiesF. Dagnæs-Hansen, M. Herskin, L. Vammen Soendergaard Aarhus, Denmark

• IV-1-466: The TIN score: assessment tool for distress in laboratory miceK. Rodriguez1, M. Aronovitz2, H. Nickerson2, R. Karas2, A. Karas1

1North Grafton, USA; 2Boston, USA

• IV-1-467: Environmental enrichment for NTP studiesA. King-Herbert, J. Tubbs, R. Chhabra, J. Harry, W. Stokes Research Triangle Park, USA

• IV-1-494: Rat aversion to isoflurane and carbon dioxideD. Wong, J. Makowska, D. Weary Vancouver, Canada

• IV-1-564: Use of thermography as refinement for indicator of animal welfareF. Dagnæs-Hansen, Y. Jasemia Aarhus, Denmark

• IV-2-306: Farm animal research in Canada’s private feedlot industry T.M. Hancock, S.J. Hannon, G.K. Jim, C.W. Booker, R.K. Fenton Okotoks, Canada

• IV-2-319: Rumen Simulation Technique (RUSITEC) — an in vitro alternative for fermentation studies in cattle A.B. Jacob, V. Balakrishnan Chennai, India

• IV-2-551: Paddock or laboratory – hat determines suitable living conditions for sheep?A. Paul1, M. Rose2

1Orange, Australia, 2Sydney, Australia

• IV-3-483: Why is ecological ethics necessary? D. Perry, H. Curzer, P. Muhlberger, G. Perry, M. Wallace Lubbock, USA

• IV-4-204: Multimodal analgesia for improved recovery of dogs surgically prepared for telemetryJ. Harrington, L. Brown, S. Young, S. Davis Macclesfield, UK

WE

DN

ES

DAY, A

UG

US

T 24, 2011

2011P

OS

TER

SE

SS

ION

S


• IV-4-279: Advancing technology and the 3Rs: simultaneous pharmacokinetic and multi-organ function assessment in ratsY. Chen, D. Brott, J. Fikes, L. Kinter, R. Bialecki Wilmington, USA

• IV-4-389: Sexual dimorphism in brain function of DBA2 mice studied with functional and structural MRI — an animal refinement and reduction approach F. Spiegel1, S. Spiegel1, B. de Celis Alonso2, A. Hess1

1Erlangen, Germany; 2Puebla, Mexico

• IV-4-392: Integrative wireless monitoring for animal wellbeingP. Van Loo1, C. Krul1, H. Lorentsen2, F. Bouwens3, D. De Groot1

1Zeist, Netherlands; 2Dalmose, Denmark; 3Eindhoven, Netherlands

• IV-5-401: Investigation about anesthesia of rodent fetuses with transplacental pentobarbital administration M. Senuma1, H. Takashima1, M. Kuwagata1, Y. Yoshida1, K. Imai21Kanagawa, Japan; 2Osaka, Japan

• IV-6-042: The appropriateness of the use of therapeutic drugs on regulatory toxicology studies and ethical considerationsO. Jumanca, W. Ruddock Montréal, Canada

• IV-6-156: Automated blood sampling – refinement of repeated blood sampling techniques in permanently catheterized miceA.C. Teilmann, K.R. Jacobsen, O. Kalliokoski, J. Hau, K.S.P. AbelsonCopenhagen, Denmark

• IV-6-251: Group housing of male mice in long term toxicity studiesA. Annas, C. Bengtsson, E. Johansson Sӧdertälje, Sweden

• IV-6-312: Novel canine housing in the United Kingdom — a welfare perspectiveN. Watts, S. Crimes Macclesfield, UK

• IV-6-349: Combination of a rapid screening PK method and lateral marginal vein sampling technique to generate pharmacokinetic and pharmacodynamic data from M. tuberculosis infected miceS. Gaonkar, N. Kumar, K.G. Vishwas, J. Reddy, M. Kumar Bangalore, India

• IV-6-370: Environmental enrichment in laboratory mice: its effects upon reproductive physiology.M.F. Ponzio, E.M. Luque, R.D. Ruiz, M. Fiol de Cuneo, A.C. MartiniCórdoba, Argentina

• IV-6-512: Double decker caging for ferretsE. Duran, N. Nguyen, R. Broome Mountain View, CaliforniaW

ED

NE

SD

AY, A

UG

US

T 24

, 201

1

PO

STE

R S

ES

SIO

NS


WE

DN

ES

DAY, A

UG

US

T 24, 2011

7:30 – 15:15

• IV-6-709: Primate life in two American laboratoriesJ. Balcombe, K. Conlee Washington DC, USA

• IV-6-719: The use of mouse inhalation insert’s: in house study to investigate welfare improvements to mice while restrained for inhalation studiesM. Emmott Harrogate, UK

• IV-6-720: Covance Animal Environmental Enrichment ProgramM. Emmott Harrogate, UK

• IV-6-721: Comparative analysis of blood sampling techniques in the ratC.-A. MathieuHarrogate, UK

Theme V Replacement and Reduction in Basic Research


• V-1-044: Abattoir-sourced isolated ileum from Gallus gallus domesticus as an experimental toolG. Kaithwas1, S.D Sharma2, D.K Majumdar3

1Silchar, India; 2Allahabad, India; 3New Delhi, India

• V-1-065: Connexin43 signalling contributes to spontaneous apoptosis in cultures of primary hepatocytes M. Vinken1, E. DeCrock2, T. Vanhaecke1, L. Leybaert2, V. Rogiers1

1Brussels, Belgium; 2Ghent, Belgium

• V-1-079: Reducing animal use: validating the ovine psoas muscle from the abattoir as a replacement model for testing in extirpated human uteri using the Gynecare VersaPoint II Electrosurgical System J. Matonick1, D. Stoloff1, R. Dent2, J. Palushi1, E. Lyons2, B. Patel1, M. Pfefferkorn3, J. Syby1, R.H. Livengood4, J.E. Coad4

1Somerville, USA; 2Cardiff, UK; 3Piscataway, USA; 4Morgantown, USA

• V-1-080: Development of an in vitro assay for the assessment of photosensitizersA. Schepky, N. Karschuk, S. Gerlach, H. Wenck, H. ReuterHamburg, Germany

• V-1-081: In vitro detection of contact allergens: development of an optimized protocol and performance of an international ring study using human peripheral blood monocyte-derived dendritic cellsA. Schepky, H. Wenck, J. Spieker, S. Gerlach, H. ReuterHamburg, Germany

• V-1-085: Evaluation of multiple drug interaction Y. Yoshiyama, H. Ariumi, T. Iizuka, T. Tamaki, H. Miyazaki Tokyo, Japan

2011P

OS

TER

SE

SS

ION

S


• V-1-092: The Slug Mucosal Irritation (SMI) Assay: a tool to predict ocular and nasal stinging, itching and burning sensationsJ. Lenoir1, I. Claerhout1, A. Klomp2, C. Bachert1, E. Adriaens3

1Ghent, Belgium; 2The Hague, Netherlands; 3Aalter, Belgium

• V-1-093: The cytotoxic and inflammatory response of bronchial epithelial cells exposed to cigarette whole smoke and vapour at the air-liquid interface D. Azzopardi, L. Haswell, K. Hewitt, G. Foss-Smith, S. Corke Southampton, UK

• V-1-094: The development of an anchorage independent growth assay for the assessment of the carcinogenicity of whole mainstream cigarette smoke O. Oke, D. Breheny, A. Banerjee, O. Oyeniyi, S. Faux, K. Luettich Southampton, UK

• V-1-096: Involvement of acetylcholine and response to reduction in phosphorylated Connexin43 in drug development research for ischemic heart disease H. Ariumi, I. Imai, T. Miyazaki, M. Kawakami, Y. Yoshiyama Tokyo, Japan

• V-1-105: Novel culture configuration accelerating and enhancing hepatocyte polarization H. Matsui1, M. Sekijima2, S. Takeuchi1, T. Fuji1, Y. Sakai11Tokyo, Japan; 2Ibaraki, Japan

• V-1-119: Endocrine disruption and steroidogenesis: integrated evaluation from gonadal steroidogenic enzymes in vitro and in vivo to hormonal balance and fertility assessment in vivoN. Quignot1, S. Desmots1, R. Barouki2, E. Lemazurier1

1Verneuil-en-Halatte, France; 2Paris, France

• V-1-122: The Doerenkamp-Zbinden Foundation´s Chairs on Alternatives to Animal Experimentation: projects F.P. Gruber, G. Krummenacher Kuesnacht, Switzerland

• V-1-124: Development of human T cell priming assay using PBLs depleted in regulatory cells for in vitro screening of weak contact allergens A. Achachi1, V. Muttez1, M. Vocanson1, M. Tailhardat2, J.-F. Nicolas1

1Lyon, France; 2St-Jean de Braye, France

• V-1-132: Modification of an existing mouse model of human skin infection to reduce animal use J. Fernandez, J.J. Hilliard, J.L. Melton, R.K. Flamm, A.M. Barron, A.S. Lynch Raritan, USA

• V-1-133: pH cycling models for evaluating the efficacy of fluoridated mouth rinses for caries control D. Sharma1, D. Ricci-Nittel2, J. Zhang2, R. Mifsud2

1Skillman, USA; 2Morris Plains, USA

• V-1-147: Alginate based 3D hydrogels as an in vitro co-culture model platform for the toxicity screening of new chemical entitiesS.-F. Lan, B. StarlyNorman, USA

WE

DN

ES

DAY

, AU

GU

ST

24, 2

011

PO

STE

R S

ES

SIO

NS


• V-1-154: An image processing analysis of corneal alteration induced by chemicals F. Pouzaud1, G. Boyer1, J. Hibatallah2, D. Mougin2, M. Pericoi11Paris, France; 2Neuilly-sur-Seine, France

• V-1-162: Evaluation of the individual and synergistic value of the HET-CAMVT and the dynamic solubility model in order to predict the potential of new IV formulations to cause injection site reactionsA. De Smedt, C. Denissen, M. Sysmans, S. Inghelbrecht, I. VervoortBeerse, Belgium

• V-1-193: Development of an integrative approach for the prediction of systemic toxicity: combination of cell toxicity, pharmacological and physical chemical propertiesR. Note1, H. Nocairi1, M. Thomas1, L. Bourouf1, J. McKim Jr2, G. Ouédraogo1, J.R. Meunier1

1Aulnay-sous-Bois, France; 2Kalamazoo, USA

• V-1-199: Development of an integrative approach for the prediction of systemic toxicity: combination of cell toxicity and metabolism data M. Thomas, R. Note, J. Eilstein, L. Bourouf, D. Duché, G. Ouédraogo, J.R. Meunier Aulnay-sous-Bois, France

• V-1-211: Cardiovascular model for cardiac toxicity testing H. Vuorenpää, L. Ikonen, J.-R. Sarkanen, T. Heinonen, K. Aalto-Setälä Tampere, Finland

• V-1-216: An organotypic microliver platform for high throughput drug testing S. Messner1, M. Uteng2, J. Hengstler3, F. Pognan2, W. Moritz1

1Zurich, Switzerland; 2Basel, Switzerland; 3Dortmund, Germany

• V-1-221: A pertinent screening tool to measure permeability coefficient: Episkin® reconstructed human skin model S. Gregoire, A. Garrigues-Mazert, J.R. Meunier Aulnay-sous-Bois, France

• V-1-225: Alternative approach to maximum flux for TTC applied to safety evaluation of cosmetic ingredients A. Garrigues-Mazert, S. Gregoire, D. Duche, J.R. Meunier Aulnay-sous-Bois, France

• V-1-227: Adaptation of the validated SkinEthic RHE skin corrosion test method to 0.5 cm2 tissue sample C. Tornier1, N. Alepee2, S. Martins1, J. Cotovio2, J. R. Meunier2

1Lyon, France; 2Aulnay-sous-Bois, France

• V-1-248: Development of alternative to oral mucosa irritation test by modified STE test Y. Yamaguchi1, X. Li2, L. Bian2, L. Qiu2

1Osaka, Japan; 2Shanghai, China

• V-1-249: Improving human vascularized mucosa/intestine models to study substance adsorption phenomena A. Jaenicke1, H.-J. Buhr1 J.-P. Ritz1, H. Walles2, U. Marx1

1Berlin, Germany; 2Stuttgart, Germany

WE

DN

ES

DAY, A

UG

US

T 24, 2011

2011P

OS

TER

SE

SS

ION

S


• V-1-268: Lactate is an ideal non-invasive marker for evaluating temporal alterations in cell stress and toxicity in repeat dose testing regimes A. Limonciel1, L. Aschauer1, A. Wilmes1, S. Prajczer1, M.O. Leonard2, W. Pfaller1, P. Jennings1

1Innsbruck, Austria; 2Dublin, Ireland

• V-1-285: Correlation of in-vivo and in-vitro degradation profiles for bio-absorbable polymer implants A. Kumar, E. Vailhe Somerville, USA

• V-1-303: Development of cell-based endocrine disruptor screens using automated image analysis to quantitate receptor binding and dynamics R. Lewis, A. Peters, J. Haskins, M. Pietila, Y. Federov Pittsburgh, USA

• V-1-305: Replacing the use of animals in antibody production S. Dozier Norfolk, USA

• V-1-317: Ex Vivo Tape Striped Human Skin Model: an alternative method to animal testing for skin pharmacology studies and the pharmacological evaluation of cosmetic ingredients and finished products M. Garay, M.l Southall, P. Lyte Skillman, USA

• V-1-331: In vitro BBB modeling: from research to high-throughput screening D. Hallier-Vanuxeem, E. Vandenhaute, A. Da Costa, R. Cecchelli Lens, France

• V-1-336: New tools for discovery: stem cells, adipose tissue engineering and small animal imagingM. Proulx, A.-M. Moisan, J. Lagueux, M.-A. Fortin, J. FradetteLaval, Canada

• V-1-337: Utility of the in vitro mutagenicity assay in MutaTM Mouse FE1 cells for regulatory assessment of genotoxicityA.S. Long, P.A. WhiteOttawa, Canada

• V-1-350: Development of multicolor luciferase assay system for in vitro chemical risk analysis Y. Nakajima1, S. Nishii2, K. Niwa1, Y. Ohmiya1

1Takamatsu, Japan; 2Tokyo, Japan

• V-1-357: Quantitative proteomic profiling for drug toxicity prediction in human organ model systemsS. Ruzek1, C. Bielow2, P. Jennings3, K. Reinert2, C.G. Huber1

1Salzburg, Austria; 2Berlin, Germany; 3Innsbruck, Austria

• V-1-358: Development of a new reconstructed human epidermis (RhE)-based screening assay for contact allergensM. Miyazawa, Y. Nukada, K. Saito, H. Sakaguchi, N. NishiyamaTochigi, JapanW

ED

NE

SD

AY, A

UG

US

T 24

, 201

1

PO

STE

R S

ES

SIO

NS


• V-1-372: A mechanistic rationale for the prediction of skin irritancy effects implemented in a workflow processC. Yang1, S. Ringeissen2, J. Rathman1, A. Detroyer2, B. Prunier2, O. Perin3, J.R. Meunier2

1Columbus, USA; 2Aulnay-sous-Bois, France; 3Romainville, France

• V-1-377: Development of a non-injuring cell test to measure acetylcholinesterase activity for neurotoxicological high-throughput alternative methods R. Bachinski1, A. Linhares2 , G. Alves2, M.V. Silva Filho2, A. Meyer1

1Rio de Janeiro, Brazil; 2Niterói, Brazil

• V-1-378: A performance evaluation of Simcyp Dog — a fully mechanistic physiologically-based pharmacokinetic dog model – based upon a variety of theophylline iv and oral formulationsD. Pade1, D.B. Turner1, M. Jamei1, A. Rostami-Hodjegan2

1Sheffield, UK; 2Manchester, UK

• V-1-396: Evaluation of neurotoxicity using automated image analysis A.M. Peters, N.M. Radio, M.L. Pietila, J.R. Haskins Pittsburgh, USA

• V-1-411: Prevalidation of the Cultex® system assessing the inhalation toxicity of nanoparticles by direct exposure of cells at the air-liquid interfaceS. Hoffmann1, N. Möhle2, M. Papritz3, C. Pohl4, M. Aufderheide2

1Cologne, Germany; 2Hannover, Germany; 3Munich, Germany; 4Mainz, Germany

• V-1-437: Need and perspectives for the implementation of relevant in-vitro methods in the field of inhalation toxcicologyM. Aufderheide, N. Möhle, J. Rach, S. Scheffler, D.-J. Budde Hannover, Germany

• V-1-474: The Bionas DiscoveryTM 2500 system – applications for in vitro alternative tests to identify eye irritants J. Unger, S. Drechsler, A. Kob, M. Wego, R. Ehret, S. Ortinau Rostock, Germany

• V-1-544: A strategy combining high-content screening and zebrafish larvae to predict human drug-induced hepatotoxicity N. Mesens1, A.D. Crawford2, M. Steemans1, A. De Smedt1, C.V. Esguerra2

1Beerse, Belgium, 2Leuven, Belgium

• V-1-547: Evaluation of an integrated testing strategy: comparison of in silico predictions with in vivo toxicity M. Dingemans1, E. Rorije2, A. Efremenko3, H. Clewell3, B. Blaauboer1 1Utrecht, Netherlands, 2Bilthoven, Netherlands, 3Research Triangle Park, USA

• V-1-560: Ex vivo tumour sphere approach as a potential alternative method for tumour xenografts in preclinical drug efficacy assaysL.-B. Weiswald1, V. Dangles-Marie2

Paris, France

WE

DN

ES

DAY, A

UG

US

T 24, 2011

2011P

OS

TER

SE

SS

ION

S


• V-1-571: Application of Upcyte® technology to primary cells for developing alternatives to current in vitro ADME-Tox models A. Nörenberg, C. Dähn, K. Scheller, S. Heinz, J. Braspenning Heidelberg, Germany

• V-1-578: Micro Electrode Chip Assay (MEA) as method to detect neurotoxicity in vitroS. Vogel1, T. Ramirez1, A. Novellino2, E. De Franchi2, B. van Raavenzwaay1, R. Landsiedel11Ludwigshafen, Germany; 2Genova, Italy

• V-1-602: Predicting dermal toxicity using the OECD TG 404 integrated testing strategy: an evaluation of the SkinEthic RHE test methods N. Alépée1, C. Tornier2, S. Martins2, J. Cotovio1, J.R. Meunier1

Aulnay-sous-Bois, France• V-1-613: Comparative sensitivity of tumor and non-tumor cell lines to anionic lysine-based surfactants

cytotoxicity D.R. Nogueira, M. Mitjans, M.R. Infante, M.P. VinardellBarcelona, Spain

• V-1-635: Validation of a 3D skin model for cosmetic, chemical and medical device phototoxicity testing (EPARS) L.F. Pratt, D.R. Cerven, G.L. DeGeorge Spinnerstown, USA

• V-1-636: In vitro phototoxicity test methods compared: 3T3 NRU PT vs. phototoxicity assay in reconstituted skin L.F. Pratt, G.L. DeGeorge Spinnerstown, USA

• V-1-637: Gene expression profiling of an in vitro human skin model after psoralen plus ultraviolet light-induced phototoxicity L.F. Pratt1, G.L. DeGeorge1, M.J. Cunningham2

1Spinnerstown, USA; 2Cary, USA

• V-1-638: Oxidative stress and hypoxia as factors in phototoxic damage to a reconstituted human skin model: gene expression profiling evidence M.J. Cunningham1, L.F. Pratt2, G.L. DeGeorge2

1Cary, USA; 2Spinnerstown, USA

• V-1-640: Decellularized liver matrix, a remarkable tool in the bio-engineering of three-dimensional in vitro liver systems J. De Kock1, L. Ceelen1, R.M. Rodrigues1, W. De Spiegelaere 2, C. Casteleyn 2, P. Claes1, T. Vanhaecke1, V. Rogiers 1

1Brussels, Belgium; 2Merelbeke, Belgium

• V-1-641: Acceptance criteria: the challenge in the development of stem cell based toxicity tests F. Pistollato, R. Ensenat-Waser, M. Klaric, K. Vojnits, S. Nerini Molteni, S. Bremer-Hoffman Ispra, Italy

WE

DN

ES

DAY

, AU

GU

ST

24, 2

011

PO

STE

R S

ES

SIO

NS


WE

DN

ES

DAY, A

UG

US

T 24, 2011

• V-1-646: Stem cells for relevant, efficient, extended and normalized toxicology S. Bremer-Hoffmann1, T.B. Andersson2, M. Ingelman-Sundberg3, G. Lazzari4, G. Stacey5, C. Dascher-Nadel6, O. Brüstle7, J. Hyllner8, D. Sourdive9, C. Elcombe10, A. Robitzki11, R. Forster12, P. Fowler13,M. Peschanski61Ispra, Italy; 2Mölndal, Sweden; 3Stockholm, Sweden; 4Cremona, Italy; 5London, UK; 6Paris, France; 7Bonn, Germany; 8Göteborg, Sweden; 9Romainville, France; 10Dundee, UK; 11Leipzig, Germany; 12Evreux, France; 13Harrogate, UK

• V-2-166: Meta-analysis of the application of weight of evidence (WoE) and read-across for the assessment of repeat-dose systemic toxicity S. Freeman1, J. Rowland1, M. Mishra2, C. Goebel3, F. Schellauf4, J. Scheel51Surrey, UK; 2Gurgaon, India; 3Darmstadt, Germany; 4Brussels, Belgium; 5Düsseldorf, Germany

• V-2-244: Less animals – more quality data with process improvement and engagement in refinement, reduction and replacement (3Rs) culture H. Parenteau, H. Maurice, M. Perez-Marcogliese, M. Roumi Montréal, Canada

• V-2-247: The ECVAM search guide — good search practice on animal alternatives A.J. Roi1, B. Grüne2, D. Butzke2, A. Luch2, G. Pellegrini1, J. Kreysa1

1Ispra, Italy; 2Berlin, Germany

• V-2-267: Reduction of animal use in toxicity studies in the pharmaceutical industry: fact of fiction?E. Johansson, B. Granath, A. Annas, E. Jalkesten, A. Blomqvist, C. Diaz-Pohl, R. Fransson-Steen, I. Cotgreave Södertolje, Sweden

• V-2-284: Reduction in the number of species required for design verification studies D. Broughton, A. Welling Cincinnati, USA

• V-2-495: Is the baboon model appropriate for endometriosis studies? J.-P. Dehoux, S. Defrère, J. Donnez Brussels, Belgium

• V-2-513: Open-access journals and the increased availability of animal alternatives information M.W. Wood1, C. Howard2, L.A. Hart1

1Davis, USA; 2Baltimore, USA

• V-2-515: People making information matterD. Jensen Beltsville, USA

• V-2-562: How the 3R’s can benefit from systematic reviews J. van Luijk, M. Leenaars, M. Ritskes-Hoitinga Radboud, Netherlands

• V-3-063: Tissue engineered human bronchial models to study asthmaF. Goulet1, J.-P. Lavoie2, S. Chabaud1, F. Simon1, V. Moulin1

1Laval, Canada; 2Saint-Hyacinthe, Canada

2011P

OS

TER

SE

SS

ION

S


WE

DN

ES

DAY

, AU

GU

ST

24, 2

011

• V-3-171: Replacement of xenobiotic components applied in the culture medium for maintenance of human keratinocytes by human equivalents S. Cereijido Altran, D. Yoshito, C. Isaac, B. da Silva Sufi, M.B. MathorSão Paulo, Brazil

• V-3-174: Expression and induction of xenobiotic metabolism genes in the StrataTest® human skin model C. Rasmussen, N. Simon, M. Vander Zanden, C. Johnston, L. Allen-Hoffmann Madison, USA

• V-3-246: Standardization of the culture of human fibroblasts in medium enriched with platelet lysate D. Yoshito, S. Cereijido Altran, M. Roma Herson, C. Isaac, M.B. Mathor São Paulo, Brazil

• V-3-278: A novel approach to assess irritant or respiratory allergenic potential of chemicals in vitroM. Singal1, D. Vitale1, L. Smith1, K. Czollner2, L. Farmer2, C. Höpfner2, H-P. Satzer2, S. Schoeffmann2, B. Schwartz2, E. Weber2

1Woodcliff Lake, USA; 2Seibersdorf, Austria

• V-3-341: HepaRG cells: a novel human model for the study of drug hepatotoxicity M.R. McGill, H. Yan, A. Ramachandran, H. Jaeschke Kansas City, USA

• V-3-347: Use of liver microsome S9 fraction-containing microcapsules to include liver biotransformation processes in cytotoxicity tests K. Komori, N. Yamamoto, H. Matsui, S. Takeuchi, Y. Sakai Tokyo, Japan

• V-3-365: Immunohistochemical characterization of a pituitary derived cell line from adult Atlantic salmon, Salmo salar U. Adamcic-Bistrivoda1, N.T.K. Vo1, M.S. Mikhaeil1, H.E. Braid2, R.H. Hanner2, L.E.J. Lee1

1Waterloo, Canada; 2Guelph, Canada

• V-3-415: The development of human skin explant cultures as an in vitro alternative to animal testing for translational research in skin careC.B. Lin, Y. Hu, D. Rossetti, A. Pappas, W.-H. Li Skillman, USA

• V-3-486: Evaluation of microbicide toxicity and efficacy using a novel three-dimensional human organotypic co-culture vaginal modelA.L. Radtke, E.M. Jackson, M.M. Herbst-Kralovetz Phoenix, USA

• V-3-489: Functional studies of proteins: towards a human knock down model using tissue-engineered skin substitutes C. Simard-Bisson1, R. Blouin2, L. Germain1

1Québec City, Canada; 2Sherbrooke, Canada

• V-3-531: Cutaneous wound healing in the EpiDerm-FT™ full-thickness in vitro human skin model: role of serum growth factors A.J. Armento, G. Stolper, M. Li, M. Klausner, P.J. Hayden Ashland, USA

PO

STE

R S

ES

SIO

NS


WE

DN

ES

DAY, A

UG

US

T 24, 2011

• V-4-525: Reducing and refining animals used in transgenesis with the use of frozen embryos E. Gomas1, M.-N. Bernhard1, C. Massonat1, M. Brown2, C. Desvignes1

1Les Oncins, France, 2Wilmington, USA

• V-4-587: Reduction of transgenic animal use by simultaneous assessment of lacZ and Pig-a mutations, micronuclei and DNA adducts in Muta™Mouse C.L. Lemieux1*, G.R. Douglas1, J. Gingerich1, S. Phonethepswath2, D. Torous2, S. Dertinger2, D.H. Philips3, V.M. Arlt3, P.A. White1

1Ottawa, Canada, 2Rochester, USA, 3Sutton, UK

• V-5-181: Comparison of three kinds of ES cells using two and three-dimensional culture systemK. Imai1, S. Takeda1, A. Tanoue2, M. Senuma3, H. Takashima3

1Osaka, Japan; 2Tokyo, Japan; 3Odawara, Japan

• V-5-318: Egg yolk extract – a novel alternative to Fetal Bovine Serum in goat stem cell culture mediaC. Anees, A.C. Majumdar, S. Bag, B.C. Das Bareilly, India

• V-5-477: A human neuronal cell line for the substitution of transgenic neurodegeneration modelsS. Schildknecht, D. Poeltl, D. Scholz, M. LeistKonstanz, Germany

• V-5-514: Generation of post-mitotic neurons from the human LUHMES cell lineD. Scholz, D. Poeltl, S. Schildknecht, M. Leist Konstanz, Germany

• V-5-617: Optimized 1- and 3 dimensional isolation and expansion of multipotent human adipose tissue-derived stem cells: evaluation of their multipotency E. Ramboer Brussels, Belgium

• V-6-074: Comparative study of propensity for amyloidogenesis in male and female mice A. Daneshvar, K. Jamshidi, P. Mortazavi Tehran, Iran

• V-6-131: The justification of animal numbers – the role of sample size, precision and power analysis in assigning and justifying animal numbersA.M. Barron Raritan, USA

• V-6-159: Improved design of animal experimentsP.L.P. Van Loo1, R. Stoop2, S. van Buuren2

1Zeist, Netherlands; 2Leiden, Netherlands

• V-6-208: Reduction through statistical tools and design – impact & implementation experiencesR. Shaw Macclesfield, UK

• V-6-235: In-vivo predictive efficacy P. Ceuppens1, I. Peers1 , S. Karathanasis2, R. Fritsche-Danielson2, B. Leigton1

1Macclesfield, UK; 2Mölndal, Sweden

2011P

OS

TER

SE

SS

ION

S


• V-6-266: Evaluation of dried blood spotting — dog study C. Smith1, S. Robinson1, A. Sykes1, L. Kinter2

1Macclesfield, UK; 2Boston, USA

• V-6-275: Improvements in behavioural pharmacology study design saves animal lives and cost, whilst enhancing quality of pre-clinical data G. Martino, E. Lessard, F. McIntosh, M. Perez-Marcogliese, M. Perkins Montréal, Canada

• V-6-283: A bibliography on the care and use of zebrafish D. J. Scholfield, K. Adams Beltsville, USA

• V-6-399: New use of an old animal model (wound healing in the ears of rabbits) to significantly reduce the total number of animals utilized in medical device product developmentT. Muench, T. Poandl, M. DengSomerville, USA

• V-6-445: Mechanical characterizations of traumatic brain injury tests on mice using computer modelsH. Mao, P. Skelton, K.H. YangDetroit, USA

• V-6-491: Deployment of the Vitrocell system for in vitro toxicity assessment of aerosols and vehicular emissions at an air-liquid interface J. Nead, J. Bourdon, P. White Ottawa, Canada

• V-6-554: Advancing technology and the 3Rs: use of cross-over study design for pharmacological assessment in rats D.A. Brott1, J. Venzie1, P. Bentley1, H. Andersson2, J. Stewart3, R. Huby, W. Porter4, D.K. Johnson5, L. Kinter1

1Wilmington, USA, 2Södertälje Sweden, 3Alderley Park, UK, 4Indianapolis, USA; 5Sisters, USA

• V-6-615: Comparative study of amyloidogenic potential of AgNO3 and Freund’s Adjuant (AF) with that of vitamin free casein on spatio-temporal pattern of experimental amyloidosis in mice by polarized microscope A. Daneshvar, K. Jamshidi, S. Moshfeqi Garmsar, Iran

WE

DN

ES

DAY

, AU

GU

ST

24, 2

011

PO

STE

R S

ES

SIO

NS


Expert Panel Reports on:• Approaches to Animal Health Risk Assessment• Integrated Testing of Pesticides

Learn more @www.scienceadvice.ca

Authoritative, Independent, Expert Assessments

COMING SOON

2011

104

Multimedia Exhibition of Alternatives in Education and Training

Location: Saint-Maurice

The multimedia exhibition will offer a program of demonstrations of selected exemplary replacement alternatives and access to a wide range of non-animal tools for delegates to trial at leisure during the WC8. Many items can also be borrowed for use after the event.

The alternatives will be available at workstations corresponding to disciplines such as Anatomy, Anaesthesia & Critical Care, Clinical Skills & Surgery, Physiology and Pharmacology. Alternatives will include Critical Care Jerry, a canine mannequin with heart and breath sounds simulation for veterinary clinical skills training; spay and neuter mannequins for simulating surgeries; ethically-sourced plastinated specimens from client-donated cadaver programs; the Pulsating Organ Perfusion (POP) trainer for live laparoscopic surgery training using ethically-sourced animal organs; advanced virtual reality (VR) software for surgical skills practice; the Biopac Student Lab for physiology self-experimentation; and a wide range of other models, mannequins, simulators and software alternatives.

Access to online alternatives and databases of alternatives within education and training will also be provided.

The alternatives provided are held in the InterNICHE Alternatives Loan System and Animalearn’s The Science Bank loan program. The InterNICHE Alternatives Loan System is a worldwide library of software, training mannequins and simulators. Animalearn’s The Science Bank is a North American-based free loan program of over 500 CD ROMs, mannequins, simulators, and ethically-sourced animal specimens.

The multimedia exhibition timetable is as follows:

Monday, August 22 10:00 – 17:30Tuesday, August 23 9:30 – 17:15 Wednesday, August 24 9:30 – 17:15

2011

MU

LTIM

ED

IA E

XHIB

ITIO

N

EXHIBITIONS

MULTIMEDIA EXHIBITION

105

EXH

IBITIN

G C

OM

PAN

IES

AN

D A

SS

OC

IATION

S

EXHIBITIONS

EXHIBITOR BOOTHS

1: Canadian Council on Animal Care 2: Vitrocell Systems3: L’Oréal4: L’Oréal5: L’Oréal6: ChanTest Corporation7: American Society for Cellular and Computational Toxicology8: Biosafety Research Center9: In Vitro Testing Industrial Platform10: Johns Hopkins Center for Alternatives to Animal Testing 11: The Humane Society of the United States12: Thermo Fisher Scientific13: Cee Tox, Inc.14: Cee Tox, Inc.15: Epithelix Sàrl16: Johnson & Johnson17: ParaTechs Corporation18: Institute for In Vitro Sciences, Inc.19: Cultex Laboratories GmbH20: InSphero AG21: Biopredic International22: Cell Systems23: Biopta Ltd.

EXHIBITOR TABLES

T1: Japanese Society for Alternative to Animal ExperimentsT2: Japanese Society for Alternative to Animal ExperimentsT3: Cefic LRIT4: AstraZenecaT5: 9th World CongressT6: Andrew Knight, Oxord Centre for Animal EthicsT7: Laboratory Animals Limited

EXHIBITING COMPANIES AND ASSOCIATIONSLocation: Hochelaga 1-3

An exhibition will take place in the WC8 venue during the scientific sessions. The exhibition timetable is as follows:

Monday, August 22 7:00 – 18:00Tuesday, August 23 7:00 – 18:00Wednesday, August 24 7:00 – 18:00

107

IND

EX O

F CH

AIR

S A

ND

PR

ES

EN

TER

S INDEX OF CHAIRS AND PRESENTERS

AAardema, M., 34Abelson, K., 46Aeby, P., 45, 59Afolabi, A.S., 33Alépée, N., 35Alvers, M., 55, 60Andrews, L., 39Anestidou, L., 38Ankley, G., 51Aschauer, L., 42Asikaga, T., 59Auger, F. A., 42Austin, C., 43

BBaca-Estrada, M., 29Bayne, K., 32, 44, 46, 48, 58Beausoleil, N., 32, 42Beaver, B., 48Behrensdorf-Nicol, H., 35Belanger, S., 51Benavides, F., 47Bennett, A., 58Beuerman, R., 35Bialecki, R., 47Biernaskie, J., 53Blaauboer, B.J., 30, 34Blakey, D., 56, 60Brekelmans, C., 33Bremer, S., 40Broome, R., 58Brown, M., 32, 37Bruckner, L., 38

CCampbell, K., 48Casey, W., 40, 55Cattet, M., 42Chapin, R., 45Chapman, K., 38, 39Chen, E., 31Constant, S., 42Cowan, M., 48

Croy, A., 47Cuervo, M.L.C., 29Curren, R., 30, 35Currie, A., 36

DDagnaes-Hansen, F., 47Daneshian, M., 48Darimont, C., 42Darling, F., 35, 47Daston, G., 45Davies, G., 38Davis, M., 54De Groot, D., 47Demers, G., 30, 37, 44Dennison, N., 38, 41, 48Descamps, J., 33Devine, J., 39Dewhurst, D., 31, 46Dix, D., 43Dorn, P.B., 51Draayer, H., 35Drewitz, M., 32Ducceschi, L., 52Duffus, S.E.G., 53

EEdwards, J., 38Ekins, S., 58Elder, A., 50Elzaabalawy, S.I., 57, 58Embry, Michelle, 51Eskes, C., 34Everitt, J., 44, 54

FFahrenkrug, S.C., 47Fakoya, F.A., 36Fenwick, N., 46Fitzpatrick, S., 36Forgacs, A.L., 45Forjan, M., 50Fowle, J.R., 36, 40Franco, N.H., 58Fraser, D., 37

Fry, D.J., 41

G

Gaspari, A., 45Gastrich, J., 41Gauthier, C., 37Giese, C., 39Griffin, G., 50, 55Grüne, B., 46, 55, 60

H

Halder, M., 35, 38, 56Hales, B., 45Hansen, K.A., 52Hart, L.A., 52Hartung, T., 50Hayashi, M., 49, 56Hayden, P.J, 33, 50Heemskerk, J., 59Hendriksen, C., 29, 39, 55Héon, H., 47Hescheler, J., 45, 54Hessler, K., 41Hiltz, M., 42Hoke, B., 51Holloway, M., 38Hosseinkhani, H., 42Huang, S., 50Hubrecht, R., 57Hudson, M., 37, 57Huxley-Jones, J., 54

I

Isbrucker, R., 29

J

Jacobs, A., 50Jaobsen, K.R., 53Jennings, M., 30, 36, 57Jennings, P., 30Jester, J.V., 36Jukes, N., 41, 52

2011

108

KKamphuis, E., 38Karas, A.Z., 53Kavlock, R., 43, 60Kiyokawa, J., 54Knight, A., 31, 57, 58Knudsen, T., 43Koëter, H., 44, 49Kojima, H., 56, 60Kreysa, J., 33, 45, 51, 60Krishnaswamy, A., 36Krul, C., 39Kulpa-Eddy, J., 34, 35Kurosawa, T.M., 37, 44, 48, 53

LLafranconi, M., 50Leach, M., 53Lee, G.H., 52Leenaars, M., 37, 38, 46Leist, M., 32, 53Lemkine, G., 47Létourneau, L., 40Lewis, D.I., 31, 36Lidbury, B.A., 32Liebsch, M., 55Lindner, G., 30Locke, P., 40Long, M., 29Louhimies, S., 37, 39Lynagh, S., 30

MMacArthur Clark, J., 38Makowska, I.J., 32Marrec-Fairley, M., 59Martinsen, S., 41Matonick, J.P., 41Maxwell, G., 59McFarland, R., 34, 38, 39Medina, L.V., 58Mekenyan, O., 30, 43Mellor, D., 32, 37Mennecozzi, M., 43Mikkelsen, L.F., 58

Milne, C., 29Miyazawa, M., 59Mogil, J. S., 53Morck, D., 57

NNevalainen, T., 46Note, R., 43

OOhl, F., 57Ohno, Y., 32Olsson, A., 57Ormandy, E.H., 36Ouédraogo, G., 42

PPatil, C.R., 41Pennie, W., 54Percie du Sert, N., 38, 44

RRaabe, H., 30Ramboer, E., 33Ramirez, T., 40Raveendran, R., 31, 41Reed, B.T., 36Remie, R., 52Richmond, J., 40, 46Ritskes-Hoitinga, M., 37, 38, 46Ritter, L., 43Robinson, S., 52Rodriguez, J.F., 35Roggen, E.L., 45Rogiers, V., 53, 54Rose, M., 31, 37, 57Rourke, W., 52Rowan, A., 29Ryan, P.C., 39

SSakai, Y., 42Sauer, U. G., 55, 60Schiffelers, M.-J., 29, 38

Schirmer, K., 51Scholz, S., 51Schwartz, M., 40Seiler, A., 45Sena, E.S., 37Sesardic, D., 55Sharma, V., 42Shepky, A., 59Silva, O. de, 33Smeak, D.D., 52Sørensen, D.B., 37Spielmann, H., 34, 43Spöler, F., 33Spreitzer, I., 30Steinberg, P., 40Stephens, M., 55, 60Stokes, W.S., 34, 51, 60Storch, M., 50Streber, M.L., 41Sullivan, K., 34Szyf, M., 56

TTasker, L., 58Tessier, S., 59Tice, R., 43Tondreau, M., 43Torres, L.R., 47Tremblay, M., 38, 58Tucker, W., 55Turner, P.V., 32, 37, 47, 48

VVailhe, E., 41van der Valk, J., 37Vanhaecke, T., 56Villeneuve, D.L., 51Vinardell, M.P., 31Vinken, M., 56von Keyserlingk, M., 37

WWallace, M.C., 42Walters, R.M., 35Weary, D., 29IN

DE

X O

F C

HA

IRS

AN

D P

RE

SE

NTE

RS

109

Westmoreland, C., 45White, P., 56Willett, C., 40Williams, V., 30, 31Woon, S.-Y., 57, 58Würbel, H., 58

YYang, C., 33Yarmush, M., 46Yarosh, O., 35, 38Ying, Y., 36Yum, Y., 60Yushchenk, A., 57, 58

ZZurlo, J., 46, 54

IND

EX O

F CH

AIR

S A

ND

PR

ES

EN

TER

S

2011

110

Plenary SessionsPlenary Session 1 Living the good life – how far can Refinement go? . . . . . . . . . . . . . . . . . . . 29

Plenary Session 2 Engineering performance or performing engineering standards? Globalization and the application of the Three Rs . . . . . . . . . . . . . . . . . . . 38

Plenary Session 3 Implementing the Three Rs through policy – The EU Directive . . . . . . . . . 39

Plenary Session 4 A challenge to the ultimate Three Rs – In silico approach to evaluate chemical safety for humans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49

Plenary Session 5 Alternative training methods for clinical education – considerations . . . . . . 50

Plenary Session 6 Pursuing Medawar’s challenge for full Replacement . . . . . . . . . . . . . . . . . . 60

Scientific SessionsSession I-1 Potency and safety testing of human vaccines . . . . . . . . . . . . . . . . . . . . . . 29

Session I-2 Addressing systems toxicology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30

Session I-3 Biological and biotechnology-based therapeutics . . . . . . . . . . . . . . . . . . . . 39

Session I-4 Validation and Three Rs strategies for assessment of endocrine-active substances . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40

Session I-5 Nanotoxicology and the Three Rs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50

Session I-6 Advances in alternative methods for ecotoxicology . . . . . . . . . . . . . . . . . . . 51

Session I-7 Potency and safety testing of veterinary vaccines . . . . . . . . . . . . . . . . . . . . 35

Session I-8 Safety testing for chemically-induced eye injuries: recent Three Rs advances . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35

Session I-9 Advances in Three Rs alternatives for reproductive and developmental toxicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45

Session I-10 Safety testing for carcinogenicity and genetic toxicity: recent Three Rs advances . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56

Session I-11 Three Rs approaches to skin sensitization . . . . . . . . . . . . . . . . . . . . . . . . . 45

Session I-12 Epigenetics and its increasing relevance in toxicology and risk assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56

Session I-16 Alternatives for potency testing for rabies . . . . . . . . . . . . . . . . . . . . . . . . . . 38

Session II-1 Public accountability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36

Session II-2 Ethics review . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30

Session II-3 Public law - the Three Rs in regulation addressing animal use . . . . . . . . . . 40

INDEX OF SESSIONS

IND

EX

OF

SE

SS

ION

S

111

IND

EX O

F SE

SS

ION

S Session II-4 Implementing the Three Rs – alternatives to legislation . . . . . . . . . . . . . . . 46

Session II-5 Validation of Three Rs alternative methods . . . . . . . . . . . . . . . . . . . . . . . . . 51

Session II-6 Setting limits and resolving conflicts between the Rs . . . . . . . . . . . . . . . . . 57

Session III-1 Innovative teaching in the life sciences . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31

Session III-2 Innovative training in human and veterinary medicine . . . . . . . . . . . . . . . . . 57

Session III-3 Development of non-animal teaching/training models . . . . . . . . . . . . . . . . . 41

Session III-4 Replacement alternatives and teaching objectives – determining . . . . . . . . .if and when student learning objectives require the use of an animal . . . . . 46

Session III-5 Introducing multi-media to the curriculum . . . . . . . . . . . . . . . . . . . . . . . . . . 52

Session III-6 Training animal-based scientists . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37

Session IV-1 Indicators of animal welfare to implement refinement . . . . . . . . . . . . . . . . . 32

Session IV-2 Farm animal research and the Three Rs . . . . . . . . . . . . . . . . . . . . . . . . . . . 37

Session IV-3 Wildlife science and the Three Rs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42

Session IV-4 Multi-imaging modalities, telemetry and the Three Rs . . . . . . . . . . . . . . . . . 47

Session IV-5 Can pain research benefit research animals? . . . . . . . . . . . . . . . . . . . . . . . 53

Session IV-6 Broadening the application of Refinement . . . . . . . . . . . . . . . . . . . . . . . . . . 58

Session V-1 Novel methodologies and their potential in vitro application for drug development and safety assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32

Session V-2 Systematic reviews of animal experiments . . . . . . . . . . . . . . . . . . . . . . . . . 37

Session V-3 Cell culture and tissue engineering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42

Session V-4 Refinement and Reduction in the use of genetically-engineered animals . . . 47

Session V-5 Developments in stem cell research as the basis for sustainable availability of differentiated human cells and tissues . . . . . . . . . . . . . . . . . . 53

Session V-6 Animal reduction through the better use of mechanistically-based translational animal disease models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58

2011

112

Additional SessionsAdditional Session I-13 Toxicity testing in the 21st Century . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43

Additional Session I-14 Comparing the challenges of implementing new non-animal methods in the US and Europe: supported jointly by ESTIV and ASCCT . . . . . . . . . . . 34

Additional Session I-15 Shellfish toxin testing: how are the Three Rs being progressed in this field? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48

Additional Session I-17 Update on new in vitro models for detection and potency assessment of botulinum neurotoxin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55

Additional Session I-18 Report on the ICCVAM international workshop on vaccines . . . . . . . . . . . . 34

Additional Session I-19 Toxicity testing strategies – progress in skin sensitization testing: A COLIPA supported session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59

Additional Session II-7 The role of partnerships in advancing the Three Rs: together it’s possible! – an ILAR-supported Session . . . . . . . . . . . . . . . . . . . . . . . . . 38

Additional Session II-8 Science and politics in food safety assessment and their impact on experimental animal use . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44

Additional Session II-9 The EPAA, a model for private-public partnerships supporting the advancement of Three R approaches – an EPAA supported session . . . . . 33

Additional Session II-10 Role of international bodies in spreading Three Rs efforts globally . . . . . . . 44

Additional Session II-11 The International cooperation on alternative test methods (ICATM) . . . . . . 60

Additional Session IV-7 VET2011: Advancing animal welfare training for veterinarians . . . . . . . . . . 48

Additional Session IV-8 Ending severe pain and distress in animal experiments by 2025? . . . . . . . 55

Additional Session IV-9 National cancer institute guidelines – a tool for implementing more humane endpoints? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35

Additional Session V-7 Relevance, reproducibility and robustness – the other Three Rs important to science and animal welfare: a SCAW- supported session . . . 54

Additional Session V-8(a) Tutorial for Go3R search engine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55

Additional Session V-8(b) Tutorial for Go3R search engine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60

Additional Session V-9 Improving reporting of animal-based research . . . . . . . . . . . . . . . . . . . . . . . 44

IND

EX

OF

SE

SS

ION

S

Humane Science in the 21st Century

Save the date24–28 August

2014

www.wc9prague.org

· Protection of animals used for scientifi c purposes· Innovative alternative technologies

and testing strategies· New approaches in testing of cosmetics· Advances in testing of pharmaceuticals and chemicals· Refi nement, reduction and advanced disease models

9th World Congress on Alternatives and Animal Use in the Life Sciences

24–28 August 2014Prague, Czech Republic

ACT2014_inzA4 4.indd 1 29.6.11 16:50

Humane Science in the 21st Century

Save the date24–28 August

2014

www.wc9prague.org

· Protection of animals used for scientifi c purposes· Innovative alternative technologies

and testing strategies· New approaches in testing of cosmetics· Advances in testing of pharmaceuticals and chemicals· Refi nement, reduction and advanced disease models

9th World Congress on Alternatives and Animal Use in the Life Sciences

24–28 August 2014Prague, Czech Republic

ACT2014_inzA4 4.indd 1 29.6.11 16:50

SPECIAL THANKS

The Co-Chairs would like to acknowledge the indispensable and absolutely outstanding assistance they have received from members of the CCAC Secretariat. Without the work of Mara Long, Felicetta Celenza, Allison Guy, Nicole Fenwick, Pascale Belleau, Emily Verlinden, Norman Lachance, Wendy Clarence, Julie Dale, Natasha Gulati, Rachelle Fauteux and Debbie Biehler, it would not have been possible to achieve what is offered to the WC8 participants today.

In addition, the expert support and professional guidance received from the local event organizers, Les Productions Gilles Blais Inc. and Les Productions M2 Inc. from the early days of the preparation for this event, are greatly appreciated.

The high level of scientific excellence could not have been achieved without the dedication and leadership of Dr. Gilly Griffin and the constructive advice, support and critical comments made by members of the Steering Committee and the Scientific Program Committee. Last but not least, the support of the Alternatives Congress Trust members throughout the submission, planning and delivery process is acknowledged with great appreciation.

Clément Gauthier and Herman Koëter

The publication of the Final Program and accompanying Abstract Book for the Eight World Congress on Alternatives and Animal Use in the Life Sciences has been made possible through a Meetings, Planning and Dissemination Grant from

the Canadian Institutes of Health Research.

Eighth World Congresson Alternatives and Animal Use in the Life Sciences

2011Eighth World Congress Secretariat1510-130 Albert St.

Ottawa ON CANADAK1P 5G4

email: [email protected]

montrÉal (canada) - ccac · montrÉal (canada) august 21-25, 2011 2011 ... program overview.....20...

Documents